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Abstract 
Focal Adhesion Kinase (FAK) is an intracellular kinase known to mediate integrin signalling 
following cell adhesion to the extracellular matrix.  It is now emerging as a promising 
therapeutic target in many tumour types due to its overexpression in tumour cells and is 
associated with various cellular processes involved in cancer progression. Given that existing 
literature demonstrating that FAK plays a key role in the transduction of HER2 signalling in 
HER2+ cells and that the levels of FAK expression strongly correlated with HER2 
overexpression in clinical samples, we explored the potential for improvement of current 
therapies for HER2+ breast cancer by combination treatment strategies with the small 
molecule FAK inhibitor, PF878. 
FAK activity was assessed in a panel of cell lines reflecting HER2- (MCF7, T47D) and HER2+ 
(BT474, MDA-361, SKBr3) disease by Western blotting. FAK activity was relatively increased 
in HER2+ versus HER2- cell lines with HER2+ cells demonstrating greatest sensitivity to 
PF878 with respect to suppression of FAK phosphorylation at Y397. The effects of PF878 on 
cell proliferation as a monotherapy and in combination with Herceptin were assessed using 
MTT and direct coulter cell counting and by Ki67 immuno-staining. Whilst PF878 did not 
affect the proliferation as a monotherapy, treatment of HER2+ cells with PF878 and 
Herceptin combined resulted in synergistic inhibitory action on cell proliferation with an 
associated suppression in AKT pathway activity. This combination treatment strategy 
produced the greatest effects in MDA-361 cells which were intrinsically insensitive to 
Herceptin-monotherapy. 
Inhibition of FAK activity also suppressed HER2+ cell migration in response to the (1) 
exogenous ligand Heregulin and (2) conditioned-media derived from fibroblasts (FCM), as 
assessed in Boyden Chamber migration assays. In this latter context, our data suggests that 
FAK may act through a STAT3-dependent mechanism to regulate fibroblast-stimulated 
migratory and invasive responses. Collectively, these data support a role for FAK in HER2+ 
breast cancer where its targeting has the potential to improve Herceptin response as well as 
suppress stromal-induced signalling that can contribute to disease progression and spread.
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1.1 Breast cancer  
1.1.1 Incidence and mortality 
Breast cancer is now the most frequently diagnosed cancer among women worldwide with 
an estimated 1.67 million new cases diagnosed in 2012, and accounts for approximately 
25% of all cancers diagnosed (GLOBOCAN 2012-latest ). In the UK, women have lifetime risk 
of being diagnosed with breast cancer of 1 in 8. In 2011 alone, approximately 50,000 
women and 390 men were diagnosed of breast cancer (Cancer Research UK 2011-latest).  
Over recent decades, the introduction of mammography screenings by the NHS (1988), the 
use of systemic adjuvant therapies and advances in treatments contributed to an observed 
decline in mortality especially in developed parts of the world. Despite this however, around 
32 women in the UK still die from breast cancer every day (Cancer Research UK 2012-latest), 
highlighting the need for better therapeutic targets and strategies.  
1.1.2 Risk factors 
A number of risk factors have been identified that are associated with increased breast 
cancer risk. Of these, the majority of which correlate with increased exposure to the 
hormone oestrogen. As such, breast cancer is often a disease linked to  older age, null 
parity, late-age at birth of first child, early menarche, late menopause and use of oral 
contraceptives (Reviewed Key et al. 2001). The use of hormonal replacement therapy (HRT) 
in post-menopausal women is also associated with increased risk, and further correlates 
with increasing total duration of use (Beral 2003). Additional risk factors also include 
lifestyle factors such as alcohol consumption, which has been proposed by a number of 
studies to increase oestrogen levels (Reviewed Gill 2000). Diet, particularly the increased 
intake of saturated fats are also attributed to increased risk (Boyd et al. 2003).  
There is also strong evidence to suggest that familial history accounts for approximately 
10% of all breast cancers (McPherson et al. 2000). Particularly in young women (under 50 
y/o), it was found that there is an approximate two-fold relative risks if they have first-
degree relatives (mothers, sisters, daughters) that are affected (Pharoah et al. 1997). This 
familial risk has been attributed through the inheritance of autosomal dominant alleles that 
carry genetic mutations. Two susceptibility genes, BRCA1 and BRCA2 which function as 
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tumour suppressors, have been identified to confer a substantial risk up to 45-90% of 
developing breast cancer (Cancer Research UK).  
1.1.3 Breast cancer subtypes 
Breast cancer is now known to be a heterogeneous disease, comprising several distinct 
biological (clinical) and molecular intrinsic subtypes. Identification of the biological subtype 
is important for prognostic information and treatment stratification whilst our increasing 
knowledge of molecular subtypes is helping to reveal new targets for therapeutic 
intervention. 
1.1.3.1 Biological (clinical) subtypes  
Breast tumours have been classified into at least three clinical subtypes defined by the 
expression of hormone receptors for oestrogen (ER), progesterone (PR), and the human 
epidermal growth factor receptor 2 (HER2).  
Importantly, each clinical subtype is associated with a different patient outcomes as 
outlined in Table 1.1 and Figure 1.1 (Onitilo et al. 2009). 
 
Table 1.1  Breast cancer clinical subtypes and their 5 year overall survival (Onitilo et al. 2009). 
 
 
 
 
 
Figure 1.1  Disease free survival based on clinical subtype (Onitilo et al. 2009). 
 
Clinical subtype 
Disease-free 
survival 
% 
ER/PR+, HER2- 83.2 
ER/PR+, HER2+ 86.8 
ER/PR-, HER2+ 66 
ER/PR-, HER2- 73.5 
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As shown above, tumours that express the hormone receptors ER  and PR are associated 
with an overall more favourable survival .Whilst those that are HER2+ (ER/PR-) and that do 
not express any of these receptors (termed triple-negative breast cancers or TNBC) present 
with poorer outcomes (Onitilo et al. 2009). 
1.1.3.2 Molecular classification of breast cancer 
The availability of gene array technology has led to the further subdivision of breast cancers 
on the basis of their gene expression patterns, allowing for deeper understanding of their 
complex diversity (Perou et al. 2000; Sørlie et al. 2001). Through these, it is now apparent 
that there are at least 5 distinct breast cancer intrinsic subtypes: the separation of ER+ 
tumours into at least two distinctive groups termed (1) Luminal A and (2) Luminal B, and the 
emergence of the (3) normal-like, (4), HER2-enriched (HER2+) and (5) basal subtypes. 
The luminal A and luminal B subtypes are both ER+ and share molecular characteristics such 
as the expression of keratin8/18 and GATA3 which are typical of the luminal cells that 
surround the mammary ducts (Creighton 2012). The luminal B subtype tumours however 
are distinct in that they present with higher expression of a cluster of genes associated with 
proliferation including  Ki67 and  PCNA; the expression of this cohort of genes are likely 
responsible for the more aggressive behaviour exhibited by these tumours which in turn 
underlies the association of this subtype with a poorer outcome versus the Luminal A 
subtype (Perou et al. 2000). Luminal B tumours are also reported to have differential 
frequencies of gene aberrations relative to Luminal A tumours; these genes include TP53, 
PTEN, PI3KCA MAP3K1 and MAP2K4 which again may be critically important in defining this 
particular subtype (Creighton 2012). The HER2+ subtype accounts for up to 30% of all breast 
tumours and is associated with amplification of the ErbB2 gene locus, resulting in the 
overexpression of the HER2 receptor protein as wells as neighbouring genes that exist in the 
ErbB2 gene locus (e.g. Grb7) that may likely contribute to the behaviour HER2+ breast 
tumours (Kauraniemi et al. 2003). The basal subtype of tumours include the TNBC clinical 
subtype described above and are also associated with the expression of the basal cluster 
genes including keratin 5,6/17, integrin-β4 and laminin. Moreover, basal tumours possess 
the highest frequency of p53 gene mutations (82% of cases) when compared to all the other 
subtypes. Lastly, the normal breast-like group have been associated with the reduced 
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expression of luminal-associated genes and instead associated with the genes expressed in 
the adipose tissue and other non-epithelial cell types (Perou et al. 2000).  
 
As shown below, these intrinsic classifications of breast tumours carry further prognostic 
significance whereby luminal subtypes are associated with a more favourable survival 
outcome, whilst the HER2+ and basal subtypes present with the worst (Sørlie et al. 2001; 
Sotiriou et al. 2003). The normal-like subtype has comparable prognosis to the luminal 
subtypes, although the significance of its genetic profile in relation to breast cancer biology 
remains very vague.  
 
 
 
 
 
 
 
 
 
Such classifications have also been widely important in identifying associations with distinct 
tumour histopathological features and the development of models to predict risk of relapse 
and response to treatments (Weigelt et al. 2008; Parker et al. 2009).  
Although current treatment decisions are largely based on the clinical subtypes, the 
contribution of these gene-expression profiling approaches will likely  impact practice with 
regards to tailoring treatment to a patient’s molecular subtype. Indeed, such approaches 
have been developed, such as the Oncotype DX testing, which is based on identifying the 21 
genes in tumour specimens and used to determine the 10 year risk of recurrence specifically 
in ER+/HER2- node-negative patients that will receive endocrine therapy. Moreover, the 
Figure 1.2 The Kaplan–Meier curves  analysis of the 49 breast cancer patients, uniformly treated in a 
prospective study, based on different gene expression classification, showing difference in overall survival  
and relapse-free survival (RFS) between the subtypes, with the triple-negative and HER2+ subtypes 
associated with the shortest survival times (Sørlie et al. 2001).  
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test is also valuable in predicting response to chemotherapy (Carlson & Roth 2013), and has 
now been validated for clinical use by in the NHS (NICE UK). A more robust test is based on 
the PAM50 gene signature, aimed at identifying the expression profile of  50  genes to 
classify a tumour as one of the molecular breast cancer subtypes, and based on these, to 
similarly measure the  risk of recurrence (Parker et al. 2009). This however is still currently 
under consideration for use in the UK by NICE.  
1.1.4 Therapeutic targeting of breast tumours 
As mentioned, the presence of receptor proteins (ER, PR and HER2)  in the tumour is current 
practice that allows for the selection of appropriate therapy. To date, ER+ tumours are 
treated with endocrine therapy and HER2+ patients can receive therapies that target HER2 
(discussed later). TNBC tumours however, due to lack of expression of these receptors are 
not amenable to targeted therapy, which partly contributes to their poorer prognosis. Their 
current mainstay treatment is adjuvant chemotherapy. Numerous therapeutic efforts are 
currently being explored for TNBC, including poly-ADP-ribose-polymerase (PARP)-1 
inhibitors, EGFR inhibitors as wells as other tyrosine kinase inhibitors (Gluz et al. 2009).  
 1.1.4.1  ER functions and its therapeutic targeting 
Approximately 70% of breast tumours express the oestrogen receptor (ER) and are 
therefore likely to be growth stimulated by the action of oestrogens. There are two known 
ER receptors; ERα and ERβ, the latter only relatively recently discovered. ERβ shares very 
similar sequence homology to ERα, particularly within its DNA and C-terminal ligand-binding 
domains, whilst its N-terminal is considerably shorter (Dickson & Stancel 2000). Since the 
role of ERβ in breast cancer is yet to be clearly established, the use of the term ‘ER’ in this 
thesis refers to the ERα receptor.  
The binding of oestradiol (E2) (most potent naturally occurring oestrogen) to the ER triggers 
the phosphorylation of several of its serine/threonine residues, allowing for receptor 
dimerization (Figure 1.3). These dimers bind to DNA at oestrogen response elements (EREs), 
present in the promoter regions of oestrogen-responsive genes. Subsequent to this, co-
activators (e.g. A1B1) are recruited to facilitate the transcriptional modulation of genes 
(Carroll & Brown 2006).  The ER can also interact with other transcription factors such as c-
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Fos/Jun to promote expression of AP-1 response element-regulated genes. Ultimately, 
these pathways regulate activity of a large number of target genes implicated in 
tumourigenesis which include; c-myc, cyclin D1, IGF-IR and VEGF (Carroll & Brown 2006).  
In addition to ER inducing effects through transcription of genes, it can exert non-genomic 
functions which are attributed to a pool of ER that resides in the cytoplasm or at the plasma 
membrane (Figure 1.3). Membrane-associated ER was been shown mediate activation of 
growth factor receptors EGFR and IGF1-R (Kahlert et al. 2000; Razandi et al. 2003), as well as 
downstream signalling proteins such as Src, PI3K and MAPK resulting in pro-survival 
signalling (Klinge et al. 2005; Wong et al. 2002; Sun et al. 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Schematic diagram mechanisms by which ERα to regulate gene expression of ERE-
regulated genes and AP1-regulated genes upon binding of oestradiol (E2). ER can also directly bind 
and regulated activity of growth-factor receptors and downstream kinases. Collectively, these 
regulate processes including cell survival and proliferation.  
E2 
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A major strategy for the treatment of ER+ breast cancers is to prevent E2 from activating 
the ER. Early interventions relied on ovarian suppression, either pharmacologically using  
luteinizing hormone releasing factor (LHRH) agonists, surgically by surgical bilateral 
oophorectomy or by ovarian irradiation, altogether to prevent production of E2. These 
however present with the major disadvantage of being irreversible, compromising fertility in 
pre-menopausal women (Jones 2004). More recently, endocrine agents have been 
developed that either target the ER directly to prevent E2 binding, or alternatively to 
suppress the synthesis of E2 in the body. 
Today, endocrine therapy is now regarded as the ‘gold standard’ for these ER+ tumours. 
Endocrine therapy acts to interfere with ER signalling, which is usually given as an adjuvant 
following surgery of the primary tumour.  
There  are  three  main  categories  of  endocrine  therapy;  
1) Selective oestrogen receptor modulators (SERM) prevent oestrogen from binding to ER.  
2) Selective oestrogen receptor degraders (SERD) trigger degradation of ER.  
3)  Aromatase  inhibitors  (AI)  bind  to  the  aromatase enzyme which is responsible for the 
production of oestrogens in peripheral tissues, resulting in a reduction of circulating 
oestrogen and depriving the tumour of oestrogen. 
 
1.1.4.2 Selective  oestrogen  receptor modulators  (SERMs)  
The most widely used SERM is Tamoxifen, which competes with E2, for binding to the ER 
receptors, and in doing so,  is able to prevent  the action  of  oestrogen, interfering with 
oestrogen signalling and transcription  of  ER-regulated genes. Tamoxifen has been available 
and in use for ER+ breast cancers for over 30 years and has proven effective and preventing 
disease recurrence. In a meta-analysis of patient data from 20 clinical trials (n=10,645) ( 
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)), 5 years Tamoxifen adjuvant 
treatment significantly reduced recurrence rates and mortality throughout the first 15 years 
after diagnosis than those in the control group following surgery (Davies et al. 2011). 
Continuing the treatment for up to 10 years led to further benefits in the reduction of 
recurrence rates and mortality (Davies et al. 2013). However, Tamoxifen is not without side 
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effects and its use is associated with an increased risk of endometrial cancer, deep vein 
thrombosis and pulmonary embolus (Hernandez et al. 2009; Swerdlow & Jones 2005). In 
breast tissues, Tamoxifen binds to the ER, antagonising oestrogen activity. But at the same 
time in other tissues (e.g. endometrium), Tamoxifen  promotes  ER activation and thus acts 
as a partial agonist, hence it is termed as “selective oestrogen receptor modulator” (SERM) 
(Davies et al. 2011). This is likely to be caused by the differential expression of co-activators 
and co-repressors involved in the transcriptional regulation of ERE-target genes in specific 
tissue types (Graham et al.2000). 
1.1.4.3 Selective oestrogen receptor degraders (SERDs) 
The limitations of SERMs outlined above have led to the development of alternative 
endocrine therapies with differing modes of action and are termed selective oestrogen 
receptor degraders (SERDs), an example of which is Faslodex (Wakeling et al. 1991). 
Faslodex has a higher affinity for the ER and has been shown to inhibit ER-mediated gene 
transcription more effectively than Tamoxifen. Additionally and in contrast to Tamoxifen, 
Faslodex also abrogates the non-genomic cytoplasmic functions of ER and induces the rapid 
turnover and degradation of ER. Most importantly, Faslodex lacks the partial-agonist effects 
observed in Tamoxifen and hence it is also regarded as a ‘pure anti-oestrogen’(reviewed 
Howell 2006). 
1.1.4.4 Aromatase Inhibitors (AIs) 
Aromatase inhibitors (AIs) act through inhibiting the aromatase enzyme which is responsible 
for the production of oestrogens in peripheral tissues, to reduce the levels of circulating 
oestrogen. AI’s are subdivided into non-steroidal which reversibly bind to aromatase (e.g. 
anastrozole and letrozole) and steroidal (e.g. exemestane) agents which are irreversible. 
Results from the ATAC trial (anastrozole, tamoxifen, or the combination of tamoxifen and 
anastrozole) demonstrated a significant improvement in 5 year disease free survival (DFS) 
compared to Tamoxifen (Howell et al. 2005). To date, AIs (anastrozole, exemestane or 
letrozole) are approved for use in postmenopausal ER+ breast cancer patients in an 
adjuvant setting, and also as extended treatment for patients that have received the 
standard adjuvant Tamoxifen therapy (NICE UK).  
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1.1.5 HER2 functions and its therapeutic targeting  
HER2 is a trans-membrane receptor tyrosine kinase (RTK) encoded for by the ErB2 proto-
oncogene. Amplification of ErbB2 gene and the consequent overexpression of HER2 is found 
in up to 30% of breast tumours and shown to be associated with a more aggressive 
phenotype and poor patient outcome (Slamon et al. 1987; Liu et al. 1992). HER2 is a 
member of ErbB receptor family, which includes EGFR, HER3 and HER4 (Figure 1.4). They 
possess an N-terminal extracellular domain (ECD), a trans-membrane domain and an 
intracellular tyrosine kinase domain. Several known ligands such as the epidermal growth 
factor (EGF), transforming growth factor alpha (TGFα), amphiregullin, heregulins (HRG) and 
beta-cellulins can bind and specifically activate these family of receptors (Olayioye et al. 
2000). Ligand binding induces receptor homo/heterodimerization stimulating their intrinsic 
tyrosine kinase activity, resulting in the trans/auto-phosphorylation of specific tyrosine 
residues within their intracellular regions. These phosphotyrosine residues then serve as 
docking sites for several downstream proteins (eg. Grb2, PI3K, Shc, Crk, Src) to stimulate 
signalling pathways such as the Ras/MAPK and the PI3K/AKT pathway, as well as a number 
of transcription factors eg. c-Fos, c-Jun and c-Myc to regulate diverse biological processes 
such as cell proliferation, survival/apoptosis and migration (Park et al. 2008; Schulze et al. 
2005). 
 Accordingly, aberrant activation of these as a result of receptor overexpression as seen in 
breast cancers will enhance and prolong signalling and thus promote tumourigenic cellular 
processes (Park et al. 2008; Olayioye 2001).  
 
 
 
 
 
 
 
Figure 1.4 ErbB family of receptors illustrated. HER2 inactive ligand binding domain and the HER3 
inactive tyrosine kinase domain depicted with X.  
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Interestingly, although the HER2 receptor is devoid of a functional ligand-binding domain 
(Figure 1.4), it still plays an important role in signal transduction by forming heterodimers 
with other ErbB receptors. In fact, HER2 is the preferred dimerization partner for all other 
ErbB receptors. This is attributed to the fact that HER2 exists in a (1) constitutively open 
ligand-bound conformation, (2) is endocytosed at a much slower rate relative to other ErbB 
receptors, and (3) more frequently recycled back to the cell surface thereby supporting a 
prolonged activation of downstream signalling pathways (Nahta 2011; Graus-Porta et al. 
1997). Notably, HER3 does not exert intrinsic tyrosine kinase activity and can only be 
activated by heterodimerisation with another ErbB receptor. In this regard, HER2/HER3 
heterodimers are considered to be the most potent oncogenic EGFR receptor family 
heterodimer combination (Alimandi et al. 1995; Yarden 2001).  
Current therapeutic strategies employed to treat HER2+ tumours are aimed at targeting the 
HER2 receptor itself. The humanised murine HER2-targeted monoclonal antibody (mAb 
4D5) Trastuzumab (Herceptin, Genentech )(Carter et al. 1992) was developed for this 
purpose and approved in the United Kingdom as an adjuvant treatment in 2006.  
The mechanism of action of Herceptin is thought to involve different aspects: 
1) Inhibition of HER2-mediated downstream signalling, particularly of the PI3K/AKT and 
MAPK pathways.  This can result from the Herceptin-mediated uncoupling and inactivation 
of HER2/HER3 heterodimers (Yakes et al. 2002; Junttila et al. 2009), and also from the 
inhibition of Src association with HER2 and thereby preventing Src-mediated 
phosphorylation of the phosphatase and tensin homolog (PTEN). This consequently 
stabilises PTEN, increasing its membrane localization and activity; that is to prevent the 
activation of the PI3K/AKT pathway (Nagata et al. 2004).  
2) Inhibition of HER2 cleavage and shedding of the p95HER2 fragment from the cell surface, 
known to retain the ability to form heterodimers with HER3 (Molina et al. 2001) and thus, 
high expression levels of this fragment correlated with poor patient outcomes and 
metastatic progression (Molina et al. 2002; Sáez et al. 2006).  
3) Induction of antibody-dependent cellular cytotoxicity (ADCC) (Collins et al. 2012). This is 
supported by clinical data wherein Herceptin-treated patients demonstrate higher 
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infiltration of leukocytes and natural killer cells in the tumours (Gennari et al. 2004; Arnould 
et al. 2006). 
4) Inhibition of angiogenesis. In vivo studies have demonstrated that Herceptin has reduced 
the expression of pro-angiogenic factors such as VEGF, TGF-α, Ang-1 and PAI-1, which  
correlated with significantly reduced diameter and volume of tumour blood vessels, 
decreased vascular permeability and importantly, decreased tumour growth (Izumi et al. 
2002).  
1.1.6 Therapeutic resistance 
1.1.6.1 Resistance to endocrine agents 
The expression of ER is indeed a marker of response to endocrine therapy however, 
resistance remains a problem, and this can be de novo (existing before treatment) or 
acquired (developed at some point during treatment) resulting in disease recurrence, 
frequently at distant sites (Osborne & Schiff 2011). 
A number of mechanisms have been proposed for this such as various modifications to ER 
function/expression; by genetic mutations such as the Tyr537Asn missense mutation 
identified in the ER gene or epigenetic modifications such as CpG island hypermethylation 
(Zhang et al. 1997; Ottaviano et al. 1994). Over-expression of ER co-activators (e.g.AIB1) and 
in converse, downregulation of co-repressors (e.g.NCoR), may consequently alter the 
transcriptional activation by ER (Ring & Dowsett 2004). In other studies, the endocrine 
therapy Tamoxifen has been shown to also trigger a compensatory  induction of parallel 
growth-signalling pathways via cross-talk with EGF receptor family members (particularly 
EGFR and HER2), which leads to increased activity of AKT and MAPK, enabling cells to adapt 
and sustain proliferation (Jordan et al. 2004; Gee et al. 2001). 
 
It is also reported that ER+ tumours that also express the HER2 receptor is correlated with 
higher relapse rates and mortality (Cheang et al. 2009). Evidence from clinical trials showed 
that patients with a HER2+ status showed a significantly poor overall response rate to 
endocrine therapy (Carlomagno et al. 1996; Houston et al. 1999; Dowsett et al. 2001). In 
vitro, breast cancer cell lines transfected with HER2 displayed oestrogen-independent 
growth and resistance to endocrine therapy (Pietras et al. 1995). Together, these suggest a 
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cross-talk between the ER and HER2 signalling pathways, and the understanding of this ER 
and HER2 cross-talk is particularly important particularly in the context of therapeutic 
resistance.   
 
It is recognised that a critical mediator in which cross-talk can occur is attributed to a pool of 
ER that resides in the cytoplasm or at the plasma membrane. As described in section 
1.1.4.1, ER can directly activate intracellular kinases such as Src and RTKs including EGFR and 
IGF1-R (Razandi et al. 2003; Kahlert et al. 2000). Conversely, the downstream components 
of HER2-signalling, AKT and MAPK signalling for example can result in ER activation by direct 
phosphorylation at ser167 and ser118 residues (Yamashita et al. 2008). Activation of MAPK 
could also regulate activity of ER indirectly by phosphorylation of the co-activator A1B1, 
enhancing its interactions with ER dimer/ERE complex (Font de Mora & Brown 2000). 
Interestingly, it has also been shown that MCF7 cells that have developed resistance to 
Tamoxifen expressed elevated EGFR/HER2 signalling with an accompanying increase in AKT 
and MAPK activity (Knowlden et al. 2003; Jordan et al. 2004). It is therefore clear that cross-
talk between ER and RTK signalling such as that mediated by HER2 is critical to the survival 
of cancer cells and is widely implicated in the development of resistance to endocrine 
therapies.  
 
1.1.6.2 Resistance to Herceptin 
 
Despite the fact that Herceptin has had significant success in HER2+ tumours, approximately 
20% and 70% of early and metastatic HER2+ breast cancer patients respectively will display 
de novo resistance to Herceptin (Wilken & Maihle 2010). In a study, the inclusion of 
Herceptin with chemotherapy significantly increased the time to disease progression (TTP) 
to 7.4 compared to  4.6 months in patients that received chemotherapy alone (Slamon et al. 
2001). Despite this benefit, this data indicates that following an initial response, acquisition 
of resistance and disease progression can occur within a year of Herceptin treatment 
initiation, thereby representing a significant hurdle. Several mechanisms underlying either 
the de novo or acquired resistance to Herceptin have been proposed. Amongst those 
mechanisms suggested to contribute to resistance, the following have attracted most 
attention. 
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1) Increased expression of the p95HER2 fragment. Truncated HER2 may be generated by 
alternative splicing or proteolytic cleavage of the full-length HER2 by the action of MMPs 
(Codony-Servat et al. 1999; Arribas et al. 2011). Transcriptome analysis of cells transfected 
with the p95HER2 fragment revealed up-regulated genes often involved in metastasis 
(e.g.MMP1, ANGPTL4, MET), and indeed, in vivo studies on p95HER2 transgenic mouse 
strains, have shown shorter tumour latency period and far more aggressive and metastatic 
tumours than those mouse strains with full-length HER2 (Pedersen et al. 2009). Clinically, 
elevated p95HER2 levels also correlated with significantly shorter progression-free survival 
in HER2+ metastatic breast cancer patients (Sperinde et al. 2010).  
2) PIK3CA mutations or low/loss of PTEN expression.  These lead to hyper-activation of the 
AKT survival pathway, and  such an amplification has  been linked with shorter time-to-
progression and poorer patient survival (Berns et al. 2007; Razis et al. 2011). 
3) Alternative compensatory growth pathways. Persistent inhibition of the HER2 signalling 
pathways by Herceptin could evoke alternative growth pathways, an example of this is the 
insulin growth factor receptor 1 (IGFR-1) pathway. This has been shown in a study by Lu et 
al.,  whereby Herceptin inhibited growth of MCF7/HER2+ cells (IGFR-1 expressing) only with 
concomitant treatment of IGFR-1 blocking antibodies.  They also demonstrate that IGFR-1 
transfection of HER2+ SKBR3 cells rendered them resistant to Herceptin (Lu et al. 2001). 
Recent studies also implicate alterations in intracellular components of the IGF-1 pathway 
particularly the balance between IGF-binding proteins IGFBP-2 and IGFBP-3 in the process of 
resistance (Lu et al. 2001; Dokmanovic et al. 2011).  
4) HER2 epitope masking. A study on the Herceptin-resistant JIMT cell line, revealed higher 
levels membrane-associated glycoprotein known as mucin (MUC4) compared to sensitive 
cell lines. This protein has been shown to contribute to the masking of membrane proteins 
including HER2, which may interfere with Herceptin binding. Accordingly, knockdown of 
MUC4 expression by siRNA increased the binding of Herceptin (Nagy et al. 2005). MUC4 
mRNA and protein expression were also elevated in a ER+/HER2+ xenograft tumours, which 
have become resistant to the combination of endocrine and HER2-targeted therapy (Chen A 
et al. 2012).  
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5) Other resistance mechanisms. These include the up-regulation of ErbB ligands. Herceptin-
treatment of HER2+ breast cancer cells was reported to trigger a negative-feedback loop 
that led to the upregulation of ADAM17 and the subsequent cleavage of ErbB ligands 
including heregulin and betacellulin, which in turn bind to ErbB receptors and consequently 
transactivate HER2 (Gijsen et al. 2010). Integrin-mediated signalling and the activation of 
downstream mediators including FAK and Src have also been implicated in Herceptin 
resistance in various independent studies (Yang et al. 2010; Zhang et al. 2011; Peiró et al. 
2014). Moreover, increased expression of the Met and the EphA receptor (Shattuck et al. 
2008; Zhuang et al. 2010), miR-21 (Gong et al. 2011) and deregulated glycolysis (Zhao et al. 
2011) are also reported to contribute to Herceptin resistance.  
1.1.7  Other HER2-target therapies 
Since relapse following Herceptin treatment frequently occurs, understanding resistance 
mechanisms are therefore crucial to aid the optimisation of existing treatments and the 
development of new therapeutic strategies for this disease.  
Accordingly, alternative ways of inhibiting the HER2 pathway have been investigated 
resulting in the development of novel anti-HER2 therapeutics. Lapatinib (Tykerb®; 
GlaxoSmithKline), an ATP competitive inhibitor of the intracellular kinase domain of EGFR 
and HER2, was able to induce apoptosis in HER2+ SKBR3 derived-Herceptin-resistant cells 
(Nahta et al. 2007). In clinical studies, Lapatinib in combination with capecitabine improved 
progression-free survival (PFS) in patients with advanced HER2+ breast cancer who have 
progressed following treatment regimens comprising of chemotherapy and Herceptin 
(Geyer et al. 2006). In a Phase III study, the combination of Herceptin with Lapatinib 
resulted in a significantly higher pathological complete response (pCR) rate than those given 
Herceptin alone (Baselga, Bradbury, et al. 2012). Lapatinib in combination with 
chemotherapy was also shown to significantly improve overall survival by a mean of 3.2 
months (Guan et al. 2013).  
Another emerging HER2 targeted therapy is Pertuzumab (Omnitarg®; Genentech) which, like 
Herceptin, is a humanized monoclonal antibody that binds to the extracellular dimerization 
domain II of HER2 and inhibits hetero-dimerization of HER2 with other ErbB receptors. In a 
study of 808 patients, those receiving Docetaxel + Herceptin had a median PFS of 12.4 
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months versus those treated with Docetaxel + Herceptin + Pertuzumab (median PFS of 18.5 
months)  (Baselga et al. 2012).  
More recently, trastuzumab-DM1 (TDM1) (Kadcyla® Roche), which is a conjugate of the 
antibody Trastuzumab (Herceptin) to a cytotoxic drug emantasine has been shown to be 
effective even in HER2+ cells as well as those that are Herceptin-resistant (Lewis Phillips et 
al. 2008). This therapy is now currently being investigated as a potential therapeutic option 
in early and metastatic HER2+ breast cancer in number of clinical trials; MARIANNE 
(NCT01120184) and KATHERINE (NCT01772472) . 
Other strategies are also currently under investigation which include inhibitors of Heat 
Shock protein 90 (Hsp90) to induce HER2 degradation, as well as vaccines that elicit a 
response to  the HER2-antigen (Meric-Bernstam & Hung 2006; Ladjemi et al. 2010). 
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1.2 Focal Adhesion Kinase (FAK) 
 
Focal Adhesion Kinase (FAK) also emerged as a key effector of HER2 signalling, and the 
levels of FAK expression strongly correlated with HER2 overexpression in breast tumour 
samples (Benlimame et al. 2005; Xu et al. 2009; Schmitz et al. 2005; Behmoaram et al. 
2008). FAK is involved in many different pathways involved in the regulation of cellular 
process including survival, growth, migration and invasion; many of these have been 
implicated in cancer. Targeting of FAK thus may be an appropriate therapeutic option in 
many cancers, including breast cancer. This thesis will focus on FAK and explore its role and 
therapeutic potential in breast tumours that overexpress HER2.  
1.2.1 Structure and activity 
 
FAK was originally described in 1992 as a 125kD protein that was tyrosine phosphorylated in 
Rous sarcoma virus-transformed chick embryos. Immuno-staining analysis showed cellular 
localisation of this protein at specialised regions on the cell surface termed focal adhesions 
(FAs). Then, the role of FAK was found to serve as a key signalling component at these sites 
in response to integrin clustering and adhesion to the extracellular matrix component 
fibronectin (Kornberg et al. 1992; Schaller et al. 1992). 
FAK is now understood to be a ubiquitous non-receptor tyrosine kinase and a key 
component of focal adhesions, essentially providing a link between the extracellular 
environment and the cell cytoplasm. It is known to be activated following integrin-clustering 
and also following the activation of several growth factor receptors where it serves to 
integrate these diverse signals to regulate biological processes such as cell adhesion, 
proliferation, survival, apoptosis, migration and invasion. As such, FAK is described to be 
essential for physiological processes such as embryonic development and wound healing. 
Interestingly, the role of FAK in the former may well involve its ability to promote 
vascularisation of tissues and organs, since endothelial cell FAK deletion disrupts mice 
vasculature  (Braren et al. 2006) and FAK-null mice have severely impaired development of  
the  cardiovascular system (Ilić et al.1995).  
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1.2.2 FAK structure 
The human FAK amino acid sequence is highly conserved between species with 
approximately 90% sequence homology to mouse and frog (Schaller 2010). It is comprised 
of three well-defined domains; (1) a central tyrosine kinase domain flanked by (2) N-
terminal and (3) C-terminal domains (Figure 1.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.3 FERM domain 
 
The FERM domain within the N-terminal region is structurally conserved in many proteins 
such as talin, JAKs, ERM (ezrin-radixin-moesin) and many non-receptor protein 
phosphotyrosine phosphatases (Girault et al. 1999). The FERM domain of FAK directly 
Figure 1.5 FAK structural domain and its interacting partners. Phosphorylated tyrosine residues 
(Y397,Y576,Y577,Y861,Y925) are represented above. These phosphotyrosine residues as well as 
proline-rich domains (Pro) provides binding sites for a number of targets which in turn elicit signals 
that regulate various cellular processes. Four-point-one, ezrin, radixin, moesin (FERM), Focal 
Adhesion target (FAT), ADP ribosylation factor [ARF]- GTPase-activating protein [GAP] containing 
SH3, ANK repeats, and PH domain (ASAP). 
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interacts with the kinase domain of the protein to repress its activity and thus acts as 
negative regulator as has been experimentally supported by studies which have shown that 
deletion of the FERM domain promotes an increase in FAK activity (Cooper et al. 2003). 
Adding to this, structural studies have shown that the FERM domain directly binds the 
kinase domain, and sterically isolates the tyrosine residues to prevent phosphorylation 
(Lietha et al. 2007).  
The FERM domain also mediates protein-protein interactions with the cytoplasmic tails of 
β1 integrins and growth factor receptors such as PDGFR and EGFR. These interactions 
release the auto-inhibitory conformation of the FERM domain, resulting in FAK activation, 
(Schaller et al. 1995; Sieg et al. 2000; Golubovskaya et al. 2002).  
Further analysis of the FERM domains reveal potential nuclear export signals (NESs) and 
some nuclear localization signals (NLSs) which allows events at the cell periphery to be 
transferred co-ordinately to the nucleus (Frame et al. 2010). The relevance of nuclear FAK is 
highlighted by a study showing the FERM domain acting as a scaffold to facilitate p53 and 
Mdm2 association leading to p53 ubiquitination and promotion of cell survival, an event 
thought to occur in cases of cellular stress or reduced integrin signalling (Lim et al. 2008). 
1.2.4   Central kinase domain 
 
The central tyrosine kinase domain is necessary for its catalytic activity and mediating 
downstream signalling activity. Located within this is the major autophosphorylation site for 
FAK, tyrosine 397 (Y397) which modulates FAK-mediated signalling by creating high-affinity 
binding sites for SH2-containing proteins such as Src, PI3K, phospholipase C  (PLC ), and 
growth-factor-receptor-bound protein-7 (GRB7) (Schaller et al. 1994; Zhang et al. 1999; Han 
& Guan 1999; Chen 1994). Binding of Src is involved in the activation of Src which, in turn, 
allows Src to phosphorylate additional tyrosine residues including two within the central 
kinase domain, Y576 and Y577, which are necessary for maximal FAK kinase activity (Calalb 
et al. 1995).  Phosphorylation at Y397 and Y576/Y577 residues were found to be crucial for 
efficient disassembly of focal adhesions and consequently for cell migration (Hamadi et al. 
2005). More recently, additional factors have been identified that can activate FAK through 
binding to the FERM domain such as has been shown with the RET receptor  that can 
directly phosphorylate the Y576/577 residues (Plaza-Menacho et al. 2011).  
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1.2.5  C-terminal domain 
The C-terminal domain harbours the FAT sequence and two proline-rich domains. The FAT 
domain is required for localization of FAK to focal adhesions and is thought to occur by the 
direct interaction of the FAT domain with other proteins such as paxillin and talin, that can 
in turn interact with the cytoplasmic tails of β1 integrins clustered at focal adhesions 
(Schlaepfer et al. 2004; Hildebrand et al. 1993) 
 
The phosphorylation sites Y861 and Y925 are also situated within the FAT domain. The Src-
dependent phosphorylation of the Y861 residue was shown to regulate interaction of 
p130Cas adaptor protein to the FAK C-terminal proline-rich regions, given its proximity to 
these sites (See Figure 1.5). This was found to mediate the Ras-induced transformation of 
fibroblasts (Lim et al. 2004). pFAK Y861 is important in promoting the association of FAK 
with an αvβ5 integrins following VEGF stimulation of endothelial cells (Eliceiri et al. 2002). 
As such, pFAK Y861 may have an essential role in VEGF-mediated vascular responses. pFAK 
Y925 on the other hand, similarly phosphorylated by Src, provides a binding site for the 
Grb2 adaptor protein, which subsequently recruits SOS, to activate Ras/MAPK survival 
signalling (Mitra et al. 2005). 
 
The two C-terminal proline-rich domains mediate interactions SH3 domain-containing 
proteins including p130Cas as described above. One of the downstream events following 
p130Cas activation is the binding of the Crk adaptor protein and subsequent activation of 
Rac, to promote membrane ruffling, lamellipodia formation and actin reorganization 
(Sharma & Mayer 2008). MAPK activation has also been suggested to occur following 
p130Cas activation, an alternative pathway in addition to that mediated by pFAK Y925/Grb2 
interactions (Schlaepfer et al. 1997). p130cas also regulates survival signalling, by activating 
the Ras/Rac1/Pak1/MAPK kinase 4 (MKK4) pathway to activate c-Jun NH2-terminal kinase 
(JNK), a pathway observed to be activated in the absence of growth factors (Almeida 2000). 
Other SH3-domain containing proteins that bind to the proline-rich domains include Graf 
and ASAP1, which have been implicated in the regulation of focal adhesion assembly and 
cytoskeletal remodelling respectively  (Schlaepfer et al. 2004).  
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1.2.6 FAK splice variants 
 
The human FAK  gene consists of at least 44 exons and  at least eight un-translated regions 
(Corsi et al. 2006) and multiple FAK transcripts have been reported as a result of alternative 
splicing or the use of alternative promoters. Whilst most alternative FAK isoforms are 
reported in rat and mouse, some have been identified in the adult human brain (Corsi et al. 
2006). The most well-characterised variant is FRNK (FAK related non kinase), which consists 
of just the C-terminal domain of FAK. FRNK competes with FAK for localisation at focal 
adhesions (via the FAT domain), and because it lacks the N-terminal and kinase domain it is 
able to attenuate normal FAK signalling functions (Schaller et al. 1993). FRNK expression in 
mammalian cells is often restricted, although it has been detected in rat aortic smooth 
muscle cells and is up-regulated two weeks after induced vascular injury (Taylor et al. 2001). 
FRNK has been considered to act as a naturally-occurring dominant negative FAK and its 
expression has been shown to inhibit cell proliferation, cell adhesion, cell invasion and 
promote  apoptosis (Schlaepfer et al. 2004). 
More recently, an alternatively spliced FAK transcript lacking exon 33 was identified in 
breast and thyroid tumour specimens. Interestingly this FAKdel33 mutant exhibited higher 
FAK phosphorylation at Y397, Y576/7 and Y925 residues than the WT-FAK, and was found to 
be associated with enhanced cell migratory behaviour (Fang et al. 2013). 
1.2.7 Regulation of FAK kinase activity 
 
It has been has previously demonstrated that point mutations (Lys to Glu) within the kinase 
domain residues FAK-K578 and FAK-K581 resulted in a “super-FAK” which  displayed 
adhesion-independent elevated catalytic activity compared with wild-type FAK (Gabarra-
Niecko et al. 2002). The occurrence of these spontaneous mutations in FAK however is not 
reported, although the characterisation of this active FAK mutant provides a useful 
experimental tool to elucidate the catalytic activities of FAK. 
There are also identified proteins that serve to inhibit FAK activity,  one which is  the FAK-
interacting protein 200 (FIP200) which directly binds to the kinase domain of FAK (Abbi et al. 
2002). Protein tyrosine phosphatases (PTPs), of which PTPα has been shown to positively 
regulate FAK phosphorylation (Zeng et al. 2003), and conversely SHP2 acts to 
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dephosphorylate FAK in response to various stimuli (Mañes et al. 1999; Vadlamudi et al. 
2002). There is also evidence that PTEN is able to interact with FAK and induce its de-
phosphorylation, resulting in the inhibition of migration and invasion  of the  glioblastoma 
cell line U87MG (Tamura et al. 1998; Tamura et al. 1999).  
 
1.2.8 FAK family members 
 
The only other member of FAK family is proline-rich tyrosine kinase 2 (Pyk2), also called cell 
adhesion kinase β (CAKβ). It shares a similar structural organization as FAK, with 
approximately 45% amino acid sequence similarity. It is highly expressed in the central 
nervous system, and whereas FAK is often activated by integrin engagement, Pyk2 is  
activated by various stimuli that lead to the increase in intracellular calcium levels (Yu et al. 
1996). Pyk2 null mice are viable, without significant developmental defects, however, it has 
been shown to crucial  for the migratory behaviour of macrophages (Okigaki et al. 2003). 
Pyk2, unlike FAK, are often located in the peri-nuclear regions than in focal adhesions 
suggesting that they may interact with different proteins (Klingbeil et al. 2001). Although, it 
has been shown that Pyk2 can partially  rescue the cell motility defects in FAK−/− mouse 
fibroblasts, which is attributed to its ability to interact with the cytoplasmic tails of β1 
integrin at focal adhesions (Klingbeil et al. 2001).  
Since many functions of FAK are shared by its isoforms, particularly Pyk2, there is 
considerable interest in understanding its distinct functions in cancer progression, although 
it still remains unclear.  
1.2.9 Role of FAK in cancer 
 
Given that FAK is the central hub of multiple signalling pathways that regulate various 
cellular processes, it is not surprising that FAK is also implicated in cancer development and 
spread. For example, evidence shows that FAK activity promotes the anchorage-
independent growth of kidney epithelial cells and renders them resistant to an apoptotic 
response known as anoikis (Frisch et al. 1996). This was one of the early suggestions of the 
important role of FAK in cancer.  
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Over the recent years, over-expression and/or increased activity of FAK has been reported 
in a wide variety of human cancers including the larynx, colon, acute myeloid leukaemia, 
melanoma and breast (van Nimwegen & van de Water 2007; Gabarra-Niecko et al. 2003; 
Kahana et al. 2002; Recher et al. 2004; Watermann et al. 2005). Contradicting work 
regarding the clinical relevance of FAK expression have also been reported; whereby FAK 
overexpression was not correlated with prognosis of pancreatic tumours (Furuyama et al. 
2006), whilst reduced FAK expression correlated with poorer outcome in cervical tumours 
(Gabriel et al. 2006). Moreover, a recent study also demonstrated that pFAK Y397 
dephosphorylation resulting from Ras activation was correlated with increase migratory and 
invasive behaviour of 3Y1 rat fibroblasts (Zheng & Lu 2014).  
In a study of several breast cancer cell lines, amplified copy numbers of the FAK gene were 
present a number of breast cancer cell lines  (Agochiya et al. 1999). High FAK gene copy 
number in invasive breast tumour specimens as detected by fluorescence in situ 
hybridization (FISH) was significantly associated with shorter overall survival and RFS (Yom 
et al. 2011). FAK protein  overexpression has been linked to progression of ductal carcinoma 
in situ (DCIS) and infiltrating ductal carcinoma (IDC) lesions, as well as in invasive and 
metastatic lesions  (Owens et al. 1995; Lightfoot et al. 2004; Lark et al. 2005). Furthermore, 
FAK overexpression has been associated with poor tumour prognostic markers including 
high mitotic index, nuclear grade 3, architectural grade 3, ER- PR- status (Lark et al. 2005). A 
more recent study has also demonstrated that the overall patient survival was significantly 
worse in those with high FAK expression in metastatic tumour (logrank p = 0.003) and 
correlated with a younger age of patients, lymphovascular invasion and with the TNBC 
subtype (Golubovskaya et al. 2014). 
Mouse studies have also demonstrated the role of FAK in breast cancer. Mammary 
epithelial-specific FAK knockout mice (FAK flox/flox) exhibit a delay in tumour formation, and 
once present, tumours are slow-growing, smaller and with significantly impaired ability to 
metastasise to the lungs compared to the FAK+/+ and FAK +/flox mice. Additionally, tumour 
cells from  FAK flox/flox   mice display proliferation and cell-cycle progression gene expression 
changes, as well as suppressed activity of Src, MAPK and p130cas (Provenzano et al. 2008). 
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Interestingly, FAK is emerging as a major player in stem cells. Luo et al. (2009) also 
demonstrated that these FAK flox/flox mice have depleted mammary cancer stem cell 
(MaCSCs) content in their primary tumours. Notably, the isolated MaCSCs had impaired self-
renewal and migratory capabilities in vitro, and subsequent transplantation onto a NOD-
SCID mice revealed compromised tumourigenicity  and impaired maintenance of self-
renewal ability, altogether suggesting an important role of FAK in the regulation of MaCSCs, 
which are now thought to be critical to tumour persistence and drivers of drug resistance 
and disease recurrence (Guan 2010). 
Unequivocally, FAK is regarded as a key mediator of signals from both integrins and growth 
factor receptors and signalling downstream of FAK regulates a variety of cellular processes. 
The evidence associating FAK with these processes will be described below, with relevance 
to those implicated in malignancy and tumour progression. 
1.2.9.1 Cell survival and proliferation 
Early findings of Frisch et al. (1996) implicated FAK as a mediator of anchorage-independent 
survival. Subsequently, experimental evidence confirmed this showing for example, that 
overexpression of FAK in glioblastoma cells rendered them resistant to ionising radiation-
induced apoptosis (Kasahara et al. 2002). In this case, FAK appeared to act through a 
mechanism involving FAK-induced PI3K/AKT survival pathway activation and induction of 
inhibitor-of-apoptosis proteins cIAP-2 and XIAP which are endogenous inhibitors of 
caspases. Further studies by this group and others subsequently revealed that FAK-
overexpressing cells had increased expression of cell cycle regulators such as cyclins D3 
(Yamamoto et al. 2003) and D1 (Zhao et al. 2001; Zhao et al. 2003) likely to promote cell 
cycle progression. Importantly, inhibition of FAK has been shown to enhance cytotoxicity of 
chemotherapeutic drugs (Halder et al. 2005; van Nimwegen et al. 2006; Chen et al. 2010) 
potentially by removing their FAK-induced survival advantage rendering them more 
sensitive to chemotherapeutic agents.  
  
1.2.9.2 Cell migration and invasion 
FAK has long been regarded as a regulator of cell migration and invasion and therefore a 
potential supportive element in the process of metastasis.  Early studies have demonstrated 
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that fibroblasts from FAK-deficient mice had increased number of focal adhesions and an 
augmented migratory capacity, implicating a role for FAK in the turnover of focal adhesions 
(Ilić et al. 1995). Overexpression of FAK in chinese-hamster ovarian (CHO) cells stimulated 
cell migration relative to that of cells expressing only endogenous levels of FAK (Cary et al. 
1996). This study and others (Owen et al. 1999; D. J. Sieg et al. 1999; Hamadi et al. 2005) 
have also illustrated the requirement for FAK kinase activity for this migratory response.  
Additional studies have also identified that the ability of FAK to control cell migration arises  
through engagement with multiple effectors which in turn regulate focal adhesion dynamics 
and cytoskeletal arrangement (see table 1.2)   
FAK target       Resulting migratory-associated effects Reference 
paxillin Focal adhesion disassembly (Webb et al. 2004) 
talin Focal adhesion disassembly (Chen et al. 1995) 
MAPK/ERK -Phosphorylates and activates MLCK to promote 
actomyosin contractility.  
-calpain activation resulting in focal adhesion disassembly 
(Webb et al. 2004; 
Cuevas et al. 2003) 
p 130cas - Binds with the adapter protein Crk, leading to Rac 
activation to enhance membrane ruffling and 
lamellipodia formation.  
-Focal adhesion disassembly 
 
(Webb et al. 2004; 
Cho & Klemke 2002; 
Sharma & Mayer 
2008) 
Grb7 -recruited at focal adhesions to modulate paxillin, MAPK 
and AKT activity 
(Han et al. 2000) 
(Chu et al. 2009) 
PI3K/AKT -cooperates with p130cas to promote migration  
-phosphorylates Girdin, an actin-binding protein to 
facilitate lamellipodia formation 
(Reiske et al. 1999; 
Enomoto et al. 2005) 
α-actinin -Release of actin stress fibres from focal contacts (Izaguirre et al. 
2001) 
p190RhoGAP  -decrease RhoA activity to promote focal adhesion 
disassembly 
 -Establishment of cell polarity 
(Ren et al. 2000; 
Tomar et al. 2009) 
P190 RhoGEF -increase RhoA activity and promote focal adhesion  
assembly 
-Stabilisation of microtubules at the leading edge of the 
migrating cell  
(Zhai et al. 2003; Y. 
Lim et al. 2008; 
Palazzo et al. 2004) 
Cdc42 -subsequent activation of N-WASP to stimulate the 
Arp2/3 complex to initiate actin fibre assembly  (Sanchez et al. 2013) 
Table 1.2  Key FAK effectors involved in FAK-mediated migratory processes  
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FAK has also been proposed to function in cell invasion, a process distinct from but involving 
migration in that it requires the active proteolytic degradation of the surrounding matrix 
(McCawley & Matrisian 2000).  FAK overexpression in v-src transformed fibroblasts was 
associated with the co-localization of FAK/Src complex together with β1 integrins at 
invadopodia protrusions and correlated with increased cell invasion through Matrigel 
(Hauck et al. 2002).  Accordingly, expression of a dominant-negative FRNK in these 
fibroblasts inhibited invasion through Matrigel, as well as suppressed experimental lung 
metastases in nude mice, without effects on cell migration. These were attributed with the 
decrease in the expression and secretion of MMP2 (matrix-metalloproteinases-2) (Hauck 
2002).  Further studies also support the role for FAK signalling in the expression of other 
proteases, such as  MMP9 and MT1-MMP (Wu et al. 2005; Hsia et al. 2003), altogether 
supporting the role for FAK in cell invasion, particularly by regulating MMP-mediated matrix 
degradation.  
1.2.9.3 Angiogenesis 
In vivo studies using targeted deletion of FAK in endothelial cells showed multiple 
phenotypes attributed to impaired embryonic angiogenesis which contributed to embryonic 
lethality (Shen et al. 2005). Conversely, overexpression of FAK in vascular endothelial cells 
potentiated angiogenesis in response to induction of skin-wound and hind-limb ischaemia in 
a transgenic mice (Peng et al. 2004). These along with the earlier work by Ilic (1995), 
suggested the role for FAK in angiogenesis; the process by which new blood vessels are 
formed from pre-existing ones. With regards to the tumour, angiogenesis  is essential  to 
facilitate the supply of oxygen and nutrients and an avenue in which tumour cells can 
migrate to distant sites (Liekens et al. 2001). The role of FAK in tumour angiogenesis was 
attributed to its phosphorylation at Y925, whereby it activates the MAPK signalling pathway, 
associated in part in regulating VEGF expression (Mitra et al. 2006). pFAK Y861 was also 
shown in a separate study to mediate VEGF-regulated endothelial cell migration and survival 
(Abu-Ghazaleh et al. 2001 ). In vivo, mice that have FAK specifically deleted in their ECs and 
were subcutaneously injected with melanoma cells displayed impaired tumour angiogenesis 
which resulted in decreased tumour growth when compared to control.  In vitro isolation of 
these ECs with FAK deletion  demonstrated impaired migratory response to VEGF, 
decreased proliferation and enhanced apoptosis (Tavora et al. 2010). In a separate study, 
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endothelial FAK deletion also resulted in decreased growth of brain tumours and is 
associated with tumour vasculature that are longer, thinner, less branched and have 
reduced permeability (Lee et al. 2010). In accordance, it has been recently demonstrated 
that endothelial FAK mediates the phosphorylation of vascular endothelial cadherin (VEC), 
in response to VEGF stimulation, subsequently leading to VEC internalisation and 
disturbance of endothelial cell-to-cell junctions, enabling tumour cell transmigration. They 
have further shown in vivo that FAK inhibition prevented VEGF-induced tumour cell 
extravasation into lung micro-vessels, and significantly inhibited the formation of lung 
metastasis (Jean et al. 2014).  
1.3 FAK as a potential therapeutic target 
Taken together, due to the substantial evidence linking elevated FAK protein levels with a 
range of human tumour types including the breast, together with the role for FAK in various 
aspects of tumour progression, FAK is emerging to be a novel therapeutic target in cancer. 
Indeed, these studies have prompted the development of various FAK inhibitors, with the 
focus on targeting the autophosphorylation site of FAK, Y397. Some of these inhibitors and 
their progress in the clinical setting are summarized in Table 1.3 below.  
 
Inhibitor Target In vitro/In vivo anti-
tumourigenic effects, clinical 
trials  
References 
TAE-226 FAK,Pyk2,IGF1-R Breast, glioma, oesophageal 
cancers 
(Wang et al. 2008; Shi et 
al. 2007; Golubovskaya, 
Virnig, et al. 2008) 
PF-562271 (PF271) FAK, Pyk2 Pancreatic, ovarian, breast, lung, 
colon, glioblastoma cancers. 
 Phase I clinical trial (Pfizer) 
(Stokes et al. 2011; Ward 
et al. 2013; Roberts et al. 
2008; Infante et al. 2012) 
PF045558878 
(PF878/VS-
6063/defactanib) 
FAK, Pyk2 Breast*, ovarian*, thyroid cancer 
  Ongoing Phase I,II trials in 
patients with non-
haematological 
malignancies (Verastem 
Inc.). 
 Ongoing Phase I/Ib trial in 
ovarian cancer (Verastem 
Inc.) 
 
(Xu et al. 2014; Pachter 
et al. 2014; Kolev et al. 
2014; O’Brien et al. 
2014) 
PND-1186 (VS4718) FAK, Pyk2 Breast*, lung (mesothelioma), 
leukaemia, ovarian cancer*  
 Ongoing Phase 1 trial in 
(Walsh et al. 2010; Kolev 
et al. 2014; Trombino 
et.al. 2014) 
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patients with metastatic 
non-haematological 
malignancies (Verastem 
Inc.) 
Y15 (Compound 14) FAK (allosteric 
inhibitor of FAK, 
also shown to 
inhibit scaffolding 
functions) 
Thyroid, colon, pancreatic, breast, 
lung, melanoma, glioblastoma 
cancer 
(O’Brien et al. 2014; 
Heffler et al. 2013; 
Golubovskaya, Nyberg, 
et al. 2008; 
Golubovskaya et al. 
2013) 
GSK2256098 FAK Pancreatic ductal adenocarcinoma, 
glioblastoma, 
 Ongoing Phase 1 trial in 
patients with lung 
(mesothelioma) or 
advance solid tumours  
(GlaxoSmithKline) 
(Chen et al. 2012; Zhang 
et al. 2014) 
Table 1.3 Compounds targeting FAK that are currently in preclinical and clinical trials. All compounds 
are ATP-competitive kinase inhibitors with the exception of Y15, which is an allosteric inhibitor. 
*Particularly potent in the cancer stem cell population 
 
1.4 FAK and HER2 in breast cancer 
 
As has already been described, FAK mediates multiple signalling pathways crucial to tumour 
progression and their overexpression correlates with poorer patient prognosis in breast 
cancer. A number of regulators of FAK have been identified including integrins and growth 
factor receptors, of which HER2 represents an important component. For example, 
Heregulin (ErbB receptor ligand) stimulated HER2 activation results in the Src-dependent 
phosphorylation of FAK at Y861 which is accompanied by changes in focal adhesion 
distribution and the formation of membrane ruffles in HER2-overexpressing MCF7 cells 
(Vadlamudi et al. 2003). Moreover, re-expression of wild-type FAK in FAK-/- HER2/3 
overexpressing cells rescued their anchorage-independent growth-defective phenotype. In 
addition, these cells induced a more aggressive tumour growth and increased incidence of 
lung metastases compared with FAK -/-HER2/3 cells when implanted into the mammary-fat 
pad of a severely immunosuppressed SCID mice (Benlimame et al. 2005). Moreover, FAK is 
key to the transduction of HER2 signalling in HER2-overexpressing MCF10A breast cancer 
cells, and in MUC4-overexpressing ovarian cells which also, have elevated HER2 activity 
(Ponnusamy et al. 2008; S. E. Wang et al. 2005). In breast tumours, a correlation between 
HER2 and FAK expression has been reported. In particular,  the levels of total FAK protein 
and pFAK Y861 also appear to be higher in HER2 overexpressing breast tumours, which 
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further correlated with increased AKT activity and poorer tumour differentiation (Schmitz et 
al. 2005). More recently, it was shown that Herceptin induced alterations in the appearance, 
localisation and dynamics of focal adhesions as well as suppressed invasion in FAK+/+ HER2+ 
cells, much less so in FAK-/-cells, though this was rescued upon re-expression of FAK, further 
supporting the link between HER2 and FAK signalling (Xu et al. 2009).  
 
1.5  Aims and Objectives 
In light of the evidence linking FAK and HER2 and the fact that HER2  cancers are a poor 
prognostic subtype that frequently exhibit resistance to targeted therapy, we hypothesised 
that FAK might represent an important target in HER2+ cancers.  
 To investigate this hypothesis we set the following objectives: 
■ Explore the functional relevance of FAK in a panel of cell models reflective of 
different HER2+ breast cancer subtypes paying particular interest to the role of FAK 
in cell proliferative responses and the underlying signalling mechanisms. 
 
■Investigate the role of FAK in HER2-mediated migratory responses implicated in 
metastatic processes. 
 
■Explore whether the use of Herceptin in combination with the novel FAK inhibitor 
(PF878) (targeting the Y397 autophosphorylation site) might be a useful strategy to 
enhance/sensitize to the growth suppressive effects of Herceptin.   
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2. Methodology 
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2.1 Materials and Reagents  
2.1.1. Key drugs or reagents used 
 The FAK inhibitors used in this project were PF-04554878 (‘PF878’, a gift from 
Pfizer) and PF-562271 (‘PF271’, purchased from Tocris Bioscience (Roberts et al. 
2008)). Both compounds work as potent competitive ATP inhibitors of FAK, 
suppressing its kinase activity. Stock solutions were prepared in DMSO at a 
concentration of 5mM. 
 
The structures of PF271 (N-Methyl-N-(3-{[2-(2-oxo-2,3-dihydro-1H-indol-5-
ylamino)trifluoromethyl-pyrimidin-4-ylamino]-methyl}-pyridin-2-yl)-
methanesulfonamide) and PF878 (N-methyl-4-(4-((3-(N-methylmethan-3-
ylsulfonamido)pyrazin-2-yl)methylamino)-5-(trifluoromethyl)pyrimidin-2-
ylamino)benzamide are illustrated below. PF878, is a derivative of PF271 but with 
a side group modification to improve oral bioavailability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Trastuzumab (Herceptin, Roche Ltd) is a recombinant humanized monoclonal 
antibody produced in Chinese Hamster ovary (CHO) cells that selectively binds to 
the extracellular domain of HER2 receptor. Herceptin, provided in the form of 
Figure 2.1 Chemical structures of the FAK inhibitors (A) PF-562271 and (B) PF-04554878 
A 
B 
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white to pale yellow lyophilized powder, was reconstituted in RNAase-free 
sterile water to give a stock concentration of 100 μM.  
 
 Heregulin β1 (HRG, Sigma Aldrich UK), was provided in the form of lyophilized 
powder  containing 2.5 mg Bovine serum albumin (BSA) and was reconstituted in 
RNAase-free sterile water to give a stock concentration of 100μg/ml. 
 
 ‘Stattic’ is an irreversible STAT3 inhibitor (Sigma Aldrich) that directly interferes 
with the SH2 binding site of STAT3. The chemical name is 6-
Nitrobenzo[b]thiophene-1,1-dioxide and the structure illustrated below.  A 110mM 
stock solution was made by reconstituting 25mg/100μl of DMSO and stored in 
aliquots at -20°C where it is stable for up to one month. 
  
 
 
 
 
 
 
 
 All drugs/reagents were diluted to the final concentration in fresh cell culture 
medium on the day of experiments.  
  
Figure 2.2 Chemical structure of Stattic C8H5NO4S 
 44 
2.1.2 Other materials 
 
All other materials used throughout this study along with the companies from which 
they were sourced are listed in table 2.1 below. 
 
Material Source 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) 
Sigma Aldrich  
3D Culture 96 well BME Cell invasion assay kit Cultrex  
5X siRNA buffer solution Thermo Scientific 
30% Acrylamide solution Sigma Aldrich 
Alexafluor Fluorophores- 488, 594 Invitrogen  
TRITC-labelled actin phalloidin  Sigma Aldrich 
Ammonium Persulphate (APS) Sigma Aldrich 
EZ View Red Protein G/A Affinity Gel beads Sigma Aldrich 
Fungizone Invitrogen, Paisley UK 
Penicillin/Streptomycin Invitrogen, Paisley UK 
Aprotinin Sigma Aldrich 
BioRad Protein Assay Reagents A, B, S BioRad Laboratories Ltd 
Blue sensitive X-ray film Photon Imaging Systems 
Bovine Serum Albumin (BSA) Sigma Aldrich 
Bromophenol Blue BDH Chemicals 
Cell Culture Medium (RPMI 1640 and Phenol Red-free RPMI 
1640) 
Invitrogen, Paisley UK 
Chemiluminescence reagents (ECL,Pico, Dura, Femto,) Fisher Scientific UK 
Corning Standard Transwell Inserts (6.5mm diameter,8um pore 
size) 
Fisher Scientific UK 
Crystal Violet Sigma Aldrich  
Dimethyl sulphoxide (DMSO) Sigma Aldrich 
Di-thiothreitol (DTT) Sigma Aldrich 
Dharmafect Transfection Reagent Thermo Scientific  
DCCM-1 culture media Biological Industries 
Fibronectin (from Human plasma): 1mg/ml Sigma Aldrich 
Foetal Calf Serum Gibco UK 
Glycerol Fisher Scientific 
Glycine Fisher Scientific UK 
Leupeptin Sigma Aldrich 
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L-glutamine Sigma Aldrich 
Methanol Fisher Scientific UK 
NP40 Sigma Aldrich 
Ponceau S solution (0.1% w/v in 5% acetic acid) Sigma Aldrich 
Phenylarsine oxide Sigma Aldrich 
Phenylmethylsulfonyl fluoride (PMSF) Sigma Aldrich 
Precision Plus Protein Blue marker BioRad 
RhoA/Rac1/Cdc42 Activation Assay Combo Kit Cytoskeleton Inc. USA 
siRNA buffer (1X) diluted in H20 Sigma Alrich 
Sodium Azide Sigma Aldrich 
Sodium dodecyl sulphate (SDS) Sigma Aldrich 
Sodium Fluoride Sigma Aldrich 
Sodium Molybdate Sigma Aldrich 
Sodium Orthovanadate Sigma Aldrich 
Stripping buffer Fisher Scientific UK 
Tetramethylethylenediamine (TEMED) Fisher Scientific UK 
Triton-X 100 Sigma Aldrich 
Tween-20 Sigma Aldrich 
Trizma Base (Tris) Fisher Scientific 
Vectashield mounting medium (hardset) containing DAPI  Vectorlabs 
        Table 2.1 List of materials used throughout the project 
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All primary and secondary antibodies used for immuno-based detection assays are 
listed in Table 2.2 below.  
Table 2.2 List of antibodies used throughout the project. For Western Blotting the antibodies  were 
used at a dilution of 1:1000 with the exception of the loading controls β-actin and GAPDH which 
were used at a dilution of 1:15,000. 
 
 
 
 
 
Target protein Species Distributor Catalogue number 
pAKT (ser473) Rabbit Cell signalling 4051 
AKT (total) Rabbit Cell signalling 9272 
B-actin mouse Sigma Aldrich A5316 
E-Cadherin Mouse R&D systems BTAI 
pEGFR (y1068) Rabbit Cell Signalling 2234 
pFAK(Y397) Rabbit Cell signalling 3283 
pFAK(y861) Rabbit Invitrogen 44-626-G 
pFAK (y576/577) Rabbit Cell Signalling 3281 
FAK (total) Rabbit Biosource AH00502 
pHER2(y1248) Rabbit Cell signalling 2247 
HER2 (total) Rabbit Cell signalling 2242 
pHER3(y1289) Rabbit Cell signalling 4791L 
HER3 (total) Rabbit SantaCruz SC-285 
pHer4(y1284) Rabbit Cell Signalling 4757 
pMAPK Rabbit Cell signalling 9101S 
MAPK (total) Rabbit Cell signalling 9102 
pSrc(Y416) Rabbit Cell signalling 21015 
pSTAT3 (Y705) Rabbit Santa Cruz SC-7993 
Total Stat3 Rabbit Santa Cruz C-20 
Src (total) Rabbit Biosource 44-656-G 
PARP goat R&D systems AF-600-NA 
GAPDH mouse SantaCruz SC-32233 
Anti-Rabbit IgG Goat Cell signalling 7074 
Anti-mouse IgG Sheep GE Healthcare NXA931 
Normal Rabbit IgG Rabbit Santa Cruz  
 
SC-2027 
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2.2 Cell Culture 
 
The human breast cancer cell lines used in this study obtained from ATCC are shown 
Table 2.3. The tissue/organ of origin from which they were derived from and the 
routine culture conditions are also detailed. 
 
Cell line ER,PR and HER2 
status 
Source Tumour type Culture 
conditions 
MCF7 HER2- ER+ PR+ PE Invasive ductal 
carcinoma 
RPMI+ 5%FCS+  
2% glutamine 
T47D HER2- ER+ PR+ PE Invasive ductal 
carcinoma 
RPMI+ 5%FCS+  
2% glutamine 
BT474 HER2+ ER+ PR+ P.Br Invasive ductal 
carcinoma 
RPMI+ 10%FCS+  
2% glutamine 
MDA361 HER2+ ER+  PR- P.Br  Breast adenocarcinoma 
from a metastatic site in 
the brain 
RPMI+ 10%FCS+  
2% glutamine 
SKBr3 HER2+ ER-   PR- PE Pleural effusion from 
Breast adenocarcinoma  
RPMI+ 10%FCS+  
2% glutamine 
Table 2.3. Characterisation of breast cancer cell lines used. Expression of ER, PR and HER2 
detailed and adapted from (Neve et al. 2006). PE: Pleural Effusion P.Br: Primary Breast. RPMI: 
(Roswell Park Memorial Institute) medium (containing phenol red). FCS: foetal calf serum. All 
culture media were also supplemented with 10IU/ml penicillin, 10ug/ml streptomycin and 
2.5ug/ml fungizone.  
 
In other studies, we also used a lung fibroblast cell line, MRC-5. These cells were 
obtained from ATCC and routinely maintained in RPMI supplemented with 5%FCS, 2% 
glutamine, 10IU/ml penicillin, 10μg/ml streptomycin and 2.5ug/ml fungizone.  
 
In experiments that required collection of conditioned media (Chapter 6), this was done 
using DCCM-1 medium, a high-protein serum-free media supplemented with 200mM 
glutamine 10μg/ml streptomycin, 2.5ug/ml fungizone. This is in order to avoid 
confounding effects caused by serum proteins. 
 
All cells were routinely sub-cultured when they reached approximately 80-90% 
confluence, usually every 7-10 days. Cells were detached from the plate by the addition 
of trypsin/EDTA solution (0.05%/0.02% in PBS respectively) and incubated for 3minutes 
at 37°C in a 5% CO2 humidified incubator. Trypsin activity was neutralised by addition of 
serum-containing cell culture medium and centrifuged at 1000rpm for 5 minutes to 
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pellet cells. The supernatant was discarded whilst the pellet was re-suspended in fresh 
culture medium and sub-cultured into flasks usually in a 1:6 – 1:10 ratio of the original 
culture. 
 
In all experiments, the culture medium was replaced every four days unless otherwise 
stated. All cell culture procedures were carried out in a laminar flow safety cabinet to 
ensure sterility of cultures. 
 
2.3 Cell proliferation assays  
2.3.1  MTT assay 
This assay involved the conversion of the water-soluble yellow compound, MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), to insoluble purple formazan 
crystals by mitochondrial dehydrogenase enzymes in actively respiring and viable cells. The 
formazan is solubilized and quantified by spectrophotometric means (Mosmann 1983). The 
colour produced is directly proportional to the number of viable cells and is therefore used 
to assess the anti-proliferative effects of various drug treatments. 
 
Cells were harvested using trypsin/EDTA as detailed in section 2.2 and seeded into 96-well 
plates at a density of 6x103 cells/well (Day 0), and were allowed to settle for 24hrs before 
treatments were added as required (Day1). Plates were incubated for 5 days at 37°C in a 
humidified incubator, with a medium change at Day 4. On day 6, medium was removed 
from each well and cells gently washed with PBS. 140ul MTT solution (0.5mg/ml in phenol-
red free RPMI filtered through a 0.2μm syringe filter) was added to cells and left to incubate 
at 37°C for 4hrs. The MTT solution was then aspirated and the cells lysed with 100 μl 10% 
(v/v) Triton-X100 (Sigma Aldrich) in PBS overnight at 4°C. The following day, the resulting 
solution was read in a spectrophotometer at 540nm.  Mean absorbance values were 
calculated and normalised to % of its corresponding control (100%). 
 
2.3.2  Cell growth measurement using a Coulter counting assay 
This approach represents the most direct way of counting cells and useful in detecting more 
discrete changes in cell number than other methods such as MTT-based assays. Coulter 
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counter is a form of electronic counting wherein cells in single suspension pass through a 
small opening between the electrodes of the counter. As they pass individually through a 
sensor, a pulse is detected and is noted as one particle count. This assay was used for when 
longer growth experiments are required (7 days or more), as the MTT assay, owing to the 
small surface area of a 96-well plate, is limited to experiments of just 5 days.  
 
Cells were harvested using trypsin/EDTA and seeded into 24-well plates at a density of 1x 
105 cells/well (Day 0), and were allowed to settle for 24hrs before treatments were added as 
required (Day1). Plates were incubated for 6 days at 37°C in a humidified incubator. 
Typically, this growth assay was run for 7 to 10 days with medium change every 4 days. 
Following the required incubation period, medium was removed from each well and the cell 
monolayer was dispersed by addition of trypsin/EDTA solution (1ml/well). Thereafter, cells 
were drawn up into a 5ml syringe through a 25G needle three times to ensure a single-cell 
suspension. Cells were then washed three times with Isoton solution (1ml), also taken up 
into the syringe each time. Cells in were syringed into a counting cup containing 6mls of 
Isoton to give a total volume of 10mls and counted using a Coulter Multisizer II. A minimum 
of two counts were taken from each well in triplicate. Mean averaged cell count was 
normalized to % of its corresponding control (100%). 
 
2.4  Antibody-based detection methods 
2.4.1   SDS-PAGE and Western Blotting 
2.4.1.1 Cell lysis for extraction of whole cellular contents 
Cells growing in 35mm diameter petri dishes ± treatments as indicated were placed on ice 
and washed with PBS three times. To each dish was added an appropriate volume of lysis 
buffer containing fresh protease inhibitors (2mM sodium orthovanadate, 50mM sodium 
fluoride, 1mM PMSF, 10mM sodium molybdate, 20μM phenylarsine, 10μg/ml leupeptin and 
8μg/ml aprotinin). This inhibitor cocktail prevents protein degradation and 
dephosphorylation by endogenous proteases and phosphatases present in the whole cell 
extracts. In doing so,   a better yield is achieved but importantly the phosphorylated residue 
of interest remains intact. The cells were scraped and collected into 1.5ml Eppendorf tubes 
and placed on ice for a further 5 minutes. Sample were then centrifuged for 15minutes at 
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12,000rpm in 4°C and the resulting supernatant containing cellular proteins was retained 
and transferred onto fresh Eppendorf tubes for storage at -20°C or prepared for protein 
quantification (see section 2.4.1.3). 
 
2.4.1.2. Cell lysis for isolation of cell nuclear and cytoplasmic fractions 
Cells growing in 60mm diameter petri dishes ± treatments as indicated were placed on ice 
and washed with PBS three times, scraped, collected in 1.5ml Eppendorf tubes and 
centrifuged at 1000rpm for 5 minutes at 4°C. The pellet was re-suspended in 5 pellet 
volumes of cytoplasmic extract (CE) buffer (containing NP40, Table 2.4) and left on ice for 
5minutes. Lysates were centrifuged as above and the supernatant (containing the CE) 
transferred into fresh Eppendorf tubes and temporarily kept on ice. The pellet, now 
containing cell nuclei, was washed with CE buffer (without NP40) by gentle pipetting and 
centrifuged as above. The supernatant was discarded and the pellet was re-suspended in 2 
pellet volumes of the NE buffer (Table 2.5) and incubated on ice for 10 minutes with 
periodic vortex mixing to loosen the pellet.  All fractions were centrifuged at maximum 
speed of 14,000rpm for 10minutes at 4°C for further clarification. Supernatants were 
transferred into fresh Eppendorf tubes and stored at -20°C until required for SDS-PAGE 
processing.  
 
10X cytoplasmic buffer (CE) Amount in 50mls Concentration (10x) 
HEPES 1.19g 100mM 
KCl 2.23g 600mM 
EDTA 0.18g 10mM 
NP40  375μl 0.75% 
         On the day of experiment  
         -Diluted to 1X with distilled H20. 
         -100ul of PMSF (100mM stock) and 1mM DTT added to 10mls of 1X buffer solution. 
Table 2.4 Cytoplasmic Extract Buffer 
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10X nuclear extract (NE) buffer Amount in 50mls Concentration (10x) 
Tris-HCl 1.576g 200mM 
NaCl 12g 4200mM 
MgCl2 0.15g 15mM 
EDTA 0.03g 2mM 
         On the day of experiment  
         Diluted to 1X with distilled H20. 
         100ul of PMSF (100mM stock) and 1mM DTT added to 10mls of 1X buffer solution. 
         Add glycerol (25% v/v) 
Table 2.5. Nuclear Extract Buffer 
 
2.4.1.3 Protein Quantitation 
To determine the amount of total protein present in each sample, a Bio-Rad DC 
colourimetric protein assay was performed. This is based on the reaction of copper tartrate 
solution with the protein sample and a subsequent reduction of Folin reagent to produce a 
characteristic blue colour.  
 
A series of BSA protein standards of known concentration (0, 0.25, 0.5, 0.75, 1.0 and 1.45 
mg/ml) were diluted in lysis buffer in cuvettes in order to obtain a standard curve.  In 
parallel, 10 μl of each protein lysate sample was aliquoted into separate cuvettes. To both 
the protein standards and lysate samples 250ul of Bio-Rad ‘reagent A’ (containing 20μl/ml 
of ‘Reagent S’) and 2mls of BioRad ‘Reagent B’ were added and gently mixed. After 5 
minutes the absorbance at 750nm of each protein standard was read using a 
spectrophotometer and values plotted to create a standard curve.  From this, the 
absorbance of the sample proteins can be deduced, which would be directly proportional to 
protein concentration. This allowed loading of approximately equal amounts of protein 
from different cellular samples on SDS-PAGE gels. 
 
2.4.1.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
To be able to separate proteins according to their size by SDS-PAGE, samples were prepared 
by mixing the samples with appropriate volumes of 3x Laemmli sample loading (with 
24mg/ml DTT (freshly added on the day). The negatively charged detergent, SDS, denatures 
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and coats proteins giving them a negative charge to allow their separation by size and 
charge when an electrical field is applied to a porous polyacrylamide gel. The glycerol 
increases the density of the sample solution ensuring that the sample remains in the 
bottom of the polyacrylamide wells, whilst the TRIS acts as a buffer to maintain pH during 
electrophoresis. The DTT causes the disruption of tertiary protein structures by breaking 
disulphide bridges to maximise the binding of SDS, whilst the bromophenol blue is a dye 
that allows the visualisation of the protein migration front. Prepared samples were boiled 
for 5 minutes at 100°C in sample buffer to ensure protein denaturation.  
 
SDS-polyacrylamide gels were prepared as detailed in Table 2.6, with the use of a gel 
stacking apparatus (BioRad Mini Protean 3). Resolving gels (lower) of 8-12% polyacrylamide 
solutions were poured between 1.5 mm glass plates positioned on a casting frame.  Water 
was added on top of each gel to ensure a flat edge, and prevent contact with air which may 
interfere with the polymerisation process. Gels were allowed to polymerise for 15 minutes, 
thereafter, the water overlay was poured out.  
 
Final Gel % (Resolving) 8% 10% 12% 
30% Acrylamide 5.4ml 6.6ml 8ml 
dH20 9.2ml 8ml 6.6ml 
Tris pH 8.8 5ml 5ml 5ml 
10% SDS 200ul 200ul 200ul 
10% APS 200ul 200ul 200ul 
TEMED 50ul 50ul 50ul 
Table 2.6 Resolving Gel  
 
Final Gel % (Stacking) 5% 
30% Acrylamide 1.67ml 
dH20 5.83ml 
Tris pH 6.8 2.5ml 
10% SDS 100ul 
10% APS 50ul 
TEMED 25ul 
 Table 2.7 Stacking gel 
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Stacking gels of 5% polyacrylamide solution (Table 2.7) were prepared and poured on top of 
the resolving gel immediately followed by insertion of 10/15-well plastic combs. The 
stacking gel was left to polymerise for a further 20 minutes. Once set, individual gels were 
transferred to a gel running tank and the reservoirs were flooded with running buffer 
(192mM glycine, 25mM Tris, 0.1% w/v SDS) and wells were loaded with the prepared 
protein samples. Precision Plus Protein All Blue marker (BioRad) (Figure 2.3) was also loaded 
alongside, to allow for estimation of the protein molecular weights. Electrophoresis was 
performed at a constant voltage of 120V for approximately 1hr 30minutes or until desired 
separation is achieved.  
 
 
 
 
 
 
 
 
Separated proteins were then transferred from the gel onto a nitrocellulose membrane (GE 
Healthcare) by construction of a Western blotting ‘sandwich’ system illustrated in Figure 
2.4. Assembled cassettes were placed in a tank filled with transfer buffer (0.25M TRIS base, 
1.92M Glycine, 20% methanol) and an ice block. Proteins were transferred over 60 minutes 
at 100-120V, allowing for the negatively charged proteins to migrate from the gel to the 
membrane. After the transfer, the membranes were immersed in Ponceau-S then washed 
briefly in distilled water to assess the efficiency of the transfer. 
 
 
 
 
 
 
 
 
Figure 2.3 Precision Plus Protein Blue Standard. 
Molecular weights in kD indicated on the right hand side. 
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Membranes were removed from the sandwich stack and blocked with 5% non-fat milk 
(Marvel) in TBS Tween-20 (0.05%) (TBST) and subsequently probed with primary antibodies 
specific for the protein(s) of interest. Membranes were incubated overnight at 4°C in falcon 
tubes on a roller bed then washed three times (10minutes per wash) with TBST to remove 
any excess unbound primary antibody and probed with Horseradish peroxidise (HRP)-
conjugated secondary antibodies diluted in 1% non-fat milk in TBST for 1hr at room 
temperature. Membranes were subsequently washed with TBST three times before the 
chemiluminescence detection as detailed below. 
 
2.4.1.5 Chemiluminescence detection 
The enzymatic activity of the bound HRP-conjugated secondary antibodies was activated by 
incubation with freshly prepared developing solution containing a luminol-based enhanced 
chemiluminescence substrate (Figure 2.5). In the dark room, the membranes are exposed to 
blue-sensitive X-ray films and processed in an automated developer to visualise reactive 
protein bands.  
 
 
 
 
 
 
 
 
                   cassette 
Scouring pad 
2xFilter paper 
  
Gel 
 
Nitrocellulose membrane 
                                                    
                                                        2x Filter paper  
Scouring pad 
 
cassette 
 
 
 
 
 
Negative 
Figure 2.4.  Wet transfer “Sandwich” set-up. The membrane and gel are placed in the direction of 
the current flow which is indicated in the apparatus diagram. All components were pre-soaked in 
transfer buffer prior to set-up. 
 
 
Positive 
Figure 2.5.  Chemiluminescence 
detection. The HRP-conjugated 
secondary antibody binds to the primary 
antibody specific for the protein of 
interest on the nitrocellulose membrane.  
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2.4.1.6 Stripping and re-probing membranes 
In some cases, membranes were re-probed with a second primary antibody to detect 
additional proteins in the same lysates. Where the first and second target proteins were of 
similar size, membranes were first stripped in order to avoid signal carry over form the first 
probing.  The stripping process involved washing membranes in Restore Plus Western Blot 
Stripping Buffer (Fisher) for approximately 15minutes at room temperature. After rinsing 
with TBST, membranes were exposed blue X-ray films for a minimum of 15minutes to check 
that the stripping had worked before incubating with antibodies. The membranes were then 
blocked with 5% milk/TBST and incubated with appropriate primary antibodies.  
 
2.4.1.7 Densitometry  
Densitometry analysis of Western blots was performed using AlphaDigiDoc program. 
Integrated density values from the bands of protein of interest are typically normalised to 
the loading protein control, GAPDH or β-actin. Normalised values are then converted to % 
values corresponding to the assigned control band (100%).  
 
2.4.2  Immuno-fluorescence staining 
 
Cells were grown on 0.13-0.17mm thick coverslips pre-coated with fibronectin (1:100 in 
sterile PBS) in 35mm culture dishes. When they reached approximately 60-70% 
confluence, treatments were added at doses and for the times indicated. Cells were 
then washed three times with PBS, fixed with paraformaldehyde (‘PFA’, 3.7% in dH20) 
for 15minutes and permeabilised using Triton-X100 (0.1% in PBS) for 8 minutes. Cells 
were blocked in 10% normal goat serum (in 1% BSA in PBS) for 40 minutes to block non-
specific antibody binding. This was followed by 40 minutes incubation with the primary 
antibodies (1:100 dilution in PBS containing 1% BSA). For double labelling, all primary 
antibodies were mixed together prior to incubation. Cells were thoroughly washed with 
PBS three times and incubated with the appropriate fluorophore-conjugated secondary 
antibodies for 40 minutes (Alexa-fluor488, Alexa-fluor 592, Alexa-fluor-conjugated 
phalloidin at 1:1000 dilution). Coverslips were again washed and mounted onto glass 
slides using Vectashield mounting media which contained DAPI (4’, 6-diamidino-2-
phenylindole) as a nuclear counterstain. Cells were viewed under oil-immersion at 63X 
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magnification using a Leica DMIRE2 microscope. Where necessary, images captured were 
imported into Image J for 8-bit conversion to generate a grayscale image. This was 
subsequently used to generate an auto-threshold image to segment features of interest. 
 
2.4.3  Immunoprecipitation 
 
All procedures performed on ice unless otherwise stated. 
500 μg of protein lysates were diluted in RIPA buffer to a volume of 1ml.  These were 
incubated with 1μg of primary antibody or an equivalent amount of normal IgG as a 
negative control for 2hrs at 4°C on a rotator allowing for antigen/antibody complexes to 
form. Meanwhile, the EZview Red protein Affinity Gel Beads (Sigma Aldrich UK) were 
equilibrated in preparation for immunoprecipitation as follows: 30μl of the bead slurry was 
aliquoted into Eppendorf tubes and mixed with 700μl RIPA buffer until uniformly re-
suspended and centrifuged for 30seconds at 9400rpm; this washing and equilibration step 
was repeated twice and after the final wash the supernatant was carefully removed and the 
bead pellet kept on ice.  
 
The antigen/antibody mix were added to the pre-washed beads and incubated for 2-3hrs at 
4°C with rotation, allowing for the antigen/antibody complexes to bind to the beads. The 
mix was then centrifuged at 9400rpm for 30seconds at 4°C and the supernatant carefully 
removed. The bead pellet was washed thrice by adding 750μl of RIPA buffer, gently mixed, 
followed by centrifugation as above. After the last centrifugation step, the supernatant was 
removed and the bound antigen/antibody complexes eluted by adding 25μl of RIPA buffer 
and 25μl of Laemmli loading buffer (2X) followed by vigorous mix by vortex; which would 
initiate the dissociation of the antigen/antibody complexes from the beads. Samples were 
then denatured by boiling at 100°C for 5 minutes. Finally, the mix was centrifuged at 
9400rpm for 1min to pellet the beads, whilst the supernatant containing the immuno-
precipitated proteins was collected and ran on SDS-PAGE.  
2.4.4 Immunocytochemistry (ICC) analysis of Ki67 
Cells were grown on coverslips in 35mm culture dishes. When they reach approximately 
60-70% confluence, treatments or stimulants were added, for the necessary times. Cells 
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were fixed with 2.5% Phenol formal saline and washed with PBS three times followed 
incubation with the primary antibody (Ki-67) for 2 hours in a humidified chamber at 
room temperature. Coverslips were washed with PBS and incubated with the 
appropriate Dako Envision secondary antibody for 2hours. After washing, sections were 
then visualized with 3,3′-diaminobenzidine (DAB) as a chromogen for 5 minutes and 
counterstained with haematoxylin. Coverslips were washed with tap water, air dried, 
mounted onto glass slides and visualised under a light microscope. Ki67-positive cells were 
counted in at least 5 different fields of view and expressed as % of the mean positive cell 
count of all cells per field against the control (100%).  
2.5 In vitro migration assay 
To monitor cellular migration, a Boyden chamber based approach was used. These 
assays were conducted using 24-well plate inserts (Corning) having a 6.5mm diameter 
microporous membrane (8 micron pore size). Inserts were first coated with fibronectin 
(1μl:100μl in PBS). Cells at a density of 0.5 x 105 cells/ml were then seeded in serum-
free RPMI supplemented with 0.1% BSA (±treatments). In the lower chamber chemo-
attractants were added to the experimental medium and cells were allowed to migrate 
to the underside of the membrane for 20hrs. Non-migratory cells were wiped from the 
top of the chamber suing a cotton bud whilst migratory cells were fixed with 3.7% PFA, 
stained with 0.5% crystal violet and allowed to dry. Stained cells were visualised by light 
microscopy and counted. Cell migration was quantified as mean cell number counts per 
field of view. Data (mean cell migration) was obtained from 5 random fields of view per 
insert. Each treatment was performed in duplicates for each experiment, which was 
independently performed  three times.   
2.6   In vitro 3D invasion assay 
Cells suspended in extra cellular matrix (ECM) (Cultrex) were seeded onto a round-bottom 
96 well plate and left to incubate for 72hrs to promote aggregation or spheroid assembly. 
“Invasion matrix” (Cultrex) was added to the spheroids and centrifuged at 200xg for 3 
minutes to eliminate bubbles. After 1hr, culture medium containing chemo-attractants 
and/or treatments were added to the top and left for 3 days to allow cells to invade into the 
surrounding matrix. The spheroids were photographed at various time-points.  
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2.7 Detection of MMP2 and MMP9 using gelatin zymography  
The principle of the assay is similar to that of SDS-PAGE with the additional incorporation of 
gelatin in the resolving gel at a final concentration of 0.1%. Samples under test were mixed 
with appropriate volumes of 2X laemmli loading buffer (1:1 ratio). Gels were ran on ice at 
~70V for 4 hours and washed in 2.5% Triton X100 for 30 minutes at least three times with 
gentle agitation. This was followed by incubation in the ‘activation’ buffer containing 50mM 
TRIS, 10mM CaCl2 (pH 7.6) at room temperature with agitation overnight. The next day, gels 
were stained for 1-2hrs with Coomassie Blue (0.1% Coomassie solution in 20% acetic acid at 
a 1:1 ratio) and de-stained with de-staining solution for approximately 1 hr, after which it 
was viewed under white light and photographed. 
2.8 In vitro RNAi transfections 
 
To transiently suppress FAK expression in our cell models, a siRNA based approach was 
taken using the ON-TARGETplus Human PTK2 (5747) pool of four highly potent siRNAs that 
target FAK (L-0003164-00-0005, Thermoscientific).  
Listed are the mRNA sequences targeted by the FAKsiRNA; 
 1. GCGAUUAUAUGUUAGAGAU 
2. GGGCAUCAUUCAGAAGAUA 
3. UAGUACAGCUCUUGCAUAU 
4.  GGACAUUAUUGGCCACUGU 
 
The siRNA pool above, along with a scrambled, non-targeting siRNA control, were re-
suspended in 1X siRNA buffer (diluted from 5X siRNA buffer in RNAse-free sterile water) to 
achieve a stock concentration of 20μM.  
For all experiments using siRNA, parallel controls were included which consisted of:  
 Culture medium control- used as baseline for growth (‘C’) 
 Lipid control- cells receiving only the DHARMAfect transfection agent  to confirm 
that the lipid and transfection procedure is minimally disruptive to the cell (‘LO’) 
 ON-TARGETplus non-targeting siRNA control – cells transfected with an siRNA 
designed to have no known mRNA targets, used to check for non-specific effects 
associated with siRNA delivery (‘NTsiRNA’) 
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Cell transfection was carried out as follows: Cells were seeded and grown to approximately 
60% confluence prior to transfection. On the day of the transfection, 20 μM stocks of the 
siRNA were diluted to 2μM in 1XsiRNA buffer. In two separate tubes, the appropriate 
volume of 2μM siRNA (to achieve a final concentration of 100nM) and DharmFECT1 
Transfection agent were diluted in serum-free phenol-red-free RPMI supplemented with 
200mM glutamine (SF-RPMI). After 5 minutes, the two mixtures were combined and 
left to incubate for 20 minutes at room temperature, allowing the formation of siRNA-
containing micelles. Subsequently, these were mixed with an appropriate volume of 
RPMI+5%FCS and were added to the cells and left to incubate for 72hrs before functional 
assays were carried out. For each cell line, optimal protein knockdown time-points were 
assessed by Western Blotting.  
2.9 Isobologram analysis 
 
Isobologram analysis was conducted as described by Tallarida (2001),  in order to 
determine whether two drugs act synergistically, additively or are antagonistic. To do this, 
firstly the IC30/50 values for each drug are plotted on the X and Y axis of a graph and 
connected with a straight line, referred to as the ‘line of additivity’  (Figure 2.6) The 
concentrations of the two drugs that, when combined, achieved a similar effect (IC 30/50) 
were then plotted on the graph. Points which fall on the straight line suggest that the 
combination drug effect was additive, whilst those that fall above are considered to be 
antagonistic and those below are synergistic. Isobologram graphs indicate the 
mechanistic interactions between the two drugs when used in combination.  
 
 
 
 
 
 
 
Figure 2.6.  Isobologram (illustration) for some 
particular effect.  IC50 dose of drug A alone is  
A = 20 and for drug B alone is B = 100. The 
straight line connecting these intercept points 
(additivity line). An actual dose pair such as 
point Q attains this effect with lesser 
quantities and is synergistic while the dose 
pair denoted by point R means higher doses 
are required and is therefore antagonistic. A 
point such as P that appears near the line are 
simply additive (Tallarida 2001). 
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2.10 Statistical analysis of data 
Data was analysed using GraphPad Prism 5 software.  A student’s independent t-test 
was used to compare pairs of data while one way analysis of variance tests (ANOVA) 
with Tukey’s multiple comparison tests (post-hoc) was used for comparing more than 
two groups of data. All data were considered significant when p≤0.05 *. Error bars, 
where appropriate, were expressed as mean ±SEM.  
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3. Results (I) 
Targeting FAK in HER2+/ ER+ breast cancer  
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3.1 Introduction 
Defining the ER/PR expression and HER2 amplification status in breast tumours is valuable 
for determining patient prognosis and guiding treatment strategy. Analysis of the molecular 
gene expression patterns of breast cancers further reveals a number of intrinsic subtypes, 
thereby deepening our understanding of the complex diversity of breast tumours and 
defining novel therapeutic strategies (Perou et al. 2000; Goldhirsch et al. 2011). It is now 
apparent that there are at least 5 distinct breast cancer subtypes: Luminal A, luminal B, 
normal-like, HER2+ and basal (Sørlie et al. 2001).  Whilst both luminal subtypes are ER+, 
Luminal B are reported to be generally more aggressive than the Luminal A subtype and 
with significantly worse outcome, having higher relapse rates and reduced patient survival 
(Sørlie et al. 2001; Millar et al. 2009; Haque et al. 2012). Studies suggest that up to 30% of 
Luminal B breast tumours may overexpress the HER2 receptor and are associated with 
increased relapse risk and mortality (Cheang et al. 2009) 
Elevated FAK expression has been observed in breast tumours. In one study, FAK has been 
shown to be elevated in pre-invasive ductal carcinoma in situ (DCIS) and infiltrating ductal 
carcinoma (IDC)  and  thus suggests that FAK may play a critical role particularly in tumours 
with the propensity to invade (Lightfoot et al. 2004). This is in further agreement with other 
studies that have identified elevated levels of FAK in invasive breast tumours (Owens et al. 
1995; Lark et al. 2005). That FAK indeed has a role in tumour progression and represents 
attractive therapeutic target  is further emphasized by numerous efforts that  have been 
made by several groups to inhibit FAK signalling in cancer cells using small molecule 
inhibitors, several of which are currently in clinical trials (See Table 1.3).  
Given that FAK plays a key role in the transduction of HER2 signalling in HER2+ cells and that 
levels of FAK expression strongly correlated with HER2 overexpression in clinical samples 
(Benlimame et al. 2005; Schmitz et al. 2005), and considering that FAK inhibitors are now in 
clinical trials, there is potential for a combination treatment approach with FAK inhibitors 
and Herceptin in Luminal B HER2+/ER+ breast cancer. Thus the aims of this chapter were to 
initially explore the role and therapeutic potential of FAK in this subtype. 
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3.2 Elevated FAK expression in breast cancer is associated with poorer patient  
survival 
 
Previous studies of breast cancer patient samples revealed that FAK overexpression was 
correlated with tumours with an aggressive phenotype, high mitotic index and high nuclear 
grade (Owens et al. 1995; Lark et al. 2005). Extending this, we explored whether a 
relationship existed between FAK expression and breast cancer outcome by investigating 
FAK mRNA levels in a series of breast cancer tissues analysed by microarray for at least 
22,227 genes which are publicly available (Kaplan-Meier analysis: www.kmplot.com) 
(Györffy et al. 2010). As shown in Figure. 3.1A, comparison of 4142 breast cancer patient 
samples with no restrictions applied on tumour grade, lymph node status or 
endocrine/chemotherapy treatments, revealed an association between high FAK mRNA 
levels and a significantly worse patient RFS (logrank P = 0.00061) over a follow-up period of 
up to twenty-five years. When patients were split according to the luminal subtypes, high 
FAK mRNA levels were associated with worse RFS in tumours with luminal B features 
(n=1173, HER2 +/-) (logrank P=0.059), whilst no association was observed in luminal A 
tumours (n=553) (Figure 3.1 B,C). Taken together, these support several lines of evidence 
indicating that FAK overexpression (PTK2 gene) is a prognostic factor for poorer survival in 
breast cancer patients, particularly those of the luminal B subtype.  
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Figure 3.1. (A) The Kaplan-Meier Plotter (http://www.kmplot.com) was queried to evaluate 
Affymetrix microarray expression of FAK mRNA (208820_at) levels in breast cancer patient tumour 
samples. Selections were: RFS, grade (all), lymph node status (all) and chemotherapy treatments 
/endocrine treatments (all). The Hazard ratio (with 95% confidence intervals) is shown. Queries were 
acquired from (A) all patients (n=4142), (B) ER+ Luminal A subtype (n=1173) and (C) ER+ Luminal B 
subtype (n=553).  
A .        All patients 
        B. ER+ Luminal A   C.       ER+ Luminal B 
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3.3 FAK activity is elevated in HER2+/ER+ versus HER2-/ER+ breast cancer cell 
lines 
Following on from the clinical analysis, we next compared the relative expression and 
activity pattern of FAK in four luminal breast cancer cell lines using Western Blotting to 
determine whether the activity of FAK may be linked to HER2 status. These cell lines 
were:  
 MCF7 and T47D (HER2-, ER+) 
 BT474 and MDA-MB 361 (MDA361) (HER2+, ER+) 
 
As shown in Figure 3.2, we verified that MCF7 and T47D cells did not express HER2 in 
contrast to BT474 and MDA361 cell models, with BT474 cells exhibiting the highest 
HER2 expression and basal level of phosphorylation. The total protein levels of FAK 
were similar between these cell lines, however, the HER2+/ER+ cells displayed a non-
significant trend for increased FAK activity (phosphorylation at Y861 but not at Y397). 
The extent of FAK phosphorylation at Y861 did not appear to correlate with the degree 
of intrinsic HER2 activity within the HER2+/ER+ cell lines, as the highest levels of FAK 
Y861 activity were observed in MDA361 cells, which had the lowest HER2 activity. 
 
FAK and HER2 signalling pathways have been suggested as being linked through 
common downstream elements including AKT and MAPK (van Nimwegen & van de 
Water 2007; Schmitz et al. 2005; Park et al. 2008). Investigation of AKT and MAPK 
activity in these cells lines revealed a degree of variation between cell lines but no 
obvious relation to HER2 nor FAK expression levels. 
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Figure 3.2. Expression of FAK in ER+/HER2- and ER+/HER2+ breast cancer cells. (A) Cell lysates from 
ER+/HER2- (MCF7, T47D) and ER+/HER2+ (BT474, MDA361) breast cancer cells, grown under 
routine cell culture conditions, lysed, process for Western Blotting and probed for FAK, HER2 and 
signalling elements common to these pathways. (B) Densitometric analysis showing the relative 
protein levels across the cells lines expressed as a ratio of active (Y397 and Y861) to total FAK and 
normalised to GAPDH. Representative protein levels represent the mean ±SEM from three 
independent experiments. 
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3.4 HER2+/ER+ cell lines are more sensitive to PF878 than HER2-/ER+ cell lines  
 
As a result of the finding that FAK was partly elevated in HER2+/ER+ vs HER2-/ER+ cell lines, 
we then sought to determine the sensitivity of these cell lines to the small molecule FAK 
inhibitor, PF878. 
Western blotting revealed that PF878 was able to suppress FAK phosphorylation at Y397 in 
both in HER2+/ER+ and HER2-/ER+ cells at sub-micromolar doses (Figure 3.3A). Whilst 
PF878 did not affect FAK phosphorylation at Y861 in T47D or BT474 cells, treatment did 
result in a partial decrease of FAK Y861 activity in MCF7 and MDA361 cells. Comparison of 
IC50 values between the cell lines suggested that HER2+/ER+ cells were more sensitive to 
PF878 than HER2-/ER+ cells, potentially pointing to an increased reliance of these cells on 
FAK (Figure 3.3B). Within the HER2+/ER+ cell line group, BT474 cells appeared to be more 
sensitive to PF878 with respect to the inhibition of FAK Y397 phosphorylation versus 
MDA361 cells. 
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Cell Line Breast 
Cancer 
Molecular 
Subtype 
IC
50 
 (µM) 
pFAKY397 
inhibition 
(±SEM) 
MCF7 HER2- (ER+) 0.25 ± 0.22 
T47D HER2-(ER+) 0.26 ± 0.39 
BT474 HER2+(ER+) 0.05 ± 0.03 
MDA361 HER2+(ER+) 0.17 ± 0.12 
 
B 
Figure 3.3. ER+/HER2+ cell lines are more sensitive to PF878 vs ER+/HER2- cells. (A) MCF7, T47D, 
BT474, MDA361 cells were treated with the PF878 (0-1μM) for 60mins. Cells were lysed, processed 
for western blotting and probed for FAK (total, Y397, Y861). GAPDH was used as loading control. (B) 
Densitometric analysis of immunoblots was carried out to calculate the IC50 values ± S.D for PF878. 
Representative blots and data are the mean of at least three independent experiments. *p=<0.05 
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3.5 Effect of FAK inhibition on downstream FAK- related signalling pathways 
 
Subsequently, we investigated whether the suppression of FAK activity by PF878 resulted in 
the inhibition of intracellular signalling intermediates implicated in FAK and/or HER2-
mediated pathways (Figure 3.4). In HER2-/ER+ cells, our data showed a reduction in the 
levels of AKT activity in MCF7 cells and of Src in T47D cells in response to PF878.   
In the HER2+/ER+ cells, data showed that in BT474 cells, FAK inhibition did not affect 
downstream FAK-related signalling, except for paxillin, a FAK binding partner (Schaller 
2001). HER2 phosphorylation at Y1248 was decreased in a dose-dependent manner in 
MDA361 cells with an accompanying slight reduction in the activity of Src, AKT and MAPK. In 
contrast, these events were not apparent in BT474 cells.  
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Figure 3.4. Inhibition of FAK activity suppresses endogenous FAK/HER2-related signalling in 
MDA361 cells. MCF7,T47D, BT474 and MDA361 cells were treated with increasing concentrations 
of PF878 (0–1 μM) for 60 min, following which the cells were lysed , process for Western Blotting 
and probed for the proteins indicated. GAPDH was used as loading control. Representative blots 
and data are the mean of at least three independent experiments 
 
C 
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3.6 Inhibition of FAK suppresses HER2+/ER+ breast cancer cell migration but not 
proliferation 
 
FAK is thought to function as a downstream effector of both integrin receptors, following 
ECM engagement, and also growth factor receptors to promote a range of cellular 
responses including proliferation and migration. We thus investigated the effect of FAK 
inhibition on these cellular characteristics. The effects of PF878 cell proliferation over a 
range of doses (0-1μM) that spanned the IC50 for FAK, despite demonstrating successful 
inhibition of pFAK Y397, only resulted in a modest inhibitory effect on cell proliferation 
across all cell lines with the greatest anti-proliferative effects observed in MDA361 cells, 
although this was only achieved at a dose of 1μM, much higher than its calculated IC50 value 
(Figure 3.5A).  
Since FAK is known to be downstream of integrin receptors that bind to extracellular matrix 
ligands, we further investigated the hypothesis that matrix proteins might contribute to 
drug sensitivity (Nista et al. 1997; Kasahara et al. 2002; Pontiggia et al. 2012) and that FAK 
inhibition might result in greater effects on proliferation when cells are cultured in the 
presence of matrix components. This is based on the rationale that matrix components are 
known to activate integrin-mediated signalling, and may be integral in regulating cell 
proliferation and survival signals (Stupack & Cheresh 2002; Kim et al. 2011). Given that FAK 
is often coupled with integrin signalling, FAK plays a more dominant role in the presence of 
matrix components (Cary & Guan 1999). 
As our data shows in Figure 3.5B, PF878 produced a modest yet more dose-dependent 
reduction in cellular proliferation in the presence of matrix components (fibronectin) 
compared with uncoated surfaces. This was particularly better observed in MDA361 cells at 
the higher concentration of 1μM PF878. 
FAK is also important in the processes of cell migration in response to growth factor or 
integrin activation, a critical step in metastasis and tumour progression. FAK was shown to 
be involved in the formation and turnover of FAs at the leading and trailing edge of the cell, 
allowing for forward movement and tail retraction, to promote migration (Carragher & 
Frame 2004) and it has been well documented that inhibition of FAK suppresses cell 
migration (D. Sieg et al. 1999; Hauck et al. 2001; Hiscox et al. 2011). We thus sought to 
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determine the potential for PF878 to impede migration of HER2+/ER+ cells. Previous data 
from our group indicated that neither of these cell lines exhibited high intrinsic migratory 
potential in Boyden Chamber assays, suggesting that any observed differences in 
endogenous FAK between these cells did not affect their intrinsic migratory nature. 
Thus in order to explore the role of FAK in the migratory response of BT474 and MDA361 
cells, we employed Heregulin β1 (HRG), a ligand for both HER3 and HER4 receptors that can 
trans-activate HER2 via hetero-dimeric interactions and is known to promote cellular 
migration and metastasis (Plowman et al. 1993; Carraway et al. 1994; Atlas et al. 2003a). 
Assessment of cell morphology by bright-field microscopy revealed  that in the presence of 
HRG (24hrs), although MDA361 cell colonies remained largely intact, cell-to-cell contacts 
within these colonies seemed to loosen (Figure 3.5C), which may indicate breakdown of 
cell-to-cell interactions and acquisition of an early migratory phenotype. These did not occur 
in BT474 cells, though a noticeable increase in protrusions amongst the cells in the 
periphery of the colonies were observed (Figure 3.5C). 
In the Boyden Chamber assays, HRG stimulation greatly augmented the migratory capacity 
of MDA361 cells (approximately 20-fold increase), an effect that was antagonised by 1μM 
PF878 (Figure 3.5D). To further validate these data, an siRNA approach was taken to 
suppress both FAK expression and activity in MDA361 cells.  Initial optimisation experiments 
were carried out to determine the concentration of FAKsiRNA to be used for functional 
assays; these data showed that FAK levels were suppressed using siRNA at concentrations 
ranging from 25 to 150nM (all for 72hrs)  (Figure 3.5E). Although 25nM FAKsiRNA was 
almost equally as effective at inhibiting FAK at the higher concentrations (100 and 150nM) 
after short-time points, a concentration of 100nM was selected as this provided effective 
and sustained knockdown over a prolonged period (up to 6 days) which was required for 
some of the subsequent experimental work (i.e. longer term growth assays). 
 
FAK siRNA (100nM) reduced the total protein level of FAK after 48h by approximately 40% 
(Figure 3.5E). This effect was time-dependent and was further reduced post-transfection, 
achieving approximately 80% inhibition at Day 6. This was also accompanied by a decrease 
in FAK phosphorylation at Y397 and Y861. Interestingly, the decrease in the kinase and 
scaffolding functions of FAK likely to occur as a consequence of the loss of the total FAK 
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protein, led to an increase in the expression and activity of HER2 and HER3 receptors. A 
similar observation was also noted for AKT. No significant changes in cell viability were 
observed between NTsiRNA and FAKsiRNA-transfected SKBr3 cells 72hrs post-transfection 
and are noteworthy when results were interpreted (Figure 3.5F). 
Accordingly, together with the observations with PF878, FAKsiRNA transfection significantly 
suppressed MDA361 cell migration in response to HRG, although to a lesser extent than the 
pharmacological inhibitor (Figure 3.5G).  
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Figure 3.5. The effect of FAK inhibition on cellular proliferation. (A) The role of FAK in HER2-/ER+ 
and HER2+/ER+ cell growth in the absence (A) or presence (B) of fibronectin substrate was 
assessed using MTT assay ±PF878 (0–1 μM) over a period of 5 days. Data are mean % cell growth 
±SEM (n=3). Continued. 
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Figure 3.5. (Continued) Effect of FAK inhibition on cellular migration. (C) The effect of 24hr HRG 
(100ng/ml) or serum stimulation (20%FCS) in cell morphology was observed by capturing bright-
field photos. (D) Heregulin-stimulated MDA361 cell migration ±PF878 (1μM) were analysed 
using fibronectin-coated Boyden Chambers. Continued. 
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Figure 3.5. (Continued) (E) For validation, MDA361 cells were transfected with FAKsiRNA. To 
optimise the siRNA transfection, MDA361 cells were grown to 50% confluence and treated with 
FAKsiRNA (25-100nM) at for 72hrs. Cells lysates were processed for Western Blotting and 
probed for the proteins indicated. Further optimisation using 25nM and 100nM FAKsiRNA was 
performed to determine whether FAK knockdown is sustained for a longer time, 6 days. (F) 
Toxicity of the transfection process was evaluated by treating cells with the DharmaFECT 
transfecting cells with the non-targeting siRNA (Nt-siRNA) and FAKsiRNA for 72hrs and effects on 
cell growth were assessed by Coulter counting. (G) Following optimisation, NT/FAKsiRNA 
MDA361 cells were subject to cell migration assays under similar conditions as in (D). Data 
represent the mean numbers of migratory cells/membrane run in duplicates from three 
independent experiments.  
* p=<0.05,**P=<0.001.  
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Interestingly, HRG failed to stimulate migration of BT474 cells (Figure 3.5H). This relative 
insensitivity of BT474 cells to HRG suggests that HER2 signalling may not predominantly 
contribute to cell migration in these cells. Despite this lack of response to HRG, it has been 
previously shown that BT474 cells can migrate in response to 20% serum (Worzfeld et al. 
2012). In accord, bright-field microscopy images of 20% serum-stimulated BT474 displayed 
more prominent cellular protrusions that differ from those formed following HRG-
stimulation (Figure 3.5C). Thus, the assay was repeated with inclusion of serum stimulation 
BT474 cells resulting in enhanced migration which was subsequently attenuated by PF878 
(Figure 3.5H).  
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Figure 3.5.(continued) (H) HRG-stimulated and migration and serum-induced (20%) migration of 
BT474 cells ±PF878 (1uM). Data represent the mean numbers of migratory cells/membrane run 
in duplicates from three independent experiments.  
* p=<0.05,**P=<0.001.  
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3.7  FAK plays a central role in Heregulin-induced cytoskeletal regulation and E-
Cadherin loss 
 
Efficient migration requires the dynamic regulation of focal adhesions (FAs) together with 
remodelling of the actin cytoskeleton. Both processes are reliant upon the functional FAK 
and are also closely associated with the re-localisation of cell-to-cell junction proteins such 
as E-Cadherin (Mitra et al. 2005, Serrels et al. 2011). Therefore, following the finding that 
PF878 can significantly suppress HRG-induced cell migration, we examined the localisation 
of FAK, filamentous-actin (F-actin) and E-cadherin in MDA361 cells following HRG 
stimulation.   
Moderately weak pFAK Y397 and strong pFAK Y861 punctate staining were observed around 
the cell periphery and at the ends of the actin-stress fibres, reminiscent of FAs (Figure 3.6A). 
HRG stimulation for 60mins increased the presence of F-actin-containing aggregates in 
some cell colonies (indicated by the arrowheads Figure 3.6A), suggestive of an active 
remodelling of the actin cytoskeleton (Stricker et al. 2010). Furthermore, its co-localisation 
with pFAK Y861 was disrupted. As we were unable to detect strong pFAK Y397 staining, the 
exposure time to laser light was extended although this resulted in a very high background, 
thus making the images difficult to interpret. Further investigations revealed that the 
dissolution of cell-cell contacts as indicated by loss of cell-to-cell E-cadherin staining was 
also apparent. 
When treated with PF878, an overall increase in pFAK Y861 staining was observed, both at 
the cell periphery and across the cytoplasm, whilst a near complete loss of pFAK Y397 
staining was observed. pFAK Y861-containing FAs were noticeably larger, elongated and are 
more prominent at the periphery whilst  intercellular E-Cadherin staining  remained intact.   
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Figure 3.6. Immunofluorescence images of MDA361 cells seeded on FN-coated plates following 
Heregulin-stimulation migration (100ng/ml) ±PF878 (1μM) for 60mins. Cells were stained for 
primary antibodies: (A) pFAK Y397 (green) + Rhodamine –phalloidin (actin) (red), (B) pFAK Y861 
(green) + Rhodamine-phalloidin(actin) (red), (C) E-Cadherin (red). All cells were stained with 
appropriate Alexa-fluor 488/594-conjugated secondary antibodies and counterstained with DAPI, 
a nuclear dye (blue). Magnification: x63, oil-immersion objective.  
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3.8  Inhibition of FAK attenuates HRG-mediated migratory signalling in 
HER2+/ER+ breast cancer cells 
 
Because of the inhibitory effects exerted by PF878 on HRG-stimulated MDA361 cell 
migration, we wished to explore the potential signalling pathways in which FAK might play a 
role during this process. Cells were seeded onto fibronectin-coated plates, since migration 
was performed on fibronectin-coated membranes, and stimulated with HRG (100ng/ml) in 
the presence or absence of PF878 (1μM) for a range of times (0-24hrs) reflecting the period 
in which the migrations assays were performed. Cells were lysed and processed for Western 
Blotting for analysis of expression and activation of ErbB receptor family members and 
related signalling components (Figure 3.7A). 
 
Our data demonstrated that HRG induced the phosphorylation of HER2, HER3 and HER4 
with peak activation observed at 16hrs. This was accompanied by phosphorylation of FAK 
(Y397, Y861 and Y576/577) as well as the downstream signalling elements, AKT and MAPK, 
all of which demonstrated a similar peak at 16hrs. In the presence of PF878, HRG-induced 
FAK phosphorylation (Y397, Y861 and Y576/577) was much less evident. Interestingly, we 
observed that treatment with PF878 alone led to an increase in the activity of HER2, HER3 
and HER4 although it did not alter AKT or MAPK phosphorylation status. FAK inhibition did 
also appear to attenuate the ability of HRG to promote maximal ErbB receptor 
phosphorylation (i.e. at 16 and 24hrs). Given that HRG promoted AKT and MAPK activation 
and that both AKT and MAPK are well described to be involved pro-survival and growth 
signalling pathways, we investigated whether HRG was able to induce growth effects in 
these cells. Moreover, we wished to determine whether FAK inhibition might suppress any 
such effects, although this may not occur via AKT/MAPK signalling as PF878 did not alter 
HRG-induced AKT or MAPK activity. However, our data revealed that despite an increase in 
growth-related signalling, HRG did not affect the proliferative ability of either cell line tested 
(Figure 3.7B). There was some modest suppression of endogenous growth in MDA361 cells 
using PF878 alone as previously demonstrated (Figure 3.5A) 
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Figure 3.7. (A) HRG stimulates downstream signalling in MDA361 cells. Cells were seeded on 
fibronectin-coated plates and cultured to 70% confluence and treated with HRG (100ng/ml) at the 
indicated time-points ± pre-treatment with PF878 (1μM) for 60mins. Cells were lysed, processed for 
Western Blotting and probed for proteins as indicated. Representative blots shown from three 
independent experiments. (B) Cells were grown in 24-well dishes in the presence of HRGβ1 (10 or 
100ng/ml) ±PF878 (1μM) for 7 days. Cell growth was then assessed by Coulter counting (n=3) 
*=p<0.05 
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3.9 Discussion 
Breast cancer represents a heterogeneous group of diseases reflecting a spectrum of 
clinical, pathological and molecular characteristics. The ER+ breast cancer subtype is the 
most common, accounting for 70% of all cases diagnosed (Sørlie et al. 2001). This chapter 
focused on the luminal B subtype of ER+ tumours, of which up to 30% may overexpress the 
HER2 receptor, and have been associated with increased relapse risk and mortality  (Cheang 
et al. 2009) 
Herceptin has revolutionised treatment of HER2+ tumours, however, it has been shown that 
response rates are low, varying between 11-26% depending on prior therapies (Baselga et 
al. 1996; Cobleigh et al. 1999; Vogel et al. 2001) and thus better treatments are warranted.  
Moreover, inclusion of Herceptin in treatment regimens benefits HER2+/ER- tumours more 
than HER2+/ER+ tumours, suggesting that the presence of ER might be a limiting factor to 
Herceptin response (Bhargava et al. 2011; Montemurro et al. 2012). Conversely, the 
presence of HER2 in ER+ tumours is shown to attenuate the response of these tumours to 
endocrine therapy (Houston et al. 1999). Key to the development of more effective 
approaches for the management of HER2+ disease is the identification of novel therapeutic 
targets that may have a potential to improve response to existing treatments. 
It has been well established that FAK is an important mediator of cell growth, survival and 
migration, all of which are frequently deregulated during malignancy. As already described, 
several studies have supported the role of FAK in various stages of tumour progression and 
its overexpression is often correlated with an aggressive cancer phenotype. FAK 
overexpression has also been reported to correlate with HER2 overexpression in breast 
cancers (Schmitz et al. 2005). Since both HER2 and FAK are elevated in breast cancer and 
given its close interplay with HER2-mediated signalling, one hypothesis is that FAK may 
represent a novel therapeutic target in HER2+ breast cancer; however, studies exploring this 
concept are limited to only a few (Benlimame et al. 2005; Xu et al. 2009; Yang et al. 2010). 
Thus, in this chapter, we investigated the therapeutic potential of FAK in HER2+ /ER+ breast 
cancer.  
Our initial observations in HER2+/ER+ cell lines revealed that there was no apparent 
correlation between HER2 status, total FAK expression and pFAK Y397. We however 
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observed that the activity of pFAK Y861 was higher in HER2+/ER+ cells, an observation also 
supported by a previous study demonstrating a correlation between pFAK Y861 and HER2 
overexpression (Schmitz et al. 2005). In addition, Vadlamudi et.al. (2003) also reported that 
FAK Y861 phosphorylation specifically occurs following HER2-initiated signalling. Taken 
together, our findings and those in the literature led us to hypothesize that HER2+/ER+ cell 
lines may be more reliant on FAK and thus be more sensitive to FAK inhibition. A number of 
pharmacological FAK inhibitors are currently at various stages of pre-clinical and clinical 
development for cancer, highlighting the critical role of FAK in tumour progression (Table 
1.3).  In this study, we used the FAK inhibitor PF878 (now VS-6063) obtained from Pfizer. 
PF878, though its precise mechanism are undisclosed, it works similarly to another Pfizer 
compound, PF271, by competitively binding to the ATP binding site of FAK at Y397 (Roberts 
et al. 2008). It has also been reported to inhibit Pyk2, another FAK-related kinase (Pachter et 
al. 2014). 
Both HER2+/ER+ cell lines (BT474 and MDA361) show increased sensitivity to PF878 with 
respect to its ability to suppress phosphorylation of Y397 compared to HER2-/ER+ cells; 
BT474 cells, which had the highest level of HER2 phosphorylation, demonstrated the 
greatest sensitivity to the compound. However, despite effective inhibition of Y397, this did 
not translate out into a suppression of cell growth for either HER2-/ER+ or HER2+/ER+ 
models with the exception of MDA361 cells, where a modest (maximally 30%) yet 
statistically significant suppression of growth was observed with the highest dose tested 
(1μM); interestingly however, this was above the calculated IC50 value of 0.17μM for 
inhibition of Y397 activity again suggesting a disconnect between FAK Y397 and growth 
signalling pathways. While concentrations of >5μM did exert growth suppressive effects in 
all cell lines (data not shown), this may likely be result of off-target (FAK-independent) 
effects, as has previously been suggested to occur in other cell lines (Slack-Davis et al. 2007).  
Several key signalling events are known to be initiated following FAK activation. Classically, 
FAK activation is characterised by auto-phosphorylation  at Y397, allowing for binding of Src 
and PI3K (Schaller et al. 1994). Src subsequently phosphorylates other FAK tyrosine residues 
including  Y576/577, Y861 and Y925 as well as other FAK-associated proteins (Cary & Guan 
1999). The phosphorylated tyrosine residues provide binding sites for SH2-domain-
containing proteins, of which PI3K and Grb2 are well described, consequently leading to the 
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activation of the AKT and MAPK signalling pathways respectively (Cary & Guan 1999). Given 
this information, we investigated the hypothesis that inhibition of FAK auto-phosphorylation  
at Y397 might result in suppression of these elements also. FAK inhibition only affected 
downstream signalling in MCF7 and MDA361 cells and only in terms of a reduction in AKT 
and MAPK activity. Loss of AKT/MAPK in this context might arise as a result of suppressed 
activity of its upstream regulator, Src, as illustrated by the decrease in Src activity in 
response to PF878 in these two cell lines (see section  3.5). 
Having investigated the effect of PF878 on elements of FAK-mediated signalling pathway 
components, we evaluated the functional consequences that may arise in these cells as a 
result of this. Both AKT and MAPK have been associated with cellular growth pathways 
(Yamamoto et al. 2003; Liang & Slingerland 2003; Behmoaram et al. 2008) but only MDA361 
cells were growth inhibited by PF878, despite PF878 suppressing AKT and MAPK in MCF7 
cells also. These conflicting data between cell lines may simply reflect the differences in the 
role of FAK in different tumour subtypes. Alternatively, FAK inhibition in MCF7 cells may 
trigger an as-yet identified alternative growth pathway, a hypothesis supported by studies 
showing that use of PI3K/AKT pathway inhibitors activate compensatory growth signalling in 
tumours, for instance via HER3 and IGFR-1 (Rodrik-Outmezguine et al. 2011; Chandarlapaty 
et al. 2011). A further point for consideration is that these growth experiments were carried 
out in RPMI media supplemented with 5% FCS. Serum is rich in various components that can 
include growth factor signalling and which may in turn stimulate parallel growth pathways 
independent of FAK. This however was unavoidable as the cells do not proliferate well in 
the absence of serum, which would then limit the time-frame of our growth assays (usually 
7 days).  
Together, the differential downstream signalling effects by PF878 on the cell lines tested 
might represent a context where this could be investigated further to determine the 
subtypes that reliant on FAK and to identify relevant predictive markers for FAK inhibitor 
response.  
FAK is known to be critical intracellular mediator of ECM signals via its interactions with 
integrin receptors and cell-matrix contact to support growth factor signalling (Stupack & 
Cheresh 2002; Cary & Guan 1999; Kim et al. 2011). Thus we sought to investigate the 
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hypothesis that FAK inhibition might suppress growth in the context of matrix interactions. 
Previous reports have shown that pFAK Y397 inhibition, whilst not affecting the growth of 
cells in 2D culture, increases cellular apoptosis in 3D culture (Tanjoni et al. 2010). This in 
turn points to the importance of the microenvironment on FAK activity, where for example 
integrin-mediated FAK activation may potentiate pro-survival signalling. However, we did 
not observe any differences in the ability of PF878 to suppress the proliferation of 
HER2+/ER+ cells growing on either matrix (fibronectin)-coated surfaces or on uncoated 
surfaces, with the exception of MDA361 cells at 1μM PF878. This could imply that these 
cells may differentially express the appropriate integrin receptors for this matrix-mediated 
downstream signalling. Interestingly, it is now well acknowledged that differentially 
activated signalling pathways exist between monolayer and 3D culture settings (Baker & 
Chen 2012, Ganghadara  et.al, submitted). This suggests perhaps that FAK-mediated growth 
signalling of HER2+/ER+ cells are significantly influenced by the distinct cell-matrix 
interactions present in the 3D cell culture settings than in monolayer cultures.  
Whilst neither of the two HER+/ER+ cell lines displayed a high intrinsic migratory behaviour, 
our data do support a role for FAK in the HRG or serum-stimulated migration of MDA361 
and BT474 cells respectively. In these studies, 1μM of PF878 significantly suppressed cell 
migration, similar to that used in the growth assays. In this regard, targeting FAK is likely to 
be more relevant with regards to metastatic dissemination rather than tumour growth. This 
finding is not unexpected since FAK is well documented to be involved in the migratory 
behaviour of cells; inhibition of FAK suppresses breast cancer migration and invasion, whilst 
FAK overexpression in FAK-/- cells rescue cell migration defects ( Sieg et al. 1999; Walsh et al. 
2010). 
Interestingly, HRG only stimulated the migration of MDA361 cells, which was subsequently 
suppressed by PF878. The same results were obtained by knockdown of FAK expression 
with FAKsiRNA (100nM), which suppressed both FAK activity and expression. We became 
interested in this approach given the accumulating evidence that the kinase-independent, 
scaffolding functions of FAK mediate several important intercellular events (Bolós et al. 
2010; Fan et al. 2013). If indeed the physical scaffold of FAK is required for MDA361 cell 
migration, then the siRNA treatment was hypothesised to lead to a much greater 
suppression than that of the pharmacological inhibitor.  Interestingly, however, was not the 
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case and might therefore suggest a potential for compensatory signalling events such as 
that mediated by HER2/HER3 or AKT, observed upon FAK knockdown versus treatment with 
PF878. Alternatively, the absence of FAK might also lead to increased expression in the FAK-
related Pyk2, which may compensate for loss of FAK as previously reported to occur in 
mouse embryonic fibroblasts, endothelial cells and cancer stem cells (Sieg et al. 1998; Weis 
et al. 2008; Fan & Guan 2011). 
HRG does not directly bind nor physically activate HER2, but instead activates HER3/4, 
which subsequently recruits and activates HER2 via hetero-dimeric interactions (Carraway 
et al. 1994; Plowman et al. 1993). HRG activates Her3/4 receptors resulting in the activation 
of FAK (Vadlamudi et al. 2002; Vadlamudi et al. 2003;). These FAK-dependent mechanisms 
most likely involve signalling and scaffolding functions through multiple interactions with 
focal adhesion (FA) components. FAK, for example, binds to paxillin and p130Cas at nascent 
FAs, which in turn facilitate activation of ERK and MLCK reported to be necessary to FAs 
disassembly, a process required for the continuous forward cell protrusion (Webb et al. 
2004). FAK has also been reported to regulate pathways involved in modulating membrane 
protrusions and cytoskeletal arrangements by interactions with Arp2/3 and RhoGTPases for 
example (Wu et al. 2004; Zhai et al. 2003; Serrels et al. 2007). These and other studies 
(Hamadi et al. 2005; Schaller 2010) are consistent with our data demonstrating that FAK 
activity modulates focal adhesion dynamics and actin remodelling to regulate HRG-
stimulated MDA361 cell migration. Although we cannot rule out the role of pFAK Y397 in 
these effects due to the high background of the IF images which made interpretation of the 
data difficult, our data does imply that pFAK Y861 plays a role in the context of HRG-induced 
migration in this HER2+ cells as others have shown (Vadlamudi et al. 2002; Vadlamudi et al. 
2003). Accompanying these changes was also a HRG-induced loss of intercellular E-
Cadherin, a key component of adherens junctions as previously reported to occur in other 
breast and colon carcinoma cell lines (Okoshi et al. 2011; Kim et al. 2013). The net effect of 
this would be to facilitate the dissemination of individual cells from the tightly packed 
colonies. Accordingly, de-localisation and/or suppressed expression of E-Cadherin is widely 
reported in the acquisition of an invasive tumour phenotype and is correlated with 
metastatic tumours including the breast (Moll et al. 1993; Canel et al. 2013). Importantly, 
our findings implicating the role of FAK in this process is supported by the work of Canel et 
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al. 2010, who showed that inhibition of the Src/FAK pathway using pharmacological Src or 
FAK inhibition disrupts E-cadherin endocytosis and strengthens cell-cell adhesions.  
In the case of BT474 cells, these were not migratory in response to HRG, which is 
contradictory to previous studies (Weingaertner et al. 2013; Pradip et al. 2013). The 
differences from ours and others’ reports lie in experimental design. In these studies, HRG is 
present in the seeding media during the setup of the assay whereas we utilised HRG as a 
chemo-attractant, suggesting the possibility of HRG to influence the initial cell-adhesion 
processes prior to migration of BT474 cells. Alternatively, it might also be explained by the 
fact that these cells already have endogenously high basal auto-phosphorylation of HER2, 
thus HRG stimulation at 100ng/ml may prove to be a saturating concentration wherein it 
can no longer elicit further HER2 phosphorylation at Y1248 (See Appendix 8.1). Studies on 
the MDAMB-468 breast cancer cell line with point-mutated HER2 receptor that renders the 
Y1248 inactive reveal the indispensable role of this residue in cell migration (Dittmar et al. 
2002). For this reason, we focused our studies on this residue. We should however also 
incorporate detection of other auto-phosphorylation sites in HER2 such as Y877, whose 
activity can also be promoted by growth factors (Bose et al. 2006; Xu et al. 2007).  
Of interest, serum stimulation elicited BT474 migratory responses in agreement with a 
previous study (Worzfeld et al. 2012) and  occurred in a FAK-dependent manner.  Given the 
plethora of ligands within the serum, BT474 cell migration can be stimulated by as many or 
as few of these ligands that can trigger downstream signalling via FAK, for instance EGF and 
PDGF (Sieg et al. 2000). Though exploring the putative serum-induced pathways represents 
an interesting avenue to pursue, we chose to focus in elucidating downstream signalling 
mediated by HRG in MDA361 cells. To do so, we stimulated MDA361 cells with HRG over a 
period of 0-24 hours reflecting the time in which our Boyden chamber assays were carried 
out. Treatment with HRG stimulated the rapid phosphorylation of the ErbB receptors HER2, 
HER3 and HER4, which might arise through hetero-dimerization-mediated transactivation of 
HER2, with peak activation observed at 16hrs.This was accompanied with increased activity 
of FAK at Y397, Y576/Y577 and Y861, all of which followed a similar activation pattern, 
which may consequently activate MAPK and AKT. Although the activation of the ErbB 
receptors in response to HRG, mirrored AKT activation, more so than MAPK, which is 
consistent with the fact that HER3 is a potent activator of the PI3K/AKT pathway due to the 
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presence of several Thr-X-X-Met motifs, the binding site for the P85 subunit of PI3K (Fedi et 
al. 1994). These effects were sustained up to the latest time-point of 24hrs. Interestingly, 
this was not the case for BT474 cells (See Appendix 8.1), wherein levels of HER2, HER3, 
pFAK Y397 and Y861 activity fell below basal levels at 24hrs, lending a potential explanation 
to the differential sensitivity of these HER2+/ER+ cell lines to HRG.  
Inhibition of FAK activity however led to increased HRG-induced phosphorylation of HER2, 
HER3 and HER4 receptors. Such a response was unexpected, but nevertheless indicate the 
possibility that the homo/heterodimeric interaction HER2 or HER4 or their auto-
phosphorylation can be markedly influenced by FAK. Immuno-precipitation studies are 
required to confirm whether this results from the direct interaction of FAK with these ErbB 
receptors, as have previously been described to occur in Schwann cells and in MCF7 cells 
stimulated with HRG (Vartanian et al. 2000; Vadlamudi et al. 2002). What seems apparent 
however, was that when FAK activity was inhibited, the phosphorylation of ErbB receptors 
appeared to saturate, as shown by limited sensitivity to the persistent HRG stimuli. 
Dissecting the dynamics of each of these heterodimers in the presence of the FAK inhibitor 
is worthy of a separate study in its own right. 
Expectedly, PF878 also inhibited HRG-stimulated FAK activity at Y397 and Y861, confirming 
the role of FAK in HRG-induced MDA361 cell migration as we have established earlier. To 
our surprise, PF878 failed to inhibit HRG-induced AKT and MAPK activity. Unlike FAK, the 
roles of AKT and MAPK in cell migration are not very well explored although a few are 
described. Enomoto et al. (2005) showed that AKT phosphorylates ser1416 in Girdin, an 
actin-binding protein to mediate formation of the lamellipodia. Although a contradictory 
study suggests that AKT activation inhibits cell invasion through inhibition of the NFAT 
transcription factor (Yoeli-Lerner et al. 2005).  Increased MAPK activity on the other hand 
was shown to be a required for stimulating cell migration in response to fibroblast growth 
factors (FGFs),platelet-derived growth factor (PDGF-BB), HRG and fibronectin (Shono et al. 
2001; Graf et al. 1997; Ruan et al. 2012; Klingbeil et al. 2001). Reports have also 
demonstrated the role for MAPK in phosphorylating the myosin-light chain kinase (MLCK), a 
regulator myosin and polymerization of actin stress fibres in a migrating cells (Klemke 1997). 
More interestingly, MAPK and MLCK were found to be key effectors of FAK–Src signalling 
along with paxillin and p130cas to regulate FAs disassembly (Webb et al. 2004). This 
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mechanism, however relevant in our context appeared to be FAK-independent, since PF878 
failed to inhibit HRG-induced AKT and MAPK phosphorylation in MDA361 cells. 
An obvious explanation to this lack of AKT and MAPK inhibition is the sustained and/or 
increased activity of the HER2/HER3 and HER2/HER4 dimers in the presence of PF878. 
Alternatively perhaps, HRG-stimulated AKT and MAPK activity have a more dominant role in 
cell proliferation and survival rather than migration as you would expect, as these are 
critical roles well reported in the literature. However, there was no correlation between 
HRG-induced AKT and MAPK and proliferation of MDA361 and BT474 cells observed, which 
was equally surprising. These observations may be explained by the presence of serum (5%) 
in the media the growth assay was performed in, in accordance with the findings of Lewis et 
al. (1996). In that study, HRG-stimulated growth responses were apparent at low serum 
concentrations (0.1-1%), whereas in higher serum concentrations (10%), HRG exerted no 
effects or were even growth-inhibitory in some cell lines.  
Taken together the data shown that MDA361 and BT474 cells respond to HRG and serum 
respectively with increased migration which might suggest that in an in vivo context, such 
tumour types may display an increased aggressive behaviour since they would be exposed 
to numerous growth factors. The importance of the tumour microenvironment in promoting 
tumour progression and spread is well established; given our data on the role of FAK in this 
process, one may propose that FAK inhibitors might be a useful therapeutic strategy 
through which to suppress tumour spread. 
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4. Results (II) 
Targeting FAK in HER2+/ ER- breast cancer 
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4.1 Introduction 
 
In the previous chapter we demonstrated a role for FAK in the luminal B (HER2+/ER+) 
subtype of breast cancer, where FAK inhibition resulted in modest growth inhibition and a 
significant suppression of ErbB-induced migratory responses.  
In light of these data, we next wished to extend these studies to explore whether FAK also 
presented a potential target in HER2+/ER- disease models. HER2+/ER- tumours generally 
have low expression of the luminal gene cluster (see Section 1.3) and a high proliferative 
index (Ki67 expression)(Prat & Perou 2011) and this subtype of breast cancer is well 
recognised to be more aggressive, with HER2+ patients having shorter survival times versus 
patients with the luminal (A or B) subtype (Sørlie et al. 2001; Prat & Perou 2011). Given the 
link between FAK and HER2 and the fact that FAK has previously been shown to be highly 
expressed in HER2+/ER- breast tumours (Schmitz et al. 2005) where it is linked to an 
aggressive behaviour, an established role in HER2 signalling (Benlimame et al. 2005; Xu et al. 
2009), and our previous chapters’ data, our hypothesis was that FAK might also play a role 
in the proliferative and/or migratory responses of HER2+ tumours.   
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4.2 FAK activity is elevated in HER2+/ER- cells  
To study FAK in the context of HER2+/ER- disease, we used SKBr3 cell line which represents 
an appropriate cell model of this type of tumour (Neve et al. 2006). Initially, we explored the 
expression of FAK, HER2 and other related signalling elements in these cells versus the 
HER2-/ER+ MCF7 cells by Western Blotting. Our data in Figure 4.1A verified that SKBr3 cells 
have elevated levels of active HER2 and were also negative for the ER. SKBr3 also displayed 
elevated basal activity of the other ErbB receptor family members, EGFR, Her3 and HER4 
versus MCF7 cells.  Whilst we observed that the levels of FAK were lower in SKBr3 cells 
versus MCF7, FAK phosphorylation at Y861 was greater in the HER2+ cell line as were the 
activity of AKT and MAPK. Moreover, the analysis also appeared to suggest that pFAK Y397 
is higher when normalised to total FAK levels in SKBr3 than in MCF7 cells (Figure 4.1B). 
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Figure 4.1 (A) Expression of FAK in ER+/HER2- and ER-/HER2+ breast cancer cells. (A) Cell lysates 
from HER2-/ER+ (MCF7) and HER2+/ER- (SKBr3) breast cancer cells grown under routine cell culture 
conditions were probed for proteins indicated. (B) Densitometric analysis values showing the levels 
of phosphorylated proteins normalised to their respective total protein expression. This revealed 
that for all signalling elements investigated, their activity as higher in HER2+ cell lines; pFAK Y397 
(6-fold higher vs. MCF7), pFAK Y861 (15-fold) , pAKT (3-fold) and pMAPK (1.6-fold).  Representative 
blot shown from three independent experiments (±SEM). 
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Cell Line Breast 
Cancer 
Molecular 
Subtype 
IC
50 
 (µM) 
pFAKY397 
inhibition 
(±SEM) 
MCF7 ER+, HER2- 0.25 ± 0.22 
SKBr3 ER- HER2+ 0.166± 0.124 
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Figure 4.2. (A) SKBr3 lysates treated with the PF878 
(0-1uM) for 60mins were probed for FAK (total, 
Y397,Y861) as well as HER2 and downstream 
FAK/HER2-related signalling proteins. GAPDH was 
used as loading control. (B) Densitometric analysis 
of immunoblots was carried out to calculate the IC50 
values ± SEM for PF878. MCF7 values obtained from 
Chapter 3. Representative blots shown are from 
three independent experiments.  
4.3  Sensitivity of HER2+/ER- cells to FAK inhibition relative to HER2-/ER+ cells  
Having shown that FAK activity is elevated in SKBr3 cells, we sought to examine whether 
these cells are also sensitive to FAK inhibition using the small molecule inhibitor, PF878. 
Treatment of SKBr3 cells with increasing doses of PF878 effectively suppressed FAK 
phosphorylation at Y397 (Figure 4.2A) with an IC50 value of 0.166μM (SEM ±0.124) (Figure 
4.2B). In comparison, the IC50 for this compound for inhibition of FAK Y397 phosphorylation 
in MCF7 cells was 0.25μM (SEM± 0.22). Although SKBr3 cells were more sensitive, it was not 
statistically significantly different to MCF7 cells (p=0.77). PF878 treatment also resulted in a 
modest decrease of FAK phosphorylation at Y861 in SKBr3 cells.  
We subsequently examined whether FAK inhibition resulted in a loss of activity in the levels 
of ErbB receptors and FAK-related signalling would be inhibited in response to increasing 
doses of PF878. As shown, suppression of FAK activity had no effect on the activity of HER2 
and Src, but led to a paradoxical increase in MAPK and AKT activity at concentrations of 
PF878 >/= 0.05 μM. 
  
SKBr3 
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4.4 Inhibition of FAK suppresses HER2+/ER- breast cancer cell  migration but not 
proliferation 
We similarly investigated the effect of PF878 on cell proliferation over a range of doses (0-
1μM) that spanned the IC50 for FAK phosphorylation at Y397. PF878 modestly suppressed 
the growth (approximately by 20%) for both cell lines but only at the highest concentration 
tested (1uM) (Figure 4.3 A,B). Subsequent experiments were performed in the presence of 
fibronectin as a substrate to which the cells could attach to test the hypothesis that matrix 
proteins might contribute to drug sensitivity similarly explored in section 3.6. However, our 
data suggested that there was no statistical difference between the effects of PF878 on 
MCF7 and SKBr3 cells seeded on fibronectin-coated or uncoated plates, with the exception 
at a higher concentration of SKBr3 cells treated with 1μM PF878 (Figure 4.3A,B).  
Next we examined the effect of PF878 on SKBR3 cell motility using a Boyden chamber 
migration assay.  In the absence of stimulation, the migratory capacity of SKBr3 cells was 
low. However, in the presence of HRG (10ng/ml), SKBr3 cell migration was significantly 
elevated, an effect that was antagonised when FAK was inhibited by PF878 (Figure 4.3C).  
To validate these data obtained with the pharmacological FAK inhibitor and to further 
explore the role of FAK in HER2+/ER- cell function, we used a siRNA approach. Initial 
optimisation experiments revealed that treatment of SKBr3 cells with 100nM FAKsiRNA  
suppressed FAK expression, an effect that lasted for at least 6 days post-transfection (Figure 
4.3D). In contrast to the sustained suppression of FAK, the activities of other signalling 
molecules known to be involved in FAK-related pathways (Src, AKT, MAPK, HER2 and HER3) 
returned to near basal levels within 48hrs post-transfection. The effects of FAK siRNA on 
growth were subsequently determined by direct Coulter counting which showed no 
significant changes in cell viability between control (NTsiRNA) and FAKsiRNA-transfected 
SKBr3 cells 72hrs post-transfection (Figure 4.3E). In contrast, SKBr3 cells transfected with 
FAKsiRNA had a significantly impaired migratory response to HRG when compared to 
controls (Figure 4.3F).  
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Figure 4.3. Effect of FAK inhibition by PF878 on the growth and migration of MCF7 and SKBr3 
cells. (A,B) The growth of MCF7 and SKBr3 cells in response to PF878 (0–1 μM) over a period of 
7 days was assessed using Coulter counting (black line). Parallel assays were performed on 
fibronectin-coated plates (red line). Data are mean cell proliferation values ±SEM (n=3). (C) The 
effects of PF878 (1 μM) on Heregulin (10ng/ml)-stimulated SKBr3 cell migration over 
fibronectin coated membranes were assessed using Boyden Chamber assays. Cells were 
allowed to migrate for 20hrs and subsequently fixed, stained with crystal violet and counted. 
Data represent the mean numbers of migratory cells/membrane run in duplicates from three 
independent experiments (±SEM).  P: *<0.05,**<0.001, *** <0.0001. Continued. 
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Figure 4.3. (Continued). (D) For validation, SKBr3 cells were transfected with FAKsiRNA. To optimise 
the siRNA transfection, SKBr3 cells were grown to 50% confluence and treated with 100nM 
Dharmafect Lipid(LO), NT/FAKsiRNA  for 72hrs. Cells were harvested and lysed at indicated time-
points up to 6 days post-transfection, processed for Western Blotting and probed for the proteins 
indicated. (E) Effect of transfection on cell viability was evaluated by direct Coulter counting 
following transfection of SKBr3 cells with NT/FAKsiRNA for 72hrs. (F) Following optimisation, 
NT/FAKsiRNA SKBr3 cells were subject to cell migration assays under similar conditions as in (C). 
Data represent the mean numbers of migratory cells/membrane run in duplicates from three 
independent experiments. P: *<0.05,**<0.001 
E F 
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4.5 FAK is involved in HRG-induced lamellipodia formation in HER2+/ER- breast 
cancer cells 
 
FAK is well established as a binding partner for cytoskeletal components where it acts to 
mediate focal adhesion regulation and actin stress fibre assembly (Mitra et al. 2005; Serrels 
et al. 2007). In light of this we wished to investigate the effects of pharmacological FAK 
inhibition on the cytoskeletal system in the context of HRG-induced migration as a possible 
underlying mechanism through which FAK might regulate HRG-induced migratory 
responses. 
Immunofluorescence staining revealed that in unstimulated SKBr3 cells FAK Y397 levels 
were generally low (Figure 4.4A) in contrast to the levels of Y861 (Figure 4.4B). This was also 
observed in the Western Blotting data (Figure 4.1) showing very little pFAK Y397 expression 
in the SKBr3 cells. In the case of pFAK Y861, punctate staining was observed around the cell 
periphery and at the end of actin-stress fibres, reminiscent of FA localisation (Parsons et al. 
2000). Additionally, actin fibres localised close to and parallel to the cell membrane, 
indicative of cortical actin which are typically associated with actin cross-linker proteins such 
as α-actinin and cortactin, that form linkages with the plasma membrane (Stricker et al. 
2010). Following HRG stimulation, a small increase in pFAK Y861 was observed together 
with formation of prominent lammelipodia extensions particularly in cells at the edge of the 
colony. Moreover, pFAK Y861 was observed to be present at these protrusive structures, 
suggesting an important role for the activity of FAK in this process. The images were further 
processed to enhance the visualisation of these membrane protrusions, particularly 
focusing on areas of interest (See Figure 4.4B lower panel). This employs a common 
processing technique whereby images are converted to a binary image (8-bit) and an 
automatic threshold range is set to distinguish features of interest apart from the 
background.  
 Inhibition of FAK using PF878 suppressed the formation of mature lamellipodia protrusions, 
with the cells instead producing small projections at the cell periphery in which pFAK Y861 
staining remained localised.   
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Figure 4.4. Immunofluorescence images of SKBr3 cells seeded on FN-coated plates following 
Heregulin-stimulation migration (10ng/ml) ±PF878 (1uM) for 60mins. Cells were stained for 
primary antibodies: (A) pFAK Y397 (green) + Rhodamine-phalloidin (F-actin) (red), (B) pFAK 
Y861 (green)+ Rhodamine-phalloidin (F-actin). All cells were stained with appropriate Alexa-
Fluor 488-conjugated secondary antibodies and counterstained with DAPI, a nuclear dye (blue). 
Magnification: x63, oil-immersion objective. To visualise membrane activity, images were 
processed by converting to 8-bit and subsequently adjusting to a fixed threshold using Image J; 
resulting images are shown in the white doted boxes.   
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4.6  Inhibition of FAK attenuates HRG-mediated migratory signalling in 
HER2+/ER-breast cancer cells 
 
In light of the ability of PF878 to suppress HRG-induced migration in SKBr3 cells, we wished 
to explore the signalling mechanisms underlying this. SKBr3 cells were stimulated with HRG 
at various time-points in the presence or absence of PF878 prior to analysis of protein 
expression and activity with Western blotting. Focusing on the 60minutes time-point, which 
corresponds with that used the immunofluorescence staining experiments where the onset 
of pro-migratory focal adhesion and cytoskeletal changes were observed, our Western blot 
data revealed that HRG stimulation of SKBr3 cells stimulated FAK activity (Y397 and Y861) 
along with promoting the rapid phosphorylation of Src, AKT and MAPK whilst decreasing the 
activity of HER3. No change was seen in the phosphorylation state of the other ErbB 
receptors, EGFR, HER2 or HER4 whilst the activity of HER3 was decreased (Figure 4.5). 
PF878 suppressed both basal and HRG-induced phosphorylation of FAK (Y397>Y861) and 
Src. Moreover, this was accompanied by a further decrease in the magnitude of HRG-
induced suppression of HER3 activity. We did not detect changes in the activity of the other 
ErbB receptors, AKT or MAPK.  
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Figure 4.5. HRG stimulates downstream signalling in SKBR3 cells. Cells were seeded on fibronectin-
coated plates and cultured to 70% confluence and treated with HRG (10ng/ml) at the indicated time-
points ± pre-treatment with PF878 (1μM) for 60mins. Cells were lysed, processed for Western 
Blotting and immuno-probed for proteins as indicated. GAPDH was used as loading control. 
Representative blots shown from three independent experiments.  
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4.7 Discussion 
We have previously explored the role of FAK in cell models of HER2+/ER+ disease where it 
appears to play an important role in regulation of cellular migration with a less prominent 
role in cell growth. Here we explored the hypothesis that FAK might also play a role, and 
possibly a more significant one, in HER2+/ER- disease given that this is a more aggressive 
subtype relative to the luminal tumours (Sørlie et al. 2001; Prat & Perou 2011) and that FAK 
itself is known to be associated with aggressive tumours. In addition, the HER2+/ER- 
subtype represents the dominant HER2+ subtype seen clinically.  
Initial characterisation of SKBr3 cells confirmed expression of a constitutively active HER2 
receptor, as well as the other ErbB receptors, EGFR, HER3 and HER4. Most notable was that 
these also correlated with increased FAK activity at Y861, as well as the downstream 
signalling proteins Src, AKT and MAPK. SKBr3 cells also showed an increased sensitivity to 
PF878 compared to MCF7 cells that were used as a comparator cell line in light of their 
HER2- status. Interestingly, inhibition of FAK activity in SKBr3 cells promoted an increase in 
the activities of AKT and MAPK, an effect also observed in FAKsiRNA-expressing cells.  This 
was surprising given that FAK has been established to bind to the p85 domain of PI3K and 
the Grb2 adaptor protein, major downstream upstream regulators of AKT and MAPK 
respectively (Zhao & Guan 2009). Our findings here also contradicted our previous 
observations in HER2+/ER+ cell lines (Chapter 3) and thus suggest potential differences 
between the regulation of AKT and MAPK signalling between HER2+/ER+ and HER2+/ER-
breast cancer cells likely resulting from intrinsic differences in the signalling circuitry in each 
cell line (Sørlie et al. 2001; Cheang et al. 2009). Importantly, the activation of these 
pathways may also reflect mechanisms by which cells adapt and defend to external stresses, 
as supported by studies demonstrating AKT activation in response to chemotherapeutic 
drugs and cellular stresses (Beitner-Johnson et al. 2001; Alvarez-Tejado et al. 2001). This 
also might in some part explain the relative insensitivity of SKBr3 cells to PF878 in terms of 
growth inhibition. 
Similarly, we examined the supporting role of the micro-environment particularly in the 
context of ECM proteins. ECM-cell interactions are mediated by integrin engagement which 
may in turn  activate FAK-mediated signalling (Kornberg et al. 1992) that can potentiate cell 
proliferation and survival (Stupack & Cheresh 2002). Moreover, there have been reports of 
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integrin-mediated survival signalling events that occur at levels independent of AKT 
(Friedland et al. 2007) or MAPK (Matter & Ruoslahti 2001) signalling pathways. Accordingly, 
we reasoned that FAK plays a more dominant role in terms of regulating growth in the 
presence of matrix proteins, and therefore hypothesised that inhibition of FAK, may 
suppress growth in this context irrespective of the increases in AKT and MAPK activity. To 
do so, cells were seeded on fibronectin-coated plates. This could model, although to a 
limited extent, the tumour microenvironment where cells are in contact with ECM proteins. 
The data however showed that the growth inhibitory effects of PF878 remained limited in 
matrix (fibronectin)-coated surfaces, with the exception at 1 μM, wherein an approximate 
30% growth inhibition was observed in SKBr3 cells seeded in fibronectin-coated plates. The 
implications on FAK activity and related downstream signalling in the presence of 
fibronectin however are yet to be determined and will require further studies. Moreover, it 
is also likely that better efficacy is achieved at higher concentrations of the FAK inhibitor. As 
such, peak serum concentrations of 2-9 μM can be achieved in the clinical setting, which are 
over and above the concentrations used in our studies (based on Phase 1 studies of a 
structurally similar FAK inhibitor PF-271 (Infante et al. 2012), and thus the therapeutic 
targeting of FAK in HER2+/ER-breast cancer needs to be explored in in vivo and clinical 
settings.  
As well as investigating a role for FAK in proliferative responses in the HER2+ context, we 
also wished to determine whether FAK played a role in the migratory responses of this cell 
type. In agreement with other reports, SKBr3 cells were non migratory basally in agreement 
with previous observations (Hijazi et al. 2000; Ruan et al. 2012), but responded to HRG  
which further supports studies that have implicated  HRG in stimulating in metastatic 
tumour progression (Xu et al. 1997; Atlas et al. 2003b; Ruan et al. 2012). In contrast to 
growth, which was not greatly affected by loss of FAK activity, suppression of FAK activity or 
expression greatly inhibited HRG-induced migration. Our data suggests that underlying this 
may be FAK’s involvement in the cortical actin cytoskeletal reorganisation. Actin is the main 
cytoskeletal element in these lamellipodia, fan-like structures that ruffle and move 
dynamically to sense the surrounding environment and promote persistent directional 
movement (Stricker et al. 2010). Our data show that HRG triggered a re-localization of pFAK 
Y861 to the leading edges of the lamellipodia protrusions which appears to be 
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phosphorylation dependent since PF878 inhibited this, as well as suppressing these 
cytoskeletal changes. Together these data imply that the recruitment of pFAK Y861 to focal 
adhesions is important for the establishment and/or persistence of lamellipodia in a 
migrating cell and are in agreement with the role of FAK as leading-edge organizer based on 
observations on FAK-siRNA transfected fibroblasts which were shown to be unable to form 
functional lamellipodia and displayed loss of directional migration (Tilghman et al. 2005). 
Additionally, an interesting observation was the increased pFAK Y861 staining in a 
localisation reminiscent of the nucleus in SKBr3 cells when treated with PF878. The evidence 
of FAK localisation in the nucleus has previously been noted (Lim et al. 2008; Lim 2013). This 
induction of nuclear FAK localisation in the presence of PF878 may reflect of that suggested 
by Lim et al. (2008), that loss of FAK from focal adhesions increases the “free” cytoplasmic 
pool of FAK available for nuclear translocation where it promotes cell survival by facilitating 
the turnover of the tumour suppressor p53. In consistent, it was also shown that FAK 
inhibition by PF-271 a triggers nuclear accumulation of FAK which acts to inhibit GATA4-
mediated transcription of VCAM-1 (Lim et al. 2012). These and our observation suggest that 
the loss of FAK activity may correlate with FAK nuclear localisation. However, the 
significance of such a localisation to the anti-migratory effect of PF878 is yet to be explored. 
To delineate the mechanisms underlying the cytoskeletal changes accompanying the 
migratory behaviour of SKBr3 cells, we performed signalling analysis by Western Blotting. 
Our data demonstrated that HRG rapidly increased FAK activity at Y861 in SKBr3 cells within 
5 minutes and remained elevated up to 24hrs. That FAK is activated in response to HRG is in 
agreement with other studies in various cellular contexts (Vartanian et al. 2000; Vadlamudi 
et al. 2002; Vadlamudi et al. 2003). Moreover, the phosphorylation of pFAK Y861 is 
accompanied by concurrent activation of Src Y416, supporting the close interplay between 
Src and FAK (Calalb et al. 1996). Previous studies however have also implicated the 
phosphorylation of another residue, Src Y215, as a unique event following HRG signalling to 
FAK Y861 in MCF7 and NIH3T3 cells (Vadlamudi et al. 2003). We however failed to detect 
Src activity at Y215 in SKBr3 cells despite several attempts to pursue this experimentally. 
Nonetheless, PF878 inhibited FAK activity at Y397 and Y861 as well as of pSrc Y416 
suggesting that the formation of lamellipodia protrusions and thus cell migration may be 
dependent on a pathway involving FAK and Src. We speculate that the resulting 
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consequences occur at the level of focal adhesions to which the actin filaments are 
attached.  Decreased FAK/Src activity therein may disrupt interactions  with and/or 
activation of multiple signalling molecules that regulate the actin polymerisation machinery 
that participate in lamellipodia formation, among which, p130cas, Arp2/3, cortactin, N-
WASP and vinculin particularly have been implicated to be regulated by FAK and/or Src 
(Cary et al. 1998; Serrels et al. 2007; W. Wang et al. 2011; Wu et al. 2004). 
An increase in the phosphorylation of AKT and MAPK were also observed in response to 
HRG, in agreement with others (Adam et al. 1998; Yang et al. 2008), albeit transient. 
PI3K/AKT signalling in particular was implicated in HRG-mediated cytoskeletal re-
organisation and migratory response in HER2-overexpressing MCF7 cells (Adam et al. 1998). 
AKT has also been described to modulate cytoskeletal remodelling by binding to the actin-
binding protein Girdin, that regulates the cross-linking and thereby integrity of actin bundles 
in African monkey kidney (Vero) cells (Enomoto et al. 2005). However, AKT nor MAPK 
activities were unchanged in the presence of PF878 and therefore do not appear to 
significantly regulate migratory behaviour of SKBr3 cells in response to HRG.  
HRG, to our surprise did not significantly increase HER2 or HER4 activation, and PF878 
neither affected their basal activities suggesting that FAK may not direct modulate ErbB 
receptor activity. In contrast, HRG was observed to promote a decrease in HER3 
phosphorylation, an effect that was greater in the absence of FAK.  
The lack of a significant increase in ErbB receptor phosphorylation in response to HRG was 
particularly surprising given that a number of reports have shown strong responses to HRG 
in terms of phosphorylation of ErbB receptors (Adam et al. 1998; Tan et al. 1999; Vadlamudi 
et al. 2003). One explanation may be that our lack of HRG response may be due to the over 
saturation of these receptors from endogenous ligands. Indeed, a lack of response to HRG 
has been demonstrated in other cell lines proposed to occur through constitutively high 
levels of receptor phosphorylation resulting in its saturation (Göstring et al. 2012). A further 
possible explanation for the discrepancy could be due to the cell culture conditions 
employed. A common approach amongst studies published showing up-regulation of ErbB 
receptor signalling in response to HRG is that they generally use at least 24hrs period of 
serum starvation prior to stimulation. In our experiments, a serum starvation period of 60 
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minutes was used, which may not suppress endogenous signalling to a great extent in order 
to see a significant difference between control (unstimulated) and HRG-treated samples.  
That the HER3 receptor activity was reduced following HRG action was surprising  although 
previous studies on have reported internalisation of ErbB receptors may be triggered in 
response to EGF and HRG leading to down-regulation of its activity (Hurrell & Outhoff 2013). 
Whether this is the case with our cell model is unknown; ideally, co-immunofluorescence 
staining experiments would be performed to determine internalisation of signalling active 
ErbB receptors and to explore possible co-localisation with FAK in the presence of HRG, 
though we were not able to do this as the primary antibodies were of the same species.  
Taken together from these experiments, our data indicates that FAK plays important roles in 
actin cytoskeletal remodelling and lamellipodia formation at the leading of SKBr3 cells in 
response to HRG and to ultimately regulate cell migration. Subsequently, our data 
demonstrated that inhibition of FAK acts to suppress SKBr3 cell migration, highlighting the 
potential of targeting FAK to reverse the aggressive nature of this breast cancer subtype.  
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5. Results (III) 
Targeting FAK in HER2+ breast cancer improves response to 
anti-HER2 targeted therapy  
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5.1 Introduction 
The anti-HER2 monoclonal antibody, Herceptin, represents the standard treatment for 
patients with HER2+ breast cancer. As a monotherapy however response rates are relatively 
low varying between 11-26% (Baselga et al. 1996; Cobleigh et al. 1999; Vogel et al. 2001). 
Better outcomes are achieved in combination with adjuvant chemotherapy. In a study, the 
inclusion of Herceptin with chemotherapy significantly increased the time to disease 
progression (TTP) to 7.4 compared to  4.6 months in patients that received chemotherapy 
alone (Slamon et al. 2001). Despite improvements, this study demonstrated that patients 
display disease progression within 1 year. Findings from the large Herceptin Adjuvant 
(HERA) study (1694 patients) demonstrated a significant 8.4% increase in disease-free 
survival benefit in patients treated with Herceptin for one year following chemotherapy 
(Piccart-Gebhart et al. 2005) and remained significant at the 3 years follow-up period (Smith 
et al. 2007). However, of the 1694 patients in the Herceptin-treatment cohort of the HERA 
study for instance, 7.5% reported recurrent events within the 1 year follow up period, and 
the majority of these presented as distant metastases. Altogether, these highlight the 
significant hurdle in treating patients with HER2+ disease.  
Given that FAK plays a key role in the transduction of HER2 signalling in HER2+ cells and that 
levels of FAK expression strongly correlated with HER2 overexpression in clinical samples 
(Benlimame et al. 2005; Schmitz et al. 2005), our hypothesis is that FAK may contribute to 
the limitation of Herceptin response. In support of this are studies which show that  
resistance to anti-HER2 therapies (Herceptin and Lapatinib) have been associated with 
increased integrin/FAK signalling (Yang et al. 2010).   
In chapters 3 and 4, we demonstrated that targeting FAK with PF878 in both HER2+/ER+ cell 
lines (BT474, MDA361) and HER2+/ER- cells (SKBr3) had significant anti-migratory effects 
but only a modest inhibition on growth. In this chapter, we explored whether the combined 
targeting of FAK alongside the HER2 receptor, using Herceptin would result in a greater 
suppression of growth, particularly given the supporting evidence for combination versus 
monotherapy approaches using small molecule inhibitors alongside traditional treatments 
in the literature (Araujo et al. 2009;Molife et al. 2014; Hudis et al. 2013). 
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5.2 Combined inhibition of FAK and HER2 in HER2+/ER+ cells results in enhanced 
suppression of proliferation  
 
We previously demonstrated that for ER+ cells, those which also co-expressed the HER2+ 
receptor were more sensitive to FAK inhibition as assessed by pFAK Y397 phosphorylation 
than cell lines which were HER2-. Although the inhibition of FAK activity alone did not 
significantly affect the proliferation of HER2+/ER+ cells, we hypothesised the FAK inhibitor 
might be more effective when combined with agents that targeted the HER2 receptor.  
Initial investigations on the two HER2+/ER+ cell lines revealed a differential sensitivity to 
Herceptin, with BT474 cells being growth inhibited whilst MDA361 cells exhibited limited 
sensitivity to this agent. IC30 values were recorded of 2.59nM (BT474) versus 21.48nM 
(MDA361) (Figure. 5.1A). The combination of Herceptin and PF878 resulted in a significantly 
enhanced the growth inhibitory effect in BT474 cells (with a low dose of Herceptin) whilst 
Herceptin-insensitive MDA361 cells appeared to regain Herceptin sensitivity; IC30 values for 
Herceptin now became 1.29nM and 5.9nM for BT474 and MDA361 cells respectively  
(Figure 5.1B,C).  
To determine whether the effect of Herceptin and PF878 combined were additive or 
synergistic, isobologram analysis was carried out, a common approach used to analyse drug 
interactions (See Section 2.9). First, the IC30 values for the individual agents were plotted on 
the X and Y axis of the graph; by connecting the two points, a ‘line of additivity’ is created. 
Thereafter, reference combinations of both drugs (dose pairs) that achieve the same level 
of growth suppression (i.e. 30% growth inhibition) were additionally plotted. As shown in 
Figure 5.1D, this analysis indicated that treatment of BT474 and MDA361 cells with 
Herceptin and PF878 in combination resulted in a synergistic effect towards the suppression 
on cell growth. 
To validate these observations, we compared the effects of Herceptin and PF878 as a 
monotherapy and in combination on cell proliferation by means of staining for the Ki67 
proliferation marker protein. Ki67 is strictly expressed in the active phases of the cell cycle 
(G1, S, G2, and mitosis), but not in resting cells (G0), and is thus commonly used as a marker 
for determining proliferative cells in a given cell population (Scholzen & Gerdes 2000). As 
shown in Figure 5.1E, combining Herceptin with PF878 resulted in a greater reduction in 
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Ki67-positive cells than monotherapies implying a reduction in the number of actively 
proliferating cells as a result of this treatment approach.  
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Figure 5.1 Targeting of FAK and HER2 together results in an improved suppression of HER2+/ER+ 
breast cancer cell proliferation vs monotherapy. (A) The ability of Herceptin to inhibit the 
proliferation of HER2+/ER+ breast cancer cells was determined by direct Coulter counting (B,C) The 
anti-proliferative effects of PF878 and Herceptin in combination in both cell lines were 
subsequently explored. (D) The nature of the interaction between Herceptin and PF878 was 
evaluated by isobologram analysis .Calculated dose pairs  that achieve the IC30 falling below the 
line of additivity are regarded to be synergistic whilst those above are antagonistic. In both cell 
lines, the Herceptin and PF878 appear to act in synergy when given in combination. Data are mean 
cell proliferation values ±SEM (n=3).(E) Parallel detection of Ki67 by immunocytochemistry on cells 
treated with Herceptin and PF878 in combination. Accompanying graph shows % mean 
proliferative counts (+Ki67) per field of view. * p=<0.05  
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5.3 Combined inhibition of FAK and HER2 suppresses signalling activity and 
results in PARP cleavage in HER2+/ER+ breast cancer cells  
 
To shed light onto the mechanism for the growth inhibitory effect arising from the 
combined Herceptin and PF878 treatment we explored the effects of this treatment 
regimen on FAK and HER2- associated signalling proteins, after a treatment time of 24hrs. 
Although signalling events could occur rapidly (within minutes), a longer time-point of 24hrs 
was chosen as it may better reflect signalling changes that mediate the effects on cell 
growth (Figure 5.2). 
Herceptin monotherapy resulted in an increase in the activity of HER2, EGFR and HER4 
whilst reducing AKT phosphorylation and MAPK (BT474 and MDA361 cells). PF878 alone had 
no obvious effect on ErbB receptor phosphorylation in either cell line or the activity of AKT 
and MAPK. However, when PF878 was combined with Herceptin, the effect was to 
attenuate Herceptin-induced ErbB activation (below control levels in MDA361 cells) and 
reduce AKT and MAPK to almost undetectable levels.  
To determine a potential contribution of apoptosis to the anti-proliferative effects of 
combination treatment, analysis of PARP cleavage, a surrogate marker for caspase-3 
activation and apoptosis, was performed again by Western blotting. These data revealed 
that the combination of Herceptin and PF878 elevated the amount of the 23kD PARP 
fragment detected in cell lysates.  
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PARP (23kD) 
Figure 5.2 Combined targeting of FAK and HER2 in HER2+/ER+ BT474 and MDA361 breast cancer 
cells and their effects on HER2 and FAK-related signalling components. Cells were treated with 
PF878 (1 μM), Herceptin (1 and 10 nM) or the combination of both the agents for 24 hrs. Cells 
were lysed and protein expression and activity were assessed by western blotting. GAPDH was 
used as a loading control. Representative blots shown from three independent experiments. 
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5.4 Targeting FAK in HER2+/ER+ breast cancer cells enhances sensitivity to 
endocrine therapy 
 
According to NICE guidelines (UK), there is variation in clinical practice for HER2+/ER+ 
tumours, and are evaluated by clinicians on a case-by-case basis. In some patients, 
treatment regimens can include endocrine therapy; however, given the prevalence of the 
HER2 receptor in the luminal B group of tumours, there is the potential for de novo 
endocrine resistance, as the HER2 is known to be a limiting factor to endocrine therapies 
(Houston et al. 1999; Davies et al. 2011). Thus we wished to investigate whether inhibition 
of FAK might improve endocrine response in HER2+/ER+ models.  
 
As previously demonstrated, BT474 cells were much more sensitive to the growth inhibitory 
effects of Herceptin versus MDA361 cells. However, the reverse was true when endocrine 
agents were used, with BT474 cells being much less sensitive to Tamoxifen. Inclusion of 
PF878 with Tamoxifen further suppressed growth of both cell lines versus monotherapy. 
This was more profound in BT474 cells suppressing growth from approximately 76% with 
Tamoxifen treatment alone to approximately 41% when combined with PF878. The 
combination treatment with the three drugs altogether led to an even further suppression 
of growth in both cell lines (Figure 5.3).  
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Figure 5.3 Inclusion of endocrine therapy (Tamoxifen (10-7M)) with Herceptin (1nM) and PF878 
(1μM) results in a further improved suppression of MDA361 and BT474 cells. Cells were seeded on 
24 well plates and treatments as indicated were added after 24hrs. After 7 days, cell proliferation 
was assessed by direct cell count using a Coulter counter. Data are mean cell count values ±SEM 
(n=3). * p=<0.05. 
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5.5 Combined inhibition of FAK and HER2 in HER2+/ER- cells results in enhanced 
suppression of proliferation  
 
Having seen a benefit from co-targeting FAK and the HER2 receptor in luminal B breast 
cancer models, we next explored whether the combination of Herceptin with PF878 can 
provide a significant enhancement of growth suppression in the HER2+/ER- SKBr3 breast 
cancer model. In the absence of an isogenic control, we employed the HER2-, ER+ cell line, 
MCF7 as a comparator. Herceptin treatment inhibited SKBr3 cell growth by 50% (IC50 
38.5nM) while MCF7 cells were unaffected (Figure 5.4A).  Combination treatment of 
Herceptin at 10 and 100nM doses plus 1uM PF878 resulted in further growth suppression 
although statistically insignificant (Figure 5.4B). Parallel immunocytochemical staining also 
demonstrated that combination treatment (10nM Herceptin + 1μM PF878) led to a greater 
decrease in Ki67-positive cells (Figure 5.4D). 
To examine the drug interactions in this context subsequent isobologram analysis was 
performed and revealed that Herceptin at lower concentrations of 10nM was synergistic 
with PF878 (Figure 5.4C). Increasing the concentration of Herceptin over and above 10nM 
elicited no further benefit, thus this data was consistent with the isobologram analysis that 
at higher Herceptin concentrations (100nM), the interaction with PF878 appeared 
antagonistic. 
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Figure 5.4. Targeting of FAK and HER2 together results in an improved suppression of HER2+/ER- 
SKBr3 breast cancer cell proliferation. (A) The ability of Herceptin to antagonise the proliferation of 
MCF7 and SKBr3 breast cancer cells for 7 days was determined by direct cell counting.(B) The anti-
proliferative effects of PF878 (1uM) and varying doses Herceptin in combination on SKBr3 cells  for 
7 days were subsequently analysed by direct Coulter counting (n=3 ±SEM). (C) The nature of the 
interaction between Herceptin and PF878 was evaluated by Isobologram analysis as in 5.2. (D) 
Parallel detection of Ki67 by immunocytochemistry on cells treated with Herceptin (10nM) and 
PF878 in combination. Accompanying graph shows % of mean proliferative counts (+Ki67) per field 
of view (n=3 ±SEM) * p=<0.05. 
Control                    Herceptin                             PF878                  Herceptin+PF878 
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5.6 Effect of FAK and HER2 inhibition on SKBr3 signalling pathways 
 
To explore the signalling pathways modulated by Herceptin in combination with PF878, we 
investigated changes in FAK and HER2-associated signalling proteins known to be involved 
in regulation of cell survival and growth, by Western Blotting (Figure 5.5). 
As previously observed in HER2+/ER+ cells, Herceptin again promoted an increase in the 
activity of HER2, EGFR and HER4. This was also accompanied by an increase in pFAK Y397, 
and pFAK Y861 as well as AKT and MAPK activity. In contrast, Herceptin resulted in 
suppression of HER3 phosphorylation. PF878 alone had no obvious effect on EGFR and HER3 
receptor phosphorylation but induced activity of HER2 and HER4. Moreover, AKT and MAPK 
activity were also increased. In particular, PF878 elicited a much greater AKT activation than 
Herceptin.  
When PF878 was combined with Herceptin, the activities of Herceptin-induced increase in 
HER2, EGFR and HER4 activity were unaffected, whilst AKT and MAPK activities were further 
increased. Activities of pFAK Y397, Y861 and HER3 were however decreased. Despite these 
paradoxical increased activation of AKT and MAPK, analysis of PARP cleavage, a surrogate 
marker for caspase-3 activation and apoptosis, revealed the combination of Herceptin and 
PF878 elevated the amount of the 23kD PARP fragment detected in cell lysates. 
 
. 
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Figure 5.5.  Combined targeting of FAK and Her in HER2+/ER- SKBR3 breast cancer cells does not 
suppress FAK-related signalling components. SKBr3 cells were treated with PF878 (1 μM), 
Herceptin (1 and 10 nM) or the combination of both the agents for 24hrs. Cells were lysed and 
protein expression and activity were assessed by western blotting.β-actin was used as a loading 
control. Representative blots shown from three independent experiments. 
SKBr3 
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5.7 Discussion 
 
Despite the clinical effectiveness of Herceptin in targeting HER2+ tumours, resistance 
remains a significant hurdle to their effective treatment. A means of improving Herceptin 
response is therefore warranted given the  number of compensatory or resistance 
mechanisms identified and one opportunity for doing this is through combination treatment 
approaches (Nahta & Esteva 2007).  
Several studies have demonstrated a role for FAK in the progression and spread of HER2+ 
breast cancers demonstrating that FAK overexpression correlates with HER2 overexpression 
and also that FAK is key effector of HER2 signalling which mediates oncogenic 
transformation and invasive behaviour (Schmitz et al. 2005; Benlimame et al. 2005; Xu et al. 
2009). Thus targeting FAK alongside the HER2 receptor may have some benefit and 
represented the focus of this chapter. Although we established that targeting FAK with the 
small molecule inhibitor PF878 only modestly affected growth of HER2+/ER+ and HER2+/ER- 
cell lines, we hypothesised that co-targeting both HER2 and FAK using a combination of 
Herceptin plus PF878 might elicit greater benefit in terms of suppression of cell growth. 
Indeed, the use of FAK inhibitors in combination treatment regimens is already supported 
by other studies showing dual FAK and EGFR inhibition in breast cancer and enhanced radio-
sensitivity of head and neck cancers (Golubovskaya et al. 2002; Eke & Cordes 2011). Dual 
targeting of insulin-like growth factor-1 receptor (IGF-1R) and FAK also in pancreatic cancer 
led to enhanced apoptosis (Zheng et al. 2010).  
The mechanism of action of Herceptin is, in part, a consequence of its ability to inhibit 
downstream signalling of HER2, of which AKT and MAPK play an important role and lead to 
HER2-mediated cell survival, proliferation and resistance to apoptosis (Marmor et al. 2004; 
Nahta & Esteva 2007). On investigating Herceptin sensitivity in the HER2+ cell lines, we 
initially showed that despite Herceptin partially inhibiting AKT and MAPK activity in BT474 
and MDA361 cells, only the former were growth inhibited in agreement with a previous 
study (Yakes et al. 2002). Interestingly, MDA361 cells expressed lower levels of HER2 activity 
than BT474 cells which may suggest that they are less reliant on HER2 signalling for growth. 
MDA361 cells may thus represent the subset of HER2+/ER+ tumours that are intrinsically 
less responsive/resistant to Herceptin. Our data also appears to suggest that AKT or MAPK 
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are not part of the dominant regulatory pathway in MDA361 cells. There is also a possibility 
that the intrinsic HER2 hetero/homo dimerization patterns might be different between 
these two cell lines, thereby providing differential inputs towards regulation of AKT and 
MAPK signalling, as supported by Ghosh et al. (2011).  Alternatively, any residual AKT or 
MAPK activity (which is still substantial) even after Herceptin treatment may be enough to 
sustain cell proliferation. Thus, combination strategies such as Herceptin plus PF878 may 
represent a better approach to target these pathways more effectively, particularly in the 
context of limited Herceptin sensitivity. Indeed, the combination of Herceptin and PF878 
produced greater growth inhibition than the effects of either of the drugs individually in 
MDA361 and BT474 cells, which concurred with the enhanced suppression of AKT and 
MAPK activity. Subsequent growth assays employing the use of AKT and MAPK inhibitors 
confirm that the significant loss of AKT (rather than MAPK) predominantly contributes to 
this enhanced growth suppression in these cell lines (See Appendix 8.2). This is further 
supported by a study that reports benefits of HER2-targeted therapy in combination with 
small molecule inhibitors in a mechanism involving suppression of AKT signalling (Yao et al. 
2009).  
The involvement of AKT is not surprising given its crucial role in regulating proliferation and 
survival. AKT mediates cell growth by phosphorylating TSC2 and PRAS40 leading to 
subsequent activation of mTOR complex 1 (mTORC1), a direct regulator of translation 
initiation. It also regulates the CDK inhibitors p21 and p27, and GSK3 by direct 
phosphorylation, all of which are critical to cell cycle progression. Other important 
mechanisms include the negative regulation of pro-apoptotic proteins such as the BH3-only 
protein BAD and the suppression of FOXO-mediated transcription of pro-apoptotic genes 
(Reviewed Manning & Cantley 2007). Our data demonstrated that combined treatment with 
Herceptin plus PF878 resulted in a decrease in the number of proliferative cells and a likely 
induction of apoptosis, given the increase in PARP cleavage detected. Collectively our data 
suggest that the anti-proliferative and pro-apoptotic responses seen with Herceptin plus 
PF878 combined may well occur through suppression of AKT. 
Cross talk between the HER2 and ER has been shown to promote resistance to anti-HER2 
therapies and studies demonstrate that ER antagonism with endocrine therapy improve 
outcome on Herceptin (Houston et al. 1999; Y.-C. Wang et al. 2011; Montemurro et al. 
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2012). Similarly, HER2 overexpression itself is associated with resistance to endocrine 
therapy (De Laurentiis et al. 2005; Dowsett et al. 2006; Davies et al. 2011). Since we are 
investigating the role of FAK in BT474 and MDA361 cells that also express ER, from a clinical 
perspective, it was crucial to explore whether targeting FAK may provide further benefit 
towards endocrine therapy such as Tamoxifen, widely used in clinical practice (Shiau et al. 
1998). Our data revealed that MDA361 cells, were more sensitive to Tamoxifen than BT474 
cells. This differential sensitivity between these two HER2+/ER+ cell models suggest  that 
response to endocrine therapy cannot be clearly defined by the ER status alone. This could 
partially be explained by differences in growth rates, where growth inhibitory effects of 
drugs are more apparent in faster growing cells, unique differences with regards to post-
translational modification or mutations within the ER which may confer differential ER 
interactions with the DNA, ultimately giving rise to distinct gene expression profiles 
between the cell lines (Dixon 2014). Encouragingly, inclusion of PF878 with Tamoxifen 
resulted in further suppression of growth in both cell lines, but was particularly more 
apparent in BT474 cells which were relatively insensitive to Tamoxifen. This is in further 
support of the notion that perhaps inhibition of FAK exerts greater benefits in the context of 
limited sensitivity. Although FAK has previously been implicated in the acquisition of 
Tamoxifen-resistance in MCF7 cells (Hiscox et al. 2009; Hiscox et al. 2011), this present data 
also indicates that FAK is also a mediator of intrinsic (de novo) resistance to Tamoxifen in 
these HER2+/ER+ cells. Moreover the inclusion of Tamoxifen with Herceptin resulted in a 
further suppression of growth in both cell lines, in agreement with  previous studies (Argiris 
2004; C.-X. Wang et al. 2005), an effect further enhanced in the presence of PF878, thereby 
strengthening the rationale of combination strategies that include FAK inhibitors. 
We also reported that the combination treatment of Herceptin and PF878 similarly resulted 
in the enhanced growth suppression of the HER2+/ER- SKBr3 cells, although to a much 
lesser extent. Notably, no further benefits were observed at when increasing Herceptin 
concentrations to 100nM, indicating a possible saturation of the HER2 receptors at higher 
concentrations or potential interference with the receptor recycling to the cell surface 
(Hurrell & Outhoff 2013).  
Differences concerning the downstream signalling modulation between HER2+/ER+ and 
HER2+/ER- cell lines involved also became apparent.  Herceptin was also unable to decrease 
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AKT and MAPK activity, but instead led to their increase in SKBr3 cells. Data from other 
studies exploring the effect of Herceptin on downstream signalling are conflicting with ours 
(Longva et al. 2005; Dokmanovic & Wu 2014) whilst others are in agreement (O’Brien et al. 
2010; Diermeier-Daucher et al. 2011), and thus firm conclusions cannot be drawn. In 
addition, we acknowledge a number of additional limitations including the concentration of 
drugs, variability of treatment time-course points or perhaps the differential growth media 
used in these studies, ranging from DMEM, McCoys and RPMI as in our case. We further 
observed that PF878 also induced AKT and MAPK in SKBr3 cells. This was similar to our data 
in section 4.3 whereby short-term exposure to PF878 (60 minutes) caused a dose-
dependent increase in AKT and MAPK activity, despite inhibition of FAK activity. In this 
regard, at longer exposures to PF878 (24hrs) of SKBr3 cells, the compensatory increase in 
AKT and MAPK signalling is sustained. Importantly, inclusion of PF878 with Herceptin 
treatment led to further increases in AKT and MAPK above control levels. These were 
surprising given our data of enhanced suppression of proliferation and increased apoptosis 
as detected by Ki67 staining and cleavage of PARP, thereby indicating that the levels of AKT 
or MAPK activity may not be an important signalling change correlating with cell survival in 
this cell line and therefore may not always correlate with Herceptin response. However, 
regarding to the pivotal role of AKT and MAPK in drug resistance (O’Brien et al. 2010; 
McCubrey et al. 2006), it is reasonable to also acknowledge that their increased activity may 
contribute to an eventual acquisition of resistance of HER2+/ER-  cells to this combination 
regimen. 
The observation of increased AKT activity by Herceptin while growth inhibition ensues was 
not unprecedented. For instance, a study on  MDAMB-468 and ZR75-1 cells demonstrated a 
transient early induction of AKT phosphorylation following treatment with Herceptin and 
other therapeutic agents such as Doxorubicin and Tamoxifen (Clark et al. 2002); this 
induction appeared to correlate with enhanced apoptosis when administered in 
combinations with LY294002, a PI3K/AKT inhibitor. In this respect, the authors suggested 
that the increase in AKT activity in response to therapeutic agents might enable them to be 
more susceptible to inhibition of the AKT pathway by LY294002. Given our evidence that 
Herceptin and PF878 led to greater suppression of growth, an alternative explanation in the 
context of SKBr3 cells would be that the inclusion of PF878 increased AKT phosphorylation 
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the result of which was to confer increased sensitivity to the growth inhibitory effects of 
Herceptin. However, to fully test this hypothesis further studies are now required that could 
include a time-course detection over a longer period of AKT activity in response to the 
combination of Herceptin and PF878 treatment.  
A further and surprising finding was that Herceptin itself appeared to induce the 
phosphorylation of ErbB receptors in BT474, MDA361 and SKBr3 cells. Although this was 
contrary to our initial assumptions, others have reported similar events in HER2+ cell 
models (Gijsen et al. 2010; Dokmanovic et al. 2014).  Dokmanovic et al., in particular 
showed that Herceptin-induced HER2 phosphorylation was also coupled with a novel 
interaction with Csk-homologous kinase (CHK). Here, cooperation with CHK was implicated 
in the degradation of HER2, the reduction of HER3 and AKT activity and resultant growth 
inhibition. Interestingly, we observed a small reduction in total HER2 levels following 
Herceptin treatment in BT474 and MDA361 cells that may represent the early stages of 
receptor recycling/degradation.  Importantly, in BT474 and MDA361 cells, we speculate that 
FAK is also involved in the direct and/or indirect activation of these ErbB receptors, as 
indicated by our data that PF878 was able to decrease total HER2 expression and the 
Herceptin-induced activation of HER2, EGFR and HER4 in these cells. 
In SKBr3 cells however, PF878 was unable to suppress the increased HER2, EGFR, HER4 
phosphorylation induced by Herceptin. But consistent with another study, Herceptin was 
able to inhibit HER3 activity (Gijsen et al. 2010). The authors have noted these observations 
following 1hr Herceptin treatment, which correlated with a decrease in AKT activity, but 
with prolonged treatment of 2 days, reactivation of AKT occurred. This was attributed to 
negative-feed loop resulting from Herceptin-mediated AKT suppression which causes an up-
regulation of ADAM-17 proteases that function to cleave ErbB ligands from the cell surface, 
in turn activating other ErbB receptors and subsequently HER2 activation and downstream 
signalling. Such a mechanism may reflect our findings at 24hrs whereby AKT activity was 
increased, though more studies will be required to determine whether these are ligand-
induced. Importantly, we demonstrated that these observations were strongly paralleled by 
the increase in FAK activity (Y397, Y861). However, that PF878 potentiated this 
phenomenon rather than suppress it, suggests the involvement of FAK in regulation of ErbB 
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signalling and lends a potential yet unidentified mechanism that may substantiate the 
current mechanisms proposed by others (Gijsen et al. 2010; Dokmanovic et al. 2014). 
This finding also raises the question of whether the induction of the ErbB receptors could 
eventually confer a signalling advantage, and if so, does it present implications in acquiring 
Herceptin resistance? In this context, previous studies have particularly attributed the 
increase in EGFR and HER2 activity to Herceptin resistance (Diermeier et al. 2005; Ritter et 
al. 2007). In contrast, it was also shown that HER2 and EGFR co-expression strongly 
potentiates apoptotic signalling in response to EGF through both receptors in a variety of 
cell lines including SKBr3 cells (Tikhomirov & Carpenter 2004). On the other hand, the 
significance of increased HER4 activity seems to be relatively unclear and paradoxical. 
Though a study has attributed HER4 expression to Herceptin resistance (Mohd Nafi et al. 
2014), many others reports are contradictory. In one study for example, the HER4 receptor 
intracellular domain (4ICD) was identified to be BH3-only protein, capable of promoting 
mitochondrial cytochrome C release and subsequent apoptosis (Naresh et al. 2006). 
Moreover, HER4 activation has been associated with anti-proliferative effects, increased 
sensitivity to Herceptin and better patient prognosis (Suo et al. 2002; Sassen et al. 2009; 
Witton et al. 2003). Taken together, these suggest the activation of ErbB receptors we 
observed in response to Herceptin may determine varying cellular outcomes and are thus 
worthy of further study as they may have important clinical implications. 
Altogether, despite differential signalling observations between the HER2+ breast cancer 
cells, the data present in this chapter support the approach of targeting elements such as 
FAK in HER2+ breast cancer alongside the HER2 itself. Importantly, our data suggests that 
the combination of Herceptin and PF878 are likely to be most effective in the context of de 
novo insensitivity given that Herceptin and PF878 worked best in Herceptin-insensitive 
MDA361 cells whilst PF878 and Tamoxifen worked best in endocrine-insensitive BT474 cells.  
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6. Results (IV) 
FAK mediates fibroblast-induced HER2+ breast cancer cell 
migration 
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6.1 Introduction 
Previously, we demonstrated a role for FAK in Heregulin (HRG)-induced breast cancer cell 
migration (see Chapter 3,4). Given that HRG is known to be present in the tumour 
microenvironment and that stromal HRG expression correlates with an aggressive tumour 
behaviour and increased disease recurrence (Visscher et al. 1997; Atlas et al. 2003a) we 
hypothesised that FAK inhibition might present an effective strategy for suppression of 
stromal-induced tumour behaviour likely to promote disease progression. Indeed, the role 
of bi-directional tumour-stroma cross-talk in facilitating tumour spread is increasingly 
apparent (Hanahan & Weinberg 2011) (illustrated in Figure 6.1). These interactions are 
mediated by a wide spectrum of tumour-secreted factors that include growth factors (e.g. 
TGFβ, PDGF, VEGF, EGF), cytokines and other soluble factors which may act in an autocrine 
manner, allowing further activation of the tumour cell itself, or through paracrine 
modulation of other cell types in the tumour microenvironment including endothelial cells, 
fibroblasts, resident immune-cells (e.g. lymphocytes, monocytes, mast cells, neutrophils), 
pericytes and smooth muscle cells. This ‘activated’ state of stromal cells, similarly observed 
during the process of wound healing, is characterised by increased secretion of additional 
growth factors, a range of proteases (e.g. MMP2, MMP9) and ECM components (e.g. 
tenascin, collagen,  elastin, fibronectin) that themselves further induce proliferative and 
pro-metastatic responses from the tumour, ultimately establishing a permissive 
environment to promote tumour progression  (Tlsty & Hein 2001, Mueller & Fusenig 2004;). 
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Of the number of stromal cells involved, the fibroblasts are considered to be predominantly 
present within the tumour bulk (Kalluri & Zeisberg 2006). The supportive role of fibroblasts 
in malignancy has been acknowledged for over two decades (van den Hooff 1988) with 
direct co-culture with fibroblasts, or exposure to fibroblast conditioned-media, being shown 
to stimulate growth of a number of breast cancer cell lines (Ryan et al. 1993; Lefebvre et al. 
1995; Gache et al. 1998; Angelucci et al. 2011). In line with this, a number of in vivo studies 
involving co-inoculation of fibroblasts and pre-neoplastic epithelial cells further 
demonstrated the ability of fibroblasts to initiate malignancy and promote tumour growth 
(Camps et al. 1990; Olumi et al. 1999; Yashiro et al. 2005; Orimo et al. 2005). In addition, the 
interplay between fibroblasts and tumour cells can also invoke reciprocal changes in gene 
expression profiles such as those involved in cell survival (Rozenchan et al. 2009). More 
recently, fibroblasts have been demonstrated to play a role in eliciting a favourable tumour 
microenvironment which supports the development of resistance of melanoma cells to 
BRAF inhibition (Hirata et al. 2015). 
 
Figure 6.1. Stromal contribution in tumour progression. Tumour cells (in brown) release soluble 
factors to activate the stroma. Stromal cells subsequently release proteases, additional growth 
factors and matrix components (e.g. collagen, fibronectin). This leads to breakdown of basement 
membrane and infiltration of stromal cells into the tumour.  Collectively, this results in angiogenesis, 
tumour growth, invasion through the degraded basement membrane and metastasis. 
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A number of studies also point to a supportive role for fibroblasts in the metastatic 
behaviour of tumour cells. Breast cancer cell migration is known to be stimulated by co-
culture with fibroblasts or exposure to  fibroblast-conditioned media (Rossi et al. 1993; 
Heylen et al. 1998). Conditioned-media from tumour-associated breast fibroblasts was also 
demonstrated to significantly induce MCF7 cell invasion when compared with those of 
patient-matched normal breast fibroblasts (Studebaker et al. 2008). Taking a step further, 
more recent data have shown that fibroblast populations isolated from the invasive tumour 
front (termed the ‘interface zone’) were significantly more potent at promoting migration 
and EMT of breast cancer cells than fibroblast populations isolated from within the tumour 
bulk (Gao et al. 2010).  
Whilst these and other studies strongly suggest that the presence of fibroblasts in the 
stroma of breast tumours foster tumour progression, the specific contributions of 
fibroblasts towards HER2+ breast cancer metastasis remains poorly understood. 
Considering that FAK was shown to be involved in the ligand-induced migratory responses 
of HER2+ breast cancer cells (Chapters 3 and 4), in this chapter we extended this work to 
explore our  hypothesis that FAK would also represent a key modulator of fibroblast-
stimulated HER2+ breast cancer cell migration and invasion. 
.  
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6.2 Optimising the harvest of fibroblast conditioned media 
 In order to explore fibroblast-induced cell migration in vitro, we used conditioned media 
from the MRC5 lung fibroblast cell line. A standardised collection protocol was used as 
shown below:  
 
 
 
 
 
 
This helped reduce inconsistencies that may arise from large differences in cell number 
from which the media was collected from. Since MRC5 fibroblasts displayed a high 
proliferative rate in culture, cell counts were obtained from culture directly after retrieving 
conditioned media (i.e. the number of cells contributing to the FCM)  to allow normalisation 
of data where FCM was used collected from different MRC5 passages (to allow for biological 
replicate experiments, for example). Media was collected and cleared by centrifugation at 
1000 rpm for 5 minutes, filtered through a 0.45 μm Millipore filter to remove non-adherent 
cells and other debris, and kept at -20°C (up to 7days) or -80°C (up to a month) for storage.  
Importantly, one further consideration is that of senescence. It is widely reported that 
MRC5 and other fibroblast cell lines rapidly reach a senescent state due to their high 
proliferation rate in in vitro culture. Once in this state, they are unable to respond to growth 
stimuli, display morphological changes (cell enlargement) and irreversible growth arrest 
(Rodier & Campisi 2011).  Our own observations also seemed to suggest that such a 
phenomenon occurs, with MRC5 cell populations at earlier passage number (p4-p7) 
displaying higher growth rates particularly between days 1-5 when compared to those at a 
later passage (p8-p11) (Figure 6.3). Thus, from these observations and for consistency, it 
was decided that FCM were collected from MRC5 cells between passage 4-7 and cultured 
for no more than 5 days and/or are subconfluent.  
Figure 6.2 Outline of timeline for harvesting conditioned-media from MRC-5 fibroblast cell line. 
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Figure 6.3. MRC-5 fibroblast cells at various passage numbers were grown on 24 well-plates and 
growth was assessed by direct coulter counting at different time-points over 7 days. Starred: 100% 
cell confluence was observed.  
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Further analysis of the protein content of the FCM was undertaken using BioRad DC 
Coloumetric assay (See section 2.4.1.3 ) to determine whether the FCM collected from 
different MRC5 culture passages varied in total protein content. The measured protein 
content was determined as a function of the total number of MRC5 cells in each flask. This 
was validated as shown by our obtained values below. 
 
MRC5 FCM harvest 
(million cells/ml) 
Protein conc. (mg/ml) 
0.3 4.09 
0.13 2.485 
0.25 2.64 
0.20 2.36 
Average protein conc: 2.09 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. Number of cells contributing to FCM and actual FCM protein concentration as analysed 
by the BioRad DC Coloumetric protein assay. Protein concentration values obtained taken from  
four independent FCM harvests.  
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6.3 Evaluating toxicity of FCM on breast cancer cells 
 
It is a possibility that MRC5-conditioned medium could be toxic to the breast cancer cells 
since it had been collected over a period of three days and thus may be severely nutrient 
depleted (albeit that DCCM was used which is a low nutrient media to avoid the use of 
serum which may confound the data due to presence of multiple growth factors and other 
elements) and/or the MRC5 cells may secrete factors that could adversely affect breast 
cancer cell viability. In order to investigate any possible toxicity incurred by the FCM on 
breast cancer cells, they were cultured with increasing concentrations of FCM ranging from 
20% to 100% for 7 days and analysed by direct Coulter counting, as shown (Figure 6.5), no 
significant toxic effects (loss in cell viability) were observed in both MFC7 and SKBr3 cells. 
There are however indications of possible toxicity to MCF7 cells at 100% FCM. In this regard, 
to ensure cell viability but at the same time maintain a high concentration of fibroblast-
secreted factors, 80% FCM diluted in fresh DCCM growth media was used in subsequent 
experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. Cell viability MCF7 and SKBr3 cells upon exposure to increasing concentration of FCM for 
7 days, as assessed by direct Coulter counting. Data are mean cell proliferation values ±SEM. (n=3) 
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6.4 HER2- and HER2+ breast cancer cells are sensitive to FAK inhibition by PF271 
 
In this chapter where FAK activity is pharmacologically inhibited, we employed the use of 
the FAK inhibitor ‘PF271’ (see Chapter 2.1.1). This is a predecessor of PF878 but has a similar 
chemical structure (one side group has been altered) and mechanism of action. The reason 
for changing from PF878 to PF271 (Roberts et al. 2008) was that, at the time of the 
experiments, PF878 was no longer available due to the commercial rights of this compound 
being acquired by another drug company. Thus for consistency throughout this chapter, 
PF271 was used. 
The sensitivity of MCF7 and SKBr3 cells to PF271 with regards to its target pFAK Y397 was 
verified using Western blotting. As shown in Figure 6.6A, PF271 induced  a dose-dependent 
decrease in pFAK Y397 in both cell lines although neither cell line  appeared to be 
differentially sensitive to PF271 with IC50 values of 0.17 μM (MCF7) and 0.10 μM (SKBr3)  
(Figure 6.6B). Accompanying a reduction in FAKY397 was a dose dependent loss of FAK 
phosphorylation at Y861 (Figure 6.6A) 
We next investigated whether the suppression of FAK activity resulted in inhibition of 
intracellular signalling intermediates that are known to be regulated by FAK and/or HER2, 
and of which, AKT and MAPK have been implicated from our findings in previous chapters. 
As shown in Figure 6.6A, accompanying FAK inhibition was a reduction in the levels of MAPK 
in both cell lines; in MCF7 cells we also observed a reduction in AKT activity.  
Interestingly, in addition to the loss of FAK and signalling pathway activity, we also observed 
that PF271 treatment resulted in a dose-dependent inhibition of MCF7 and SKBr3 cell 
proliferation; interestingly, the IC50 values for pFAK Y397 inhibition correlated with the IC50 
required for growth inhibition (Figure 6.6 C,D ). 
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Cancer 
Molecular 
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 (µM) 
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MCF7 HER2-, ER+ 0.17± 0.048 
SKBr3 HER2+, ER-  0.10± 0.032 
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Figure 6.6. Sensitivity of ER+/HER2- and ER-/HER2+ breast cancer cells to PF271. (A) MCF7 and 
SKBr3 lysates treated with the PF271 (0-1μM) for 60mins were probed for proteins as 
indicated.  GAPDH was used as loading control. (B) Densitometric analysis of immunoblots 
was carried out to calculate the IC50 values ± SEM for PF271 with regards to pFAK Y397 
inhibition. Representative blots shown are from three independent experiments. Continued. 
pFAK Y397 inhibition 
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Figure 6.6. (Continued)  (C) The growth of MCF7 and SKBr3 cells in response to PF271 (0–1 
μM) over a period of 7 days was assessed using Coulter counting. Calculated data are mean 
cell proliferation values ±SEM (n=3). Plotted dose-response curves were subsequently used to 
calculate IC50 values ± SEM for PF271 with regards to growth inhibition (D).  
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6.5 FAK mediates fibroblast conditioned media-stimulated HER2+ breast cancer 
cell migration and invasion 
In view of our previous observations on the effects of extracellular ligands on cell migration, 
we next investigated whether the behaviour of MCF7 and SKBr3 cells was influenced by 
fibroblasts by culturing the cells in the presence of conditioned media from MRC5 cells. The 
ability of FCM to promote the migration of breast cancer cells was determined using a 
Boyden Chamber assay in which FCM was used as a chemo-attractant on the lower chamber 
and MCF7 or SKBr3 cells were seeded into the upper chamber. FCM promoted a 
concentration-dependent increase in the migratory capacity of SKBr3 cells, whilst having 
minimal effects on MCF7 cells (Figure 6.7A) The effects on SKBr3 cells was significantly 
inhibited by PF271 (1μM). The function of FAK in this context was further validated by siRNA 
knockdown of FAK which again inhibited FCM-induced migration (Figure 6.7D). 
Accompanying the fibroblast-induced migration of SKBr3 cells were changes in the 
cytoskeletal organisation, with the formation of cellular protrusions wherein actin clusters 
were prominently observed, particularly at the leading edge of the cell. In addition, we also 
observed that the normally punctate pFAK Y861 localization in focal adhesions were 
strongly enhanced at the protrusions following stimulation with FCM; inclusion of PF271 
with FCM reversed this phenotype (Figure 6.7C). 
To analyse the significance of the HER2 signalling in the migratory response of the HER2+ 
SKBr3 cells, we employed the use of Herceptin. Indeed, data has shown that HER2 signalling 
is a key regulator of the migratory response of SKBr3 cells to FCM with Herceptin treatment 
resulting in inhibition of FCM-induced SKBr3 cell migration. We also found that the 
combination of Herceptin and PF271 further enhanced the anti-migratory effect (Figure 
6.7E). Together, these studies suggest that factors present in FCM responsible for induction 
of cell migration can occur via HER2/FAK signalling, however, there also exists a HER2-
mediated migratory signalling that occurs in a FAK-dependent manner. Signalling studies 
exploring the effect of Herceptin on FAK activity in the presence of FCM would further 
substantiate this hypothesis.  
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Figure 6.7. (A,B) Inhibition of FAK by PF271 (1μM) impairs  SKBr3 cell migration (and not 
MCF7 cells) through fibronectin-coated Boyden chamber assay in response to two 
concentrations (60%, 80%) of MRC-5 conditioned media (FCM) over a 20hr period. Cells were 
subsequently fixed and stained with crystal violet. Experiments were performed in DCCM 
culture media and data represent the mean numbers of migratory cells/membrane run in 
duplicates from three independent experiments. Data shown have also been normalized to 
the MRC-5 cell number of the specific cell passage the FCM was obtained. Representative 
images of stained migratory cells are shown. P value: *<0.05, ** <0.001. Continued. 
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Figure 6.7. (Continued)  (C) Immunofluorescence images of SKBr3 cells seeded on FN-
coated plates following 80%FCM ±PF271 (1μM) for 60mins. Cells were stained 
Rhodamine-phalloidin (F-actin) (red), pFAK Y861 (green) and DAPI as a nuclear 
counterstain (blue). Continued. 
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Figure 6.7. (Continued) (D) Parallel migration assays were performed on SKBr3 cells 
transfected with non-targeting siRNA (NTsiRNA) or FAKsiRNA revealing comparable 
inhibition of migratory response to FCM. (E) Effect of Herceptin treatment (10nM) alone or 
in combination with PF271 on SKBr3 cell migration in response to two FCM over a 20hr 
period. P value:*<0.05, ** <0.001, *** <0.0001. 
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The effects of FCM on SKBr3 cell invasion were also explored using a 3D basement-
membrane extract (BME) invasion assay, wherein cells were pre-formed into spheroids and 
allowed to invade into the surrounding matrix in the presence of medium containing 
treatment or chemo-attractants (See section 2.6). This in-vitro assay provides the advantage 
of more closely mimicking in-vivo conditions with regards to cell-cell physical interactions 
and cell-matrix interactions. SKBr3 cells successfully formed spheroid cell-aggregates after 
Day 1 (Figure 6.7F) and subsequent treatment with FCM promoted SKBr3 cell invasion, as 
demonstrated by the images captured after 3 days incubation which revealed the 
appearance of budding edges and a number of individual cells detached from the spheroid 
colony that have invaded into the surrounding matrix (Figure 6.7F). Suppression of FAK 
activity appeared to suppress this invasive behaviour however, due to the irregularity of the 
colony edges and the single-cell mode of invasion, quantification and accurate comparison 
between replicate colonies proved challenging. A semi-quantitative analysis attempt based 
on the direct count of detached cells from the spheroid appeared to confirm that FCM-
stimulated SKBr3 cell invasion was also significantly inhibited by PF271.  
Since invasion required proteolysis of the ECM, we delved and further explored the 
secretion of MMPs. These proteolytic enzymes, through their ability to degrade ECM are 
closely associated with cancer cell invasion (Egeblad & Werb 2002). Since secretion of 
MMPs are known to be regulated by a number of growth factors in the tumour 
microenvironment (Birkedal-Hansen et al. 1993) and fibroblasts are an abundant source of 
these soluble factors, we explored the ability of MRC5 cells to stimulate MMP secretion by 
SKBr3 cells using gel zymography (see section  2.7). FCM contained detectable proteolytic 
activity to that correlated with MMP-2 which has a molecular weight of 72 kDa. FCM 
however failed to induce MMP2 activity in SKBr3 cells over and above that likely to be 
detected from the FCM alone (Figure 6.7H). In addition, this method can also identify the 
proteolytic activity of MMP9 (molecular weight 92kD). As shown, no additional bands 
appeared in the gel suggesting that no active MMP9 can be detected, neither from 
fibroblasts or SKBr3 cells. 
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Figure 6.7. (Continued) (F) SKBr3 cell invasion in a 3D-BME assay (Trevigen) in response to 
50%FCM over a period of 3 days. Representative photographs are shown. (G) 
Quantification of E based on images converted to 8-bit grayscale on Image J and 
processed by auto-threshold to distinctly define cells that appear detached. (H) Gelatin 
zymography showing MMP-2 activity (72kDA). Integrated density values (IDV) are 
indicated for quantification of band intensities. P value:*<0.05 
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6.6 FAK inhibition suppresses fibroblast conditioned media-induced STAT3 
activation in SKBr3 cells 
 
We next sought to investigate the signalling pathway(s) involved in fibroblast-induced 
migratory and invasive responses of SKBr3 cells that might be governed by FAK. SKBr3 cells 
were stimulated with FCM for different time points and subsequently analysed by Western 
Blotting.  
Whilst little was observed in terms of the activity of the ErbB members HER2, HER3 and 
HER4, FCM treatment promoted a rapid and transient phosphorylation of AKT and MAPK 
(Figure 6.8). Importantly, FCM also enhanced the phosphorylation of FAK (at Y861 but not 
Y397); this was accompanied by the strong activation of the transcription factor STAT3 at 
Y705, and a decreased E-Cadherin expression (boxed).  
In the presence of the FAK inhibitor PF271, FCM failed to promote FAK or STAT3 activation 
indicating that FAK can influence STAT3 phosphorylation. Moreover, the levels of E-cadherin 
were not affected, but rather appeared much higher at the 24hrs time point. 
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Figure 6.8. FCM stimulates downstream signalling in SKBr3 cells. Cells were grown to 70% 
confluence and treated with 80% MRC-5 fibroblast conditioned media (FCM) at the indicated 
time-points ± pre-treatment with PF271 (1μM) for 60mins. Subsequent cell lysates were 
processed for Western Blotting and immuno-probed for proteins as indicated. GAPDH was used as 
loading control. Representative blots shown from three independent experiments.  
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We then investigated whether the FAK was implicated in the nuclear translocation of STAT3 
since this is known to be preceded by STAT3 activation and subsequent formation of homo- 
or heterodimers with other STAT family members; in the nucleus, STAT3 dimers can then 
bind to DNA elements and regulate transcription of target genes (Ihle 2001). Our 
immunofluorescence microscopy data demonstrated that FCM stimulation enhanced 
nuclear translocation of pSTAT3 Y705 (Figure 6.9A) Importantly, treatment with PF271 
partially prevented this pSTAT3 Y705 nuclear accumulation. This was further confirmed by 
Western Blot analysis of the SKBr3 cytoplasmic and nuclear fraction, where a higher amount 
of pSTAT3 Y705 could be detected in nuclear fraction following FCM stimulation, and also 
reduced in the presence of PF271 (Figure 6.9B). Interestingly, a small pool of total FAK 
protein was also detected in the nuclear fraction suggesting that FAK may have a role in 
nucleus under certain circumstances. 
The localisation of STAT3 to focal adhesions has previously been implicated in ovarian 
cancer cell migration (Silver et al. 2004) and thus we also sought to investigate this in our 
cell model. Due to our pSTAT3 and FAK antibodies originating from the same species, we 
needed to use an alternative marker protein for focal adhesions, namely vinculin. Visualising 
the cells at a different plane of view as in Figure 6.9A, we demonstrated that in the control 
cells, pSTAT3 co-localised with vinculin at the focal adhesions around the cell periphery 
(Figure 6.9C). When stimulated with FCM, the focal adhesions formed were larger, more 
prominently localised at the leading edge of the cell, and maintaining strong co-localisation 
with pSTAT3 Y705. Treatment with PF271 (1μM) decreased pSTAT3 and vinculin staining and 
more importantly disrupted this co-localisation.  
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Figure 6.9. (A) Immunofluorescence staining for pSTAT3 Y705 on SKBr3 cells seeded on FN-
coated plates demonstrate nuclear accumulation in response to 80% FCM-stimulation 
migration for 60mins. Pre-treatment with PF271 (1μM) for 60mins suppressed this. (B) Nuclear 
and cytoplasmic fractionation of SKBr3 cells further support nuclear accumulation in response 
to 80% FCM as analysed by Western Blotting. SP-1 nuclear transcription factor was used as a 
nuclear marker, whilst β-actin was used as a loading control. (C) Co-staining of SKBr3 cells for 
pSTAT3 (Y705) (green) + vinculin (red) and counterstained with DAPI, a nuclear dye (blue). 
Magnification: x63, oil-immersion objective. White boxes denote areas of interest further 
magnified directly below. Data represent at least three independent experiments.  
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To further confirm that STAT3 mediates migratory responses in HER2+ breast cancer cells, 
we tested the effect of Stattic, an inhibitor of STAT3 activation (Schust et al. 2006), on SKBr3 
cell signalling and migration. Initial optimisation experiments demonstrate the 1μM Stattic 
was sufficient to inhibit FCM-induced STAT3 activation in SKBr3 cells. Subsequent Boyden 
chamber migration assays show that Stattic was significantly able to inhibit FCM-induced 
SKBr3 cell migration, though to lesser extent than PF271 (Figure 6.10A). When Stattic and 
PF271 were used in combination this resulted in an additional level of inhibition of SKBr3 
cell migration. 
Western blotting further revealed that Stattic was not only able to decrease pSTAT3 Y705 
activity in response to FCM, but also that of FAK Y861 as well. When Stattic and PF271 were 
used in combination both pFAK Y861 and pSTAT3 Y705 activity were completely abolished 
(Figure 6.10B).   
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Figure 6.10. Inhibition of STAT3 and/or FAK activation suppresses FCM-induced SKBr3 cell 
migration. (A) Effects of pSTAT3 and FAK inhibition by Stattic (1μM) and PF271 (1μM) 
respectively on SKBr3 cell migration in response to two 80% FCM through fibronectin-coated 
Boyden chamber assay over a 20hrs. Experiments were performed in DCCM culture media and 
data represent the mean numbers of migratory cells/membrane run in duplicates from three 
independent experiments. (B) SKBr3 cell lysates treated in parallel were analysed for STAT3 and 
FAK activity by Western Blotting. GAPDH was used as a loading control. P values: * <0.05, **< 
0.01. 
A 
B 
FCM 
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6.8 Activated STAT3 physically interacts with FAK upon FCM stimulation 
 
Though our data suggests a link between FAK and STAT3, whether this is a direct physical 
interaction is not yet known. Thus we performed co-immuno-precipitation (IP) on SKBr3 
cells using the STAT Y705 and FAK antibody.  
As shown in Figure 6.11, pSTAT3 Y705 co-immunoprecipitated with FAK in control 
(untreated) samples supporting an association between FAK and STAT3.  These interactions 
became more abundant following stimulation by FCM and reduced when treated with 
PF271. No signal was detected in the negative control which consisted of cell lysate 
incubated with non-specific IgG antibodies. Altogether, these events further establish a link 
between FAK and STAT3. 
 
  
Figure 6.11. Co-immunoprecipitation of pSTAT Y705 with FAK in SKBr3 cells. pSTAT3 Y705 
(1.5μg/500μg of lysate) was immunoprecipitated in SKBr3 cell lysates and the complex analysed by 
Western Blotting for total FAK and pSTAT3 Y705. SKBr3 cells incubated with Rabbit IgG was used as 
control.   
IP: pSTAT3 Y705          con      FCM      FCM      Rb      
                            +PF        IgG 
 SKBr3 IP lysates 
  
total FAK 
 
 
pSTAT3 Y705 
 
 
 
IgG 
IB 
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6.9 Inhibition of FAK in MRC5 cells does not affect their pro-migratory effects on 
HER2+ breast cancer cells 
 
Having established that fibroblasts exert pro-migratory effects towards SKBr3 cells, we 
examined whether FAK might play a role in the fibroblast cells themselves, for example, by 
playing a part in signalling pathways that lead to the production of pro-migratory factors 
secreted by these cells. Importantly, this hypothesis is recently supported by other reports 
(Barker et al. 2013; Min et al. 2014).  
We investigated the effect of FAK inhibition on the ability of MRC5 cells to produce pro-
migratory factors. To avoid any confounding effects that may result from the presence of 
any residual drug in the FCM collected, MRC5 were pre-treated with PF271 (1μM) for 24hrs, 
and replaced by fresh media thereafter. Parallel Western Blot analysis however 
demonstrated that inhibition of pFAK Y397 by PF271 was only partial and returned to near 
basal activity levels 3 days following PF271 pre-treatment, the time period in which FCM 
was harvested in (Figure 6.12A). This suggested that this approach was not appropriate and 
alternative method for FAK inhibition was sought and siRNA chosen. Optimisation studies 
confirmed that 100nM FAK siRNA transfection was sufficient to effectively suppress FAK 
expression and activity for upto 6 days post-transfection in MRC5 cells (Figure 6.12B) albeit 
with some level of toxicity (Figure 6.12C). MRC5 transfected with control (non-targeting 
‘NT’) or FAK siRNA were re-seeded onto fresh flasks to ensure equal number of cells, and 
allowed to adhere for 24hrs.  Collection of conditioned media then proceeded as described 
in 6.1. When tested for its pro-migratory effects, FCM collected from FAK-suppressed MRC5 
cells appeared to induce migration to a similar extent as that seen with FCM from control 
MRC5 cells (Figure 6.12D). 
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  Figure 6.12. SKBr3 cell migration in response to CM derived from MRC-5 cells in which FAK was 
inhibited by 24hr PF271 (1μM) pre-treatment or FAKsiRNA 72hr transfection (100nM). Western 
Blot analysis  of MRC-5 cells to determine the extent of sustained FAK inhibition by PF271 (A) or 
FAKsiRNA post-treatment for up to at least 3 days (B).  FAKsiRNA was reasoned to be ideal for 
sustained FAK inhibition in MRC-5 cells. (C) Toxicity of the lipid and the transfection process was 
evaluated by treating cells with the DharmaFECT transfection reagent- lipid only (LO) and lipid + 
the non-targeting siRNA (Nt-siRNA) for 72hrs and effects on cell growth were assessed by Coulter 
counting. (D) SKBr3 cell migration through fibronectin-coated Boyden chamber over a 20hr period 
in response to FCM from MRC-5 cells transfected with NT/FAKsiRNA. Experiments were performed 
in DCCM culture media and data represent the mean numbers of migratory cells/membrane run in 
duplicates from three independent experiments. P values: * <0.05,**< 0.01, ***< 0.0001. NT: Non-
targeting  
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6.10  FAK plays a role in the cross talk between MRC5 cells and HER2+ breast 
cancer cells 
 
Our studies to date show that fibroblast conditioned media can promote SKBr3 cell 
migration in a FAK-dependent manner. However, these studies have used FCM and 
therefore do not address the bidirectional cross talk suggested to exist between tumour 
cells and surrounding cells in the tumour microenvironment. Indeed, this is supported by 
studies that demonstrate the ability of tumour cells to alter or reprogram stromal cells to 
facilitate tumour progression. For instance, fibroblast MMP9 secretion was significantly 
enhanced by co-culturing with breast cancer cells, and the level of secretion correlates with 
the malignancy of the cells (Stuelten et al. 2005). In another study, cancer-associated 
fibroblasts (CAFs) were shown to secrete higher levels of hepatocyte growth factor (HGF) 
than normal fibroblasts (NAFs). Pre-co culture of these NAFs with MDA-MB468 breast 
cancer cells significantly induced their ability to secrete HGF. Subsequent introduction of 
these pre-co cultured NAFs to mammary fat pad of NOD SCID mice then led to enhanced 
tumour progression (Tyan et al. 2011).  
Therefore, to study the reciprocal influence between fibroblasts and breast cancer cells, 2D 
co-culture experiments using a transwell (8.0 μm pores insert) Boyden Chamber set up were 
performed. MRC5 cells were cultured on the lower well whilst SKBr3 cells on the transwell 
insert. The porous membrane allows for exchange of secreted factors between the 
compartments and hence the two cell types, schematic illustrated below.  
  
Figure 6.13. Transwell membrane co-culture set up.  
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We employed the use of siRNA to knock-down FAK in MRC5 fibroblasts or SKBR3 cells. Post-
transfected MRC5 cells were seeded onto the lower well of the Boyden Chamber set up 
(50,000 cells/well) in RPMI +5% FCS media. After 24hrs, media was changed to DCCM media 
and subsequently after 48hrs, SKBr3 cells were then seeded onto the inserts and allowed to 
migrate for 20hrs.  
Co-culture with MRC5 fibroblasts stimulated SKBr3 cell migration, an effect that was 
modestly reduced when FAK expression was suppressed (up to 1.7-fold decrease) in MRC5 
cells. In contrast, FAK knockdown in SKBr3 cells significantly suppressed their ability to 
migrate in response to MRC5.  
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Figure 6.13. Co-culture of SKBr3 cells with MRC-5 in a Boyden Chamber assay set up.  (A) FAK was 
inhibited in (A) MRC5 fibroblasts (lower chamber) or in (B) SKBr3 cells (transwell insert) by  
FAKsiRNA (100nM) transfection for 72hrs. The effect of FAK knockdown on SKBr3 cell migration 
was assessed over a 20hr period. Experiments were performed in DCCM culture media and data 
represent the mean numbers of migratory cells/membrane run in duplicates from three 
independent experiments. * p <0.05 
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6.11 Discussion 
 
The extensive cross-talk between the tumour cells and their surrounding environment are 
now widely reported to support various stages of tumour progression. Tumour cells secrete 
numerous growth factors, cytokines, interleukins and other soluble factors, acting in an 
autocrine or paracrine manner to influence the surrounding pre-neoplastic and stromal 
cells. The subsequent activation and recruitment of these stromal cells consequently leads 
to secretion of additional factors and in turn, these promote an aggressive tumour 
behaviour, further activation of nearby stromal cells and concomitant remodelling of the 
ECM and degradation of the basement membrane.  This continuous cycle of reciprocal 
reprogramming of the stromal cells, tumour cells, surrounding pre-neoplastic cells and ECM 
altogether assemble into an evolving tumour stroma that will ultimately provide a 
permissive environment that mediate tumour progression, allowing tumour cell escape and 
ultimately metastatic dissemination (Mueller & Fusenig 2004).  
We reported previously that Heregulin, exogenously added to HER2+ breast cancer cells 
caused an increase in migratory response in a FAK-dependent manner. In the present 
chapter, we have extended these observations to show that HER2+ breast cancer cell 
migration and invasion can also be induced by conditioned media derived from fibroblasts,  
the most prominent stromal cell type (Kalluri & Zeisberg 2006). Importantly, we explored 
the hypothesis that, irrespective of the range of growth factors or cytokines likely to be 
secreted by fibroblasts in the conditioned medium, FAK represented a dominant signalling 
element in HER2+ cells through which fibroblasts exert their migratory and invasive 
promoting behaviour.  
 
In these studies, we used 3 day conditioned-media from the MRC5 human lung fibroblast 
cell line (‘FCM’) to model fibroblasts effects on HER2+ SKBr3 cells and compared it to the 
effects seen in HER2- MCF7 cells. The conditioned-media was collected in serum-free DCCM 
to ensure that only fibroblast-secreted factors would be present in the experimental system 
as a stimulating/inhibitory factor for the breast cancer cells under test. Further, MRC5 cells 
represented a good model of fibroblasts for this work given previous reports that 
conditioned medium from these cells is  able to induce migration and invasion of 
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MDAMB231 cells along with two invasive variants of MCF7 cells (Heylen et al. 1998) and of 
HER2+ BT474 cells (Studebaker et al. 2008).   
In contrast to some other studies that have demonstrated the ability of FCM to promote the 
growth of a range of breast cancer cells  (Studebaker et al. 2008; Yashiro et al. 2005; Gache 
et al. 1998; Tyan et al. 2011), we did not observe any effects of FCM on MCF7 or SKBr3 cell 
proliferation. However, it should be noted that growth-promoting effects of FCM are 
reported either in co-culture or a 3D context. In such settings, interactions between tumour 
cells and extracellular matrix components may sensitise cells to growth factors and other 
ligands in the FCM, or the bidirectional crosstalk between tumour cells and fibroblasts may 
act to promote growth-regulatory ligand secretion from the fibroblasts and/or tumour cells 
(Cukierman et al. 2001; Baker & Chen 2012). Alternatively, there is a possibility that breast 
cancer cells are more sensitive accordingly to their subtype-specific fibroblasts. This is 
supported by significant gene-expression profile differences between fibroblasts isolated 
from ER+, HER2+ or triple-negative breast tumours (Tchou et al. 2012). In saying that, 
although MRC5 cells are lung fibroblasts and thus from a different organ, Studebaker et al. 
have shown that MRC5 cells promote similar behaviour to that of fibroblasts isolated from 
breast tumour tissues. 
 
In this study, we revealed a differential response to FCM between MCF7 and SKBr3 cells 
with the migratory and invasive capacity of the latter being significantly augmented in 
response to FCM. Accompanying this was what appeared to be cytoskeletal remodelling, 
wherein actin became localised at the number of acquired protrusions all around the edges 
of the cell. Morphologically, cell-to-cell contacts appear disorganised or disrupted. 
Altogether, these changes can be attributed to changes in cell polarity and are generally 
accepted as common feature of cell migration and EMT (Lamouille et al. 2014). 
Interestingly, these actin cytoskeletal response to FCM appeared different to the larger fan-
like lamellipodial protrusions observed following stimulation of SKBr3 cells with HRG 
(Chapter 3.7), suggesting that the actin filament assembly are differentially regulated, such 
as through a differential actin nucleation mechanism (Le Clainche & Carlier 2008). The 
Arp2/3 nucleation complex for example can be regulated by either Wiskott-Aldrich 
syndrome proteins (WASP) and WASP family verprolin homologous (WAVE) family of 
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proteins which are also differentially regulated by RhoGTPases, phosphorylation and 
subsequent binding of SH2-domain protein in response to extracellular stimuli (Bompard & 
Caron 2004). This may indicate that the migratory process in SKBr3 cells can be regulated by 
various fibroblast-secreted factors and influence distinct changes in actin-cytoskeletal 
arrangements as we have observed. Importantly, these changes were suppressed when FAK 
activity was inhibited by PF271, implicating a central role for FAK in FCM-induced SKBr3 cell 
migration.  
 
Since the migration assays were performed over a short period (20hrs) and therefore the 
inhibitory effects of PF271 on migration are unlikely to be due to PF271-induced cell death. 
It should however be noted that it was observed that SKBr3 cells were particularly sensitive 
to PF271 in terms of growth suppression in a 7 day growth assay (Fig 6.6c). Interestingly, 
this was in contrast to our data obtained with the alternative FAK inhibitor, PF878 (Chapter 
4). On further investigation it could be seen that the IC50 values for PF271-mediated 
inhibition of FAK phosphorylation at Y397 in of both cell lines correlated with the IC50 for 
growth inhibition whereas this was not the case for PF878 . Since both PF271 and PF878 are 
ATP-competitive, reversible inhibitors of FAK and almost structurally identical, containing 
the key amino-methyl pyridinyl sulfonamide group that forms interactions with Asp-Phe-Gly 
(DFG) motif-containing residues within the FAK activation loop, we hypothesise that the 
differential effects on cell growth must arise as a consequence of the modification to the 
side-group in PF271.Whether this side group modification affects binding to FAK, cellular 
uptake, lipid permeability or a combination of these is not known but these observations 
highlight the importance that minor differences can make in a drugs’ structure, which affect 
its binding to the target and ultimately the effect on the cell.  
Furthermore, SKBr3 cell invasiveness was seen to increase in response to FCM, an effect 
that was partially inhibited by PF271. This is consistent with previous reports (Benlimame et 
al. 2005) and further substantiates the widely reported role for FAK in cell invasion (Hauck 
et al. 2002). One mechanism by which FAK can promote an invasive response is through 
modulation of MMP production (Sein et al. 2000; Hauck et al. 2001). FCM however failed to 
induce gelatinase (MMP2) production in SKBr3 cells. Other literature points to the fact that  
MMP expression is associated with HER2 overexpression (Pellikainen et al. 2004; Tan et al. 
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1997) and thus it is surprising that no MMPs were detected in these cells. However, only 
MMP2 and 9 were investigated since these are known to be involved in collagen 
degradation  and are amenable to analysis using zymography with a gelatin (denatured 
collagen type I) substrate (Toth & Fridman 2001). The major components of BME used in the 
assay however also included laminin, collagen IV, entactin, and heparin sulfate 
proteoglycan, thus it is possible that inhibition of FAK modifies other MMPs implicated in 
the invasive potential of HER2+ breast cancer for instance MMP1 and MMP13 (Bosc et al. 
2001; Yong et al. 2010; Westermarck & Kähäri 1999) or perhaps another group of 
metastasis-associated enzymes reported to regulate ErbB2 driven cell invasion, cathepsins 
(Rafn et al. 2012). Alternatively, the cellular context might influence MMP production: our 
invasion assays were performed in a 3D-setting whilst the samples used for gelatin 
zymography were from conditioned-media harvested from SKBr3 cells grown as 
monolayers. Indeed, there is evidence to suggest differential MMP expression in 3D culture 
versus 2D (Mishra et al. 2012).  
 
Nevertheless, our findings that FCM induced migratory responses on SKBr3 cells, led us to 
investigate the underlying signalling events mediated by FAK. We demonstrated that FCM 
induced ErbB receptor (HER2, HER4) activation but only at 24hrs post treatment suggesting 
that effects of fibroblast-secreted factors on these receptors was indirect, possibly in  an 
autocrine or paracrine manner. An example for instance is of the ligand TGFβ, which 
previously has been reported to up-regulate expression several ErbB ligands in fibroblasts 
(Andrianifahanana et al. 2010). These observations also suggest that the pro-migratory 
effects of FCM were not exclusively dependent on ErbB signalling as we originally 
hypothesised. However, since Herceptin was able to suppress FCM-stimulated SKBr3 cell 
migration , a role for ErbB signalling cannot be ruled out entirely. The effects of Herceptin 
were further enhanced when combined with PF271 which might imply differential control of 
migration through ErbB and FAK; in this context, additional inhibition of FAK activity could 
potentially further increase these anti-metastatic effects of Herceptin.  
 
Relatively more rapidly, FCM also induced activity at pFAK Y861 (not Y397) in SKBr3 cells. 
Furthermore, pFAK Y861 activity correlated with the activation of the transcription factor 
STAT3. Our observations that FCM-induced STAT3 activity was at least in part activated via 
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FAK as treatment with PF271 reduced the phosphorylation of pSTAT3 Y705. Following 
activation, STAT monomers are known to form homo/heterodimers and translocate into the 
nucleus, where it binds to gene promoters to allow transcription of genes involved in cell 
proliferation, migration, invasion and survival including BCL-2, Mcl-1, Cyclin D1, MMP1 and 
2, VEGF and survivin (Hsieh et al. 2005; Snyder et al. 2008). In agreement, our data 
demonstrated that STAT3 is redistributed to the nucleus following FCM treatment 
suggested that FCM promotes STAT3-dependent gene transcription that might contribute to 
the migratory responses seen. Pharmacological inhibition of STAT3 using Stattic also 
suppressed FCM-induced migration, confirming the role of STAT3 in driving migratory 
processes. This is consistent with previous studies that established the relationship between 
STAT and FAK leading to migratory responses (Xie et al. 2001; Silver et al. 2005) although in 
our cell lines, to be fully confident of this link, FCM could be used to stimulate SKBr3 cells 
transfected with mutant STAT3 through expression of STAT3 Y705F mutant construct  
(recently acquired from J. Bromberg).  
 
Co-immunoprecipitation assays provided evidence for a physical interaction between FAK 
and STAT3 in conditions of STAT3 activation in the presence of FCM. Some of these 
interactions are likely exist in the nucleus as supported by our data that FAK and STAT3 are 
present in the nuclear fraction of SKBr3 cells. This is in agreement with recent evidences 
supporting the localisation of FAK in the nucleus where it has been shown to be bind  and 
facilitate turnover of transcription factors including p53,GATA4 and NF-1 (Kweh et al. 2009; 
Lim 2013). For this reason, we can speculate a possible cooperation between FAK and STAT3 
within the nucleus to regulate specific pro-migratory genes yet to be identified.  In support 
of these, a correlation between decreased FAK and STAT3 activity and increased levels of E-
cadherin expression was observed, indicating that one such STAT3-regulated gene may be 
that of E-cadherin, as have been reported to be STAT3-mediated in Ras-transformed 
MCF10A cells and colorectal cancer cells (Leslie et al. 2010; Xiong et al. 2012). 
 
Apart from our inference that FAK can cooperate STAT3 directly in the nucleus,  a previous 
report also demonstrated that FAK activity is required for interleukin 6 (IL-6) gene 
expression (Schlaepfer et al. 2007). As IL-6 is an established activator of STAT3 signalling to 
promote metastatic cell phenotypes (Guo et al. 2012; Berishaj et al. 2007; Studebaker et al. 
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2008), it is also conceivable that FAK may activate STAT3 in an indirect manner by regulation 
of IL-6 expression in SKBr3 cells, though further studies are required to confirm this. STAT 
proteins are also known to be activated by various cytokine receptors, growth factor 
receptors e.g. EGFR, PDGF-R, as well as direct phosphorylation by cytoplasmic kinases such 
as Src and Abl (Bowman et al. 2000). Whether FAK is involved in these interactions remains 
to be accomplished, though our data revealing that the combination of PF271 and Stattic 
led to greater inhibition of migration than either agents alone, indicated some FAK-
independent non-redundant STAT3-mediated pathways.  
 
Immunofluorescence studies further revealed the co-localisation of pSTAT3 Y705 with 
vinculin, a focal adhesion marker, in the presence of FCM (Fig 6.9d). This was disturbed in 
the presence of PF271, providing evidence to suggest that FAK activity is required not only 
for pSTAT3 activation and the classical paradigm of nuclear accumulation, but also 
localisation at focal adhesions. Analysis of the cytoplasmic fraction of SKBr3 cells reveals a 
pool of STAT3 Y705 remaining in the cytoplasm following FCM stimulation. In addition, 
these immuno-staining experiments were performed following 60mins exposure to FCM, 
strengthening the interpretation that STAT3 can also have transcription-independent 
functions to regulate SKBr3 cell migration. This is  in agreement with previous studies which 
demonstrated the involvement of  FAK/STAT signalling and their association at focal 
adhesion to regulate migratory processes in  squamous cell carcinoma (Xie et al. 2001) and 
ovarian cancer cells (Silver et al. 2004; Badgwell et al. 2012). However to our knowledge, 
our data were the first to demonstrate the interaction and functional cooperation between 
FAK and STAT3 in HER2+ breast cancer cells.  
 
There are number of studies that support transcription-independent roles of STAT3. In the 
context of migration, in Drosophila for example, STAT3 activation was required for the 
initiation and maintenance of border cell migration (Silver et al. 2005). STAT3 can modulate 
microtubule dynamics in migrating cells by interaction with stathmin, a microtubule-
destabilizing protein (Ng et al. 2006).  The same group subsequently reported that STAT3 
activity also regulates directional migratory persistence, membrane ruffling and lamellipodia 
formation in mouse embryonic fibroblasts by modulation of Rac1-GTPase interaction with 
βPIX , a RAC-1 GEF  (Teng et al. 2009). Some however had opposing observations wherein 
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STAT3-deficient MEFs displayed reduced actin-stress fibre formation which corresponded 
with RhoA-GTPase induced migration, thus reflecting that the STAT3 interplay with various 
RhoGTPases direct differential pro-migratory processes (Debidda et al. 2005). Emerging 
from these studies is the implication that STAT3 may modulate cell migration through a 
direct functional interaction with cytoplasmic proteins. Interestingly, a genome-wide study, 
aimed at identifying STAT3 interacting proteins in human myeloma cell line U266, revealed 
FAK amongst many others, as a key STAT3 binding protein (Zheng et al. 2012), in further 
support of our data. By the same approach, another group, though not reporting on 
FAK/STAT3 binding, identified a number of STAT3-interacting partners are cytoskeleton-
related proteins including cortactin, talin-1 and filamin A in HEK293 cells (Blumert et al. 
2013). Based on these studies, it is reasonable to assume that following FCM-stimulation, a 
pool of STAT3 may remain in cytoplasm where it may serve as an adapter to mediate 
protein-protein interactions critical to the formation of focal adhesion complexes or 
cytoskeletal arrangements. Moreover, our data demonstrating that Stattic treatment alone 
suppressed pFAK Y861 activity implicate that activated STAT3 also exert catalytic activities 
directly towards FAK or via its upstream regulators to mediate signalling events, likely be  
associated with cytoskeletal regulation and migration.  
 
Having investigated the role of FAK in the HER2+ SKBr3 cells, we asked an alternative 
approach and examined whether FAK might play a role in the fibroblast cells, for example, 
by playing a part in signalling pathways that lead to the production of pro-migratory factors 
secreted by these cells. siRNA-mediated FAK suppression in MRC5 cells resulted in growth 
inhibition suggesting that FAK played an important growth-regulatory function in these cells 
as reported by others (Hungerford 1996; Zouq et al. 2009). Interestingly, whilst FCM from 
FAKsiRNA-treated fibroblasts was still able to promote SKBr3 migration, FAK siRNA in MRC5 
cells attenuated their pro-migratory effect towards SKBr3 cells when both cells were 
cultured together. The differential effects of FAK inhibition in these two culture settings 
suggest that FAK in MRC5 cells might be involved in the bi-directional crosstalk between 
them as implicated in other studies (Stuelten et al. 2005; Barker et al. 2013). 
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Taken together, these findings demonstrate that FAK mediates fibroblast induction of 
HER2+ breast cancer cell migration potentially via a mechanism involving, STAT3. This data 
suggests that FAK is an attractive target in HER2+ breast tumours where it may suppress 
tumour cell migration but additionally can exert added benefits within the tumour 
microenvironment such as the interference of cross-talk between tumour cells and 
fibroblasts that can promote migratory tumour behaviour and potentially metastatic 
progression.  
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7. General discussion  
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7.1 HER2+ breast cancer 
Up to 25-30% of breast cancer patients are diagnosed with HER2+ tumours which is 
associated with a poorer prognosis (Slamon et al. 1987). Despite the clinical effectiveness of 
Herceptin  in targeting these HER2+ tumours, a large proportion of patients do not respond 
(de novo resistance) and the majority that do respond display disease progression within a 
year of treatment initiation, indicative of rapid acquired resistance (see section 1.1.5.2). In 
light of this there is a clear need for the identification of novel therapeutic targets that may 
have a potential to improve outcome patients with HER2+ tumours.   
7.2 FAK as an anti-cancer target in HER2+ breast cancer 
FAK is now emerging as a promising therapeutic target in many tumour types (Golubovskaya 
2010), due to its overexpression in tumour cells and association with various cellular 
processes involved in cancer progression (Owens et al. 1995; Lark et al. 2005; Schaller 
2010). More recently, it has also been implicated in tumour metabolism and maintenance of 
cancer stem cells (Luo et al. 2009; Zhang & Hochwald 2013; Guan 2010).  In addition to 
integrin mediated signalling, FAK is also involved downstream of growth factors receptors 
such as the HER2 (Vadlamudi et al. 2003; Benlimame et al. 2005; Xu et al. 2009) with a 
number of studies reporting that that HER2 and FAK overexpression are co-expressed in 
breast cancer (Schmitz et al. 2005; Lark et al. 2005). High levels of FAK activity are both 
associated with progression in ductal carcinoma in situ (DCIS) and infiltrating ductal 
carcinoma (IDC) lesions, as well as in invasive and metastatic lesions (Owens et al. 1995; 
Lark et al. 2005; Lightfoot et al. 2004). In our HER2+ breast cancer cell models, although we 
were unable to show increased levels of total FAK protein levels relative to HER2- cells, 
analysis of FAK activity (particularly at Y861) appeared to be elevated in HER2+ cells versus 
HER2- cells suggesting a potential link between FAK activity and HER2+ breast cancer.  
The suggested role of FAK in cancer progression has led to the development of a number of 
inhibitors for FAK such as PF271 (Pfizer, see Table 1.3)  is a small ATP competitive inhibitor 
of FAK (and Pyk2) and been shown to inhibit tumour growth in multiple tumour xenograft 
models including pancreatic, prostate and lung (Roberts et al. 2008). In mouse models of 
pancreatic ductal adenocarcinoma (PDA), PF271 was shown to significantly inhibit tumour 
growth and reduce the incidence of metastasis (Stokes et al. 2011) in addition to reducing 
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the fibroblast and macrophage infiltration into the stroma. Importantly systemic 
administration of PF271 into mice has not been reported to result in severe side effects 
which is  encouraging given that FAK is ubiquitously expressed in most tissues and thus its 
inhibition has the potential to disrupt key FAK-mediated signalling important for 
physiological processes, although given that the expression of FAK are reported to be 
greatest during  embryonic development (Turner et al. 1993) suggests that FAK inhibition in 
adults may have less consequence. Clinically, this inhibitor has been tested in a Phase 1 
clinical trial (Infante et al. 2012) which, despite yielding no firm conclusions on efficacy 
largely due to the heterogeneity of tumour types involved, did result in stable disease in 
34% of patients (n=99) tested after 6 weeks of treatment initiation. Given the favourable 
toxicology and pharmacokinetic profiles of these agents in human studies, clinical trials on 
small molecule FAK inhibitors are ongoing (See Table 1.3); of these, PF878 (now VS-6063), a 
chemical relative of  PF271 but having more favourable oral availability, appears to be 
progressing well (See Table 1.3) with encouraging pre-clinical data in xenograft studies (Xu 
et al. 2014).  
Given the emerging prominence of FAK in cancer and its relationship with growth factor 
signalling, in this thesis we have explored the role of FAK in HER2+ breast cancer and 
investigated the potential for improvement of current therapies for this breast cancer 
subtype using inhibitors of FAK.  
Our initial findings revealed that targeting the Y397 auto-phosphorylation site of FAK using 
PF878 in two HER2+/ER+ cell models (BT474 and MDA361 cells) and HER2+/ER- cells (SKBr3) 
did not directly correlate with growth inhibition despite inhibition of FAK activity. This was 
particularly interesting in MDA361 cells where FAK inhibition led to concomitant decrease in 
AKT and MAPK activity, key regulators of cell survival, apoptosis and proliferation  (Marmor 
et al. 2004; Nahta & Esteva 2007). In contrast, FAK inhibition in SKBr3 cells resulted in 
paradoxical increases in AKT and MAPK. These combined data lead us to speculate that the 
changes in downstream signalling towards AKT and MAPK were not useful markers of 
sensitivity to PF878.   
Interestingly, our data shows that the effects of different inhibitors on the same cells can 
vary. The unavoidable decision to switch from PF878 to PF271 for the last set of 
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experiments (Chapter 6) revealed that, despite both compounds inhibiting pFAK Y397 and 
being produced by the same company, the latter was able to exert modest suppression on  
SKBr3 cell growth compared to the former. Both PF271 and PF878 are ATP-competitive, 
reversible inhibitors of FAK and almost structurally identical, containing the key amino-
methyl pyridinyl sulfonamide group that forms interactions with Asp-Phe-Gly (DFG) motif-
containing residues within the FAK activation loop. PF878 was developed from its 
predecessor PF271 with minor side-group modifications for increased oral availability. Our 
data indicates however that the differential effects on cell growth must arise as a 
consequence of this modification. Whether this side group modification affects binding to 
FAK, cellular uptake, lipid permeability or a combination of these is not known but these 
observations highlight the importance the minor differences can make in a drugs’ structure, 
which affect binding to the target and ultimately modify its effects on the cell. This is a 
recognised  phenomenon referred to as ‘Structure Activity Relationship’ (SAR) paradox; 
‘that it is not the case that all similar molecules have similar activities’ (Brown N. 2012). 
Importantly, this underscores the importance of fully testing inhibitors to explore their 
effects on signalling and cell function and also may suggest that when used in the clinic, may 
have differential effectiveness.  
Overall, our in vitro data suggests that inhibition of FAK may not represent an effective 
strategy to inhibit HER2+ tumour growth although, as discussed later in this chapter, the 
strength of FAK inhibitor monotherapy may lie in its ability to suppress the aggressive 
tumour cell behaviour associated with metastasis. 
7.3 FAK inhibitor in combination with Herceptin as a therapeutic strategy 
In light of the lack of effect of FAK inhibition of cell growth, we explored in the potential of 
combining PF878 with Herceptin, an established treatment for HER2+ breast cancer. Initial 
studies revealed that BT474 cells were relatively more sensitive to Herceptin than MDA361 
cells in agreement with a previous study (Yakes et al. 2002). This could reflect the fact that 
MDA361 cells expressed lower levels of HER2 activity than BT474 cells which may suggest 
that they are less reliant on HER2 signalling for growth. One study on a number of HER2+ 
cell lines suggested that Herceptin sensitivity correlates with HER2 phosphorylation, 
however, the authors acknowledged the challenge of predicting the relation between the 
HER2 phosphorylation and the clinical benefit from Herceptin due to the significant 
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influence of other factors including the expression of other ErbB receptors and RTKs, the 
potential input from cross-talk and alternate signalling mechanisms, as well as the 
regulation of downstream signalling proteins for example of AKT by PTEN inactivation 
(Ginestier et al. 2007). In this regard, MDA361 cells may reflect a subset of HER2+/ER+ 
tumours that display de novo resistance to Herceptin and that together with BT474 cells, 
these cell lines may therefore provide a unique opportunity to begin to identify treatment-
regulated genes that may potentially explain the differential sensitivity of these cells to 
Herceptin, for example,  by initially examining  their  gene expression profiles by microarray 
analysis; with the ultimate goal of enabling to select those individuals most likely to benefit 
from FAK inhibitors.  
Encouragingly, our data suggested that combination treatment of HER2+ breast cancer cells 
with Herceptin and PF878 resulted in a synergistic inhibition of cell growth that appeared to 
be linked to the suppression of AKT, at least for BT474 and MDA361 cells. AKT has been 
reported to play a key growth regulatory role in these cell lines where its inhibition results in 
suppression of cell proliferation (Yakes et al. 2002; Will et al. 2014). Although Herceptin 
alone separately reduced AKT activity in both HER2+/ER+ cells (with the effects in MDA361 
greater than BT474 cells), this was not to the extent seen when both Herceptin was used in 
combination with PF878. Thus this data argues for a threshold of AKT activity below which 
cell growth may be affected; this is further supported by our data showing that treatment of 
these cells with the AKT inhibitor, MK2206, led to a significant decrease in cell number 
(Appendix 8.2). In addition, loss of AKT may result in an inhibition of cell cycle progression 
and induction of apoptosis, as supported by the loss of Ki67 staining and gain in PARP 
cleavage. Interestingly, this synergistic growth suppression was more significant in MDA361 
cells, which were relatively insensitive to Herceptin monotherapy, than BT474 cells, 
suggesting that this combinatorial strategy may prove more beneficial in the context of 
refractory diseases.  
In light of this data, it could be further argued that AKT itself might represent a potential 
target in HER2+ disease.  As such various PI3K/AKT inhibitors under development have 
shown encouraging data in a pre-clinical study to enhance efficacy of existing targeted 
therapies (Clark et al. 2002 ; Karaca B et al. 2014). Targeting mTOR, a downstream effector 
of AKT and a critical regulator of protein synthesis is also an emerging target currently being 
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tested in a number of clinical trials (Reviewed Vicier et al. 2014). For example, an ongoing 
phase III trial will evaluate the combination of an mTOR inhibitor everolimus with endocrine 
treatment for patients with ER+/HER2- breast cancer (NCT01805271). The BOLERO-1 trial is 
also an ongoing phase III randomised trial in patients with HER2+ advanced breast cancer to 
evaluating the role of everolimus to overcome de novo Herceptin resistance 
(NCT00876395). The outcome of such trials are critical, however, it is not clear whether this 
strategy would provide the additional benefits of the suppression of cell migration seen 
with FAK inhibitors.  
In addition to Herceptin, HER2+/ER+ breast cancers may also receive endocrine therapy.  
The effectiveness of these is limited by HER2/ER cross talk, as this is a well-known 
mechanism of endocrine resistance (Houston et al. 1999; Dowsett 2001; Shou et al. 2004; 
Montemurro et al. 2012). Herceptin and Tamoxifen together has been previously shown to 
be beneficial in pre-clinical (Witters et al. 1997; Kunisue et al. 2000) and clinical studies 
(Reviewed Prat & Baselga 2008). Our data supports this in the context of HER2+/ER+ breast 
cancer but, importantly, demonstrates that inclusion of FAK in the treatment regimen 
further enhances growth suppression, particularly in BT474 cells that were relatively 
Tamoxifen-insensitive. This is in further support of the recurring theme that perhaps 
inhibition of FAK exerts greater benefits in the context of limited drug sensitivity. 
Clinical studies evaluating the combination of Herceptin and endocrine therapies have 
clearly demonstrated improvement in relapse and overall survival and similar benefits have 
been achieved in patients that had been treated with the combination of chemotherapy and 
Herceptin (Piccart-Gebhart et al. 2005; Marty et al. 2005). And as such, current treatment 
practice for patients with HER2+/ER+ tumours based on NICE guidelines state that these 
patients are more likely to receive anti-HER2 therapy plus chemotherapy whilst endocrine 
therapy only becomes an option if the patient presents an adverse reaction to these (NICE 
UK). 
The combination of Herceptin with PF878 similarly proved beneficial in the HER2+/ER- 
SKBr3 cells, though statistically insignificant and only occurring at the Herceptin 
concentration of 10nM. This enhanced growth suppression was however not correlated 
with AKT suppression, and in fact, the combination of Herceptin and PF878 induced AKT 
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activation. Thus, the effects of dual targeting of HER2 and FAK on downstream signalling 
likely vary from cell line to cell line. However, we have yet to prove whether this increased 
AKT activity is only transient and whether activity levels declined at time-points longer than 
24hrs, in which our growth assays were performed in. Interestingly no further benefits were 
observed when the concentration of Herceptin used was increased from 10 to 100 nM and 
it may be that at high concentrations, saturation of the HER2 receptors or potential 
interference with the receptor recycling to the cell surface (Hurrell & Outhoff 2013) could 
explain this phenomenon. Nonetheless, in the short term, we have data to support that the 
combined treatment suppressed proliferation and promoted apoptosis in the context of 
enhanced AKT and MAPK activity.  Whether such effects are unique to this cell line or 
mediated by the HER2 needs to be verified. As such, studies can be extended to another 
HER2+/ER- cell lines such as ZR751. However, there is the likelihood of these different 
HER2+/ER- cell lines to have acquired mutations during the course of tumour progression 
(intrinsic differences) or during in vitro culturing, making direct comparison between cell 
lines difficult. An alternative approach is to generate an isogenic cell line model such as that 
of MCF7 modified to express HER2.  
7.4 FAK as an anti-cancer target to reduce metastasis 
 
Anti-metastatic therapies have focused on MMP inhibitors that have largely failed in clinical 
development. This has been attributed to various reasons including the number of MMPs 
involved in metastasis and that they are produced by various stromal cells, making effective 
drug delivery a challenge (Reveiwed Zucker & Cao 2009). Although there are an increasing 
number of targets identified to be associated with metastatic progression, no anti-
metastatic drugs are clinically licensed to date. 
 
Herein, we demonstrated that pharmacological inhibition of FAK activity might represent a 
potential method to reduce metastatic progression given that FAK appears to be involved in 
the migratory responses of HER2+ breast cancer cells. Indeed, stimulation of these cells with 
Heregulins resulted in a change in the localisation of FAK at focal adhesions and FAK-
dependent cytoskeletal rearrangements, in agreement with the established role of FAK in 
these processes (Mitra et al. 2005). In MDA361 cells in particular, HRG also promoted the 
loss of peripheral E-Cadherin staining which favours dissociation of single cell from the 
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colony as we have observed. Deregulated E-cadherin localisation is a described marker of 
epithelial-mesenchymal transition (EMT), a process ascribed to the initial stages of 
metastatic dissemination (Kalluri & Weinberg 2009). That PF878 was able to reverse this, 
suggest the role of FAK in this critical process as reported by others (Serrels et al. 
2011).These anti-migratory effects were further confirmed with the use of FAKsiRNA. Such 
an approach has also allowed us, to a limited extent, to explore the accumulating evidence 
that the kinase-independent, scaffolding functions of FAK mediate several important 
intercellular events (Sieg et al. 1999; Fan et al. 2013). The data that FAKsiRNA transfection 
exerted no differential magnitude of migratory inhibition when compared with PF878 
suggests the dispensable scaffolding functions of FAK in regulating the migratory behaviour 
of these cells. 
Our data also showed that in MDA361 cells, HRG was associated with the increase the 
activity of HER2 receptor, which is likely to occur via hetero-dimerisation with the other 
ErbB receptors and literature suggests that signals emanating from HER2/HER3 
heterodimers are likely to be formed in response to HRG (Wallasch et al. 1995).  Studies 
have also shown that in HER3 is an obligate partner for HER2 in  HER2+ breast tumour cells 
and provides an potent oncogenic input, (Alimandi et al. 1995) whilst expression of HER2 
and HER3 in non-tumourigenic MCF10A cells induces their migratory behaviour in response 
to HRG (Aceto et al. 2012). Importantly, the activation of ErbB receptors in MDA361 cells 
was accompanied by an increase in FAK activity (Y397,Y861) supporting a the role for ErbB 
signalling in cell migration through regulation of focal adhesions (Xu et al. 2009).  
In SKBR3 cells, HRG induced migration was associated with the FAK-dependent formation of 
lamellipodia structures together with activation of  FAK (Y397,Y861) and Src. HRG however 
had only minor effects on the activation of ErbB receptors contrary to other reports (Adam 
et al. 1998; Tan et al. 1999; Vadlamudi et al. 2003). The elevated basal phosphorylation of 
the ErbB receptors may result from  these cells having established an autocrine loop to 
secrete ErbB ligands such as HRG, and will thereby have high ErbB receptor activity as has 
been reported (Venkateswarlu et al. 2002; Li et al. 2004). These saturating conditions are 
more likely to reflect the tumour micro-environment where they are exposed to such 
ligands however to understand the underlying mechanisms, a better experimental approach 
should have been adopted wherein at least a 24hrs period of serum starvation, rather than 
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60 minutes, prior to additional HRG stimulation. Alternatively, our data may indicate that 
the spatial localisation of FAK is more important for HRG-induced migratory response rather 
than global changes in downstream HER2 signalling.  
An important point to take in account is that our data supported the role of FAK activity in 
HRG-induced HER2+ migration, while our immunofluorescence data can only confirm this 
for activated FAK  at Y861 and not Y397. We however cannot discount or validate the 
involvement of pFAK Y397, which were particularly tricky to detect by immunofluorescence 
with our particular antibody. However, that pFAK Y861 is expressed at higher levels than 
Y397 in HER2+ breast cancer cells supports the drive for development of inhibitors that 
target other tyrosine residues of FAK. This is starting to be explored by others in the group 
currently.  
HRG is known to be present in the tumour microenvironment and its expression correlates 
with an aggressive tumour behaviour and increased disease recurrence (Visscher et al. 
1997; Atlas et al. 2003). Stemming from our data that FAK is involved in HRG-mediated 
HER2+ cell migration, in Chapter 6, we extended our work to explore whether FAK 
represented a dominant signalling element in HER2+ cells through which stromal cell 
components, specifically fibroblasts exert their pro-metastatic behaviour. Fibroblasts 
represent a prominent stromal cell component (Kalluri & Zeisberg 2006), and supports 
tumour progression by paracrine signalling towards pre-neoplastic and other stromal cell 
types (Mueller & Fusenig 2004).  
Our data demonstrated that the migratory capacity of SKBr3 breast cancer cells was 
stimulated in a FAK-dependent manner in agreement with previous reports on HER2+ breast 
cancer cells (Heylen et al. 1998; Studebaker et al. 2008).  In this context, our data suggested 
that FAK acts through a mechanism involving activation of STAT3 (at Y705), a key effector of 
cytokine and growth factor signalling (Yu et al. 2009). This may involve a physical association 
between FAK and STAT3, as supported by our co- immune-precipitation data which in turn 
may facilitate nuclear accumulation of STAT3, supporting its established role as a 
transcription factor to regulate pro-metastatic genes (Carpenter & Lo 2014). It was 
therefore encouraging to detect FAK in the nuclear fraction of FCM-stimulated SKBr3 cells in 
agreement with the emerging role of FAK in the nucleus where it has been shown to 
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regulate transcription factors such as p53 (Lim 2013). In this regard, it is likely that FAK could 
cooperate with STAT3 in the nucleus though this subject needs further exploration. The first 
of which is to optimise the cellular fractionation assay to be fully confident of the presence 
of FAK in the nuclear fraction. As though minimal, a small amount of Grb2 protein 
(cytoplasmic marker) can be detected in the nuclear fraction, and thus the FAK detected in 
the nuclear fraction my reflect contamination from the cytoplasmic fraction proteins.   
The role of FAK in STAT3 activation is consistent with previous studies demonstrating the 
cooperation and interactions between STAT proteins and FAK to regulate migratory 
responses (Xie et al. 2001; Silver et al. 2005). Whether these physical interactions are 
phosphorylation dependent cannot be confidently confirmed. Further studies to explore 
whether FCM could stimulate interactions between STAT3 and FAK in SKBr3 cells 
transfected with a phospho-mutant of FAK termed FRNK (FAK-related non-kinase domain). 
Generation of mutants by site-directed mutagenesis of the key FAK phosphorylation sites 
may further reveal which residue(s) are critical for its cooperation with STAT3. Conversely, 
SKBr3 cells could also be transfected with STAT3 Y705F mutant construct (recently acquired 
from J. Bromberg), to further complete the picture; focusing on the implications on 
migratory behaviour. Our immunofluorescence data also showed that localisation of 
activated STAT3 at focal adhesions (co localised with vinculin) upon exposure to FCM was 
disrupted by PF271, thereby suggesting an additional transcription-independent role of 
STAT3. Such a localisation of STAT proteins at focal adhesions has previously been reported 
(Xie et al. 2001; Silver et al. 2004) but to our knowledge we are the first to document this in 
HER2+ breast cancer cells. Likely, FAK may phosphorylate STAT3 by direct interactions. Dual 
immunofluorescence staining with FAK and STAT3 using appropriate antibodies however 
are required to confirm this at the least, or a proximity-ligation assay (DuoLink), which has 
been recently been optimised by colleagues in the lab. On the other hand, FAK may also be 
indirectly involved by interaction with JAK2 as has been reported (Zhu et al. 1998), and that 
FAK also exist in a complex with JAK and STAT3 is also worth exploring.  
In spite of this we demonstrated the linkage between FAK and STAT3 and that FAK activity 
was a requirement for STAT3 at focal adhesions. The role of STAT3 therein could be further 
examined. Some potential insights have been reported in the literature, wherein STAT3 has 
been shown to physically interact with proteins associated with cytoskeletal regulation (Ng 
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et al. 2006; Teng et al. 2009; Debidda et al. 2005) and other focal adhesion proteins such as 
paxillin (Silver et al. 2004). Moreover, at the time of these experiments, it was reported that 
STAT3 localised at focal adhesions in a complex with FAK and NEDD9  in ovarian cancer cells 
(Xiao & Connolly 2014). NEDD9 is a non-catalytic scaffolding protein also associated with an 
aggressive tumour behaviour (Sima et al. 2013; Izumchenko et al. 2009). This supports the 
idea that STAT3 and FAK exist in a complex with other proteins and is thus capable of 
interplay. Our data demonstrating that Stattic treatment alone suppressed pFAK Y861 
activity implicate that activated STAT3 also exert direct activities towards FAK or via its 
upstream regulators to mediate signalling events associated with migration. This part of the 
study can extended by investigating the possibility of FAK and STAT3 existing in a complex of 
other focal adhesion proteins, by co-immunoprecipitation, and the effects of PF271 and/or 
Stattic on these interactions and/or activity to further sought the role of STAT3 in HER2+ cell 
migration.  
The association between FAK and STAT3 is also primarily observed to be dependent on 
FCM-derived factors and therefore requires a receptor-input in order to activate these 
cytoplasmic proteins. However, we observed that ErbB receptors are minimally affected by 
FCM stimulation, suggesting that these receptors may be irrelevant in the context of SKBr3 
cell migration.  In agreement, it has been demonstrated that HER2-induced STAT3 activation 
promoted EMT and cancer stem cell traits only in breast cancer cells that also express ER 
(HER2-overexpressing MCF7 cells) implicating the critical role of HER2-ER-STAT3 pathway 
(Chung et al.2012).  
In relation to the above, from a mechanistic view, exploring the receptor(s) that mediate 
SKBr3 cell migratory responses would be interesting to pursue. Potential candidates include 
PDGFR, IL-6R/GP130 and C-Met, known to require STAT3 to mediate a wide variety of 
cellular responses (Zhang et al. 2002; Yu et al. 2009;). It is also likely that FAK may represent 
a critical mediator of cross-talk between various cytokine, interleukin or growth factor 
receptors; crosstalk between the IL-6/GP130 receptor and the RET receptor was described 
to be mediated by FAK ( Morandi & Isacke 2014).  
Finally, we further explored the role of FAK in fibroblasts. Our data demonstrated that 
though FAK was critical to their survival. Importantly, FAKsiRNA-transfected MRC-5 
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suppressed its pro-migratory role towards SKBr3 in a co-culture setting, whilst no changes 
were observed when only the conditioned media was used. The differential effects of FAK 
inhibition in these two culture settings suggest that FAK in MRC5 cells might be involved in 
the bi-directional crosstalk between them as implicated in other studies (Stuelten et al. 
2005; Barker et al. 2013). Having explored this crosstalk between fibroblasts and breast 
cancer cells in paracrine manner, this work could be extend to determine whether 
additional or differential effects following cell-to-cell contact. A recent study for instance 
demonstrated that a transmembrane protein TSPAN12 in fibroblasts promoted cancer cell 
proliferation and invasion of non-small cell lung carcinoma cell line, which only occurred in a 
direct-contact co-culture system (Otomo et al. 2014).  
It is not enough to understand the internal mechanisms that FAK is involved in to regulate 
cell migration. These cells exist within the tumour surrounded by various external cues 
which others and we have shown to affect their signalling and migratory behaviour and thus 
propensity to metastasize. Our studies have contributed to understanding these, but 
importantly yielding the conclusion that targeting FAK in HER2+ breast cancer is a 
potentially a viable strategy suppress tumour cell migration but additionally interfering with 
fibroblasts and their cross-talk with tumour cells.  
Recent studies exploring the role of FAK in other cell types however raised very important 
issues. In an in vivo study, loss of FAK in the haematopoetic environment led to increased 
circulating granulocytes which contributed to enhanced experimental metastasis (Batista et 
al. 2014). Low dosage pharmacological inhibition of FAK in mice models was able to 
promote tumour growth and angiogenesis (Kostourou et al. 2013). These indicate that the 
beneficial effects of FAK inhibition are therefore context and dose dependent and together 
highlights the careful analysis of the role of FAK not only in tumour cells but in the 
surrounding tissues as well. Extensive studies will enable the understanding of the 
mechanisms underlying these paradoxical effects. Considerations in exploring the possibility 
to counteract or minimize these effects or optimising FAK inhibitor dosing regimens will 
ensure the successful incorporation of FAK inhibitors in combination treatment approaches.  
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7.5 Experimental limitations and considerations   
Although we have provided evidence for an important role of FAK in HER2+ breast cancer 
particularly in the response of these cells to treatment with Herceptin, additional studies 
are required to resolve the limitations of this current study, of which some are outlined 
below.  
 
(1) Our current data are based on 2D in vitro growth studies which do not wholly represent 
the micro-environment of the tumours in vivo and the potential for interactions with ECM 
and stromal cells which themselves may alter drug response. Indeed, studies have 
demonstrated that tumour cells grown in suspension or in 3D cell culture systems are more 
sensitive to the growth inhibitory effects of a FAK inhibitor (Tanjoni et al. 2010) and 
Herceptin (Pickl & Ries 2009). Pickl and colleagues specifically described the differential 
signalling in 3D cell cultures of SKBr3 cells, wherein there is an increase in HER2 
phosphorylation, accompanied by a decrease in AKT activity and an increase in MAPK 
activity, and has strong implications for our data. These data underscore the importance of 
not extrapolating the effects of inhibitors in 2D culture into 3D/in vivo systems. In this 
regard, it would be very interesting to it is likely that the benefits of Herceptin and PF878 in 
combination are much greater than we actually have seen. 
(2) Longer term clonogenic assays would also address the question of whether these effects 
of enhanced growth suppressive effects yielded by the Herceptin and PF878 combination 
are transient or are maintained over a much longer term. This is particularly important in  
HER2+/ER- SKBr3 cell lines, where the increased AKT and MAPK activity may contribute 
towards development of resistance to the combination treatment in the long term.  
(3) There is the suggestion that the timing and order of administration of combinatorial drug 
regimens can be critical to efficacy. In our studies, cells were subjected to the simultaneous 
treatment of Herceptin and PF878. However, others have indicated that treatment with the 
first drug may alter signalling networks that make the cells more susceptible to the effects 
of the second drug (Lee et al. 2012). Modifications of the treatment schedules may further 
improve the synergistic growth inhibitory effects of Herceptin and PF878, although at this 
point, we can only speculate. 
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(4) Acquired resistance to Herceptin has been attributed to a number of cellular processes 
including a compensatory increase in growth factor receptor signalling pathways that can 
also involve integrins (Huang et al. 2011). As FAK plays a role these signalling pathways, we 
hypothesised that FAK may also be an important mediator of such phenomenon. An 
interesting question therefore is whether the combination of FAK inhibitor with Herceptin 
might delay or prevent the acquisition of Herceptin resistance? One such strategy would be 
to generate Herceptin-resistant derivatives of our parental-HER2+ breast cancer cell lines by 
long-term culture with chronic exposure to Herceptin.  This approach has previously been 
performed in our lab to generate Tamoxifen and Faslodex-resistant (TamR, FasR) derivatives 
of the MCF7 cell line (McClelland et al. 2001; Knowlden et al. 2003). Interestingly, these 
resistant derivatives were shown to have elevated levels of FAK activity (Y397, Y861) 
compared to their parental MCF7 cell counterparts. Importantly, inhibition of FAK activity 
partially restored the sensitivity of TamR cells to the anti-proliferative effects of Tamoxifen 
(Hiscox et al. 2011). Given our data showing that Herceptin induced the activation of FAK 
activity (Y397, Y861) in SKBr3 cells, it is reasonable to hypothesise that FAK acts a regulatory 
signalling protein that may in the long term represent as an escape mechanism to the 
growth suppressive effects of Herceptin.  
(5) Further examination of our hypotheses in in vivo models would prove beneficial and will 
also address other characteristics that are unique to an in vivo setting, such as tumour 
hypoxia and angiogenesis that may also contribute to drug responses.  
7.6 Final conclusions 
A wealth of studies have emerged over the last decade supporting a role for FAK in tumour 
progression and the prominence of FAK in this context is reflected by the number of 
ongoing clinical trials with small molecule FAK inhibitors. In this thesis we have added 
further data that supports a rationale for targeting FAK in the context of HER2+ breast 
cancer. Importantly, our studies have shown that FAK inhibition may have benefit in 
Herceptin-insensitive breast cancer when used alongside Herceptin and that anti-FAK 
monotherapies represent a potential strategy to suppress stromal-induced cellular 
migration of breast cancer cells. In this latter context, our data suggests that FAK may act 
through a STAT3-dependent mechanism to regulate migration exogenously-stimulated 
migratory and invasive responses (Figure 7.1).  
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Figure 7.1 Schematic hypothesis of the role of FAK in fibroblast driven HER2+ breast cancer cell 
migration/invasion.  
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8. Appendix 
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Appendix 8.1 BT474 cells stimulated with 100ng/ml HRGβ1 at various time points for up to 
24hrs, subsequently lysed and analysed by Western Blotting 
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Appendix 8.2 BT474 and MDA361 treated with increasing dosage of AKT (MK2206) and MEK 
(U0126) inhibitor for 5 days and cell growth assessed by the MTT viability assay. (n=3, ±SEM) 
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